

PAUL L. KAUFMAN, MD, MD (HC) – CURRICULUM VITAE

02/08/2018

OFFICE ADDRESS

Department of Ophthalmology and Visual Sciences
University of Wisconsin School of Medicine and Public Health
600 Highland Avenue, K4/430
Madison, Wisconsin 53792-4673
Tel: (608) 263-6074
Fax: (608) 263-0543
Email: paul.kaufman@ wisc.edu

HOME ADDRESS

3006 Harvard Drive
Madison, WI 53705-2107

DATE & PLACE OF BIRTH

September 16, 1943 (New York, NY)

MARITAL STATUS/CHILDREN

Married Margaret George, April 12, 1970, Arlington, VA
Alison Rachel, born January 7, 1973, St. Louis, MO

CITIZENSHIP

United States

EDUCATION AND TRAINING

1957-1960 Bronx High School of Science, New York, NY
1960-1963 Tufts University, Medford, Chemistry-Biology
1963-1967 MD, New York University School of Medicine, New York, NY
1967-1968 Intern, Straight Medicine, Bellevue Hospital, Columbia University Medical Division, New York, NY
1968-1970 Military Service: Staff Associate, Biometry Branch, National Cancer Institute, National Institutes of Health, US Public Health Service, Bethesda, MD
1970-1973 Resident in Ophthalmology, Washington University School of Medicine and Barnes Hospital, St. Louis, MO
1973-1975 Seeing Eye and NIH Research Fellow in Ocular Pharmacology, Departments of Pharmacology and Physiology, University of Uppsala, Uppsala, Sweden (Drs. Ernst Bárány and Anders Bill)

POSITIONS HELD AT UNIVERSITY OF WISCONSIN-MADISON

1975-1980 Assistant Professor of Ophthalmology
1978-date Affiliate Scientist, Wisconsin Regional Primate Research Center
1980-1983 Associate Professor of Ophthalmology
1983-date Professor of Ophthalmology and Visual Sciences
1984-2003 Affiliate Professor of Veterinary Science, Veterinary Science Graduate Program
2003-date Affiliate Professor of Veterinary Science, Comparative Biomedical Sciences Graduate Program
1992 Acting Chairman, Department of Ophthalmology and Visual Sciences
2004 Walter H. Helmerich/Retina Research Foundation Chair
2004-2014 Peter A. Duehr Professor and Chairman, Department of Ophthalmology and Visual Sciences
2011-date Ernst H. Bárány Professor of Ocular Pharmacology

MEDICAL LICENSURE

California G19225
Wisconsin 19748

BOARD CERTIFICATION

Diplomate, National Board of Medical Examiners, July 1, 1968
Diplomate, American Board of Ophthalmology, December 6, 197

HONORS AND AWARDS

- 1973-1974 The Seeing Eye, Inc. Research Fellowship
- 1974 The Fight for Sight, Inc. Research Fellowship
- 1974-1975 NIH Special Research Fellowship
- 1979-1984 NIH Research Career Development Award
- 1984 Alcon Research Institute Recognition Award for Outstanding Contributions to Vision Research
- 1985-1986 NIH Fogarty Center Senior International Fellowship
- 1989 Essilor International Award for Outstanding Research in Presbyopia
- 1994 Research to Prevent Blindness Senior Scientific Investigator Award
- 1998 Wisconsin Alumni Research Foundation Mid-Career Award
- 1998 Washington University Department of Ophthalmology and Visual Sciences Distinguished Alumnus Award
- 1998 Glaucoma Research Foundation Center of Excellence Award
- 1999 Association for Research in Vision and Ophthalmology Special Recognition Award
- 1999 American Academy of Ophthalmology Honor Award
- 1999 International Society for Refractive Surgery Video Competition, October 22-23, Orlando, FL, 2nd Place
Award for video: Glasser A, Kaufman P: Edinger-Westphal stimulated accommodation in rhesus and Cynomolgus monkeys.
- 2000 13th Annual Meeting of German Ophthalmic Surgeons, Nürnberg, Germany, June 15-18, 2000. Video-Film Festival Grand Prize for Glasser A, Kaufman P: Edinger-Westphal stimulated accommodation in rhesus monkeys.
- 2002 Research to Prevent Blindness Physician Scientist Award
- 2003 Honorary Presidency of the International Glaucoma Surgical Congress, Luxor, Egypt, February 6-7, 2003
- 2003 Doctor Honoris Causa, Medical Faculty, University of Uppsala, Uppsala, Sweden
- 2003 UW Hospital and Clinics Best Doctors, In Business Magazine, May 2003
- 2004 Association of International Glaucoma Societies Award (formerly International Glaucoma Reviews Award) for best glaucoma paper of 2003 (#261: Gabelt BT, Gottanka J, Lütjen-Drecoll E, Kaufman PL: Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci 44:2118-2125, 2003.)
Ernst H. Bárány prize, International Society for Eye Research
- 2006 ARVO Distinguished Service Award
- 2007 ARVO Distinguished Service Award
- 2009 2009 AGS Guest of Honor, American Glaucoma Society, 19th Annual Meeting, San Diego, CA, March 5-8, 2009
- 2009 ARVO Gold Fellow. The title of ARVO Fellow recognizes members for their accomplishments, leadership and contributions to the Association
- 2010 The Glaucoma Foundation: The Robert Ritch Award for Excellence and Innovation in Glaucoma WARF Named Professorship (Ernst H. Bárány Professor of Ocular Pharmacology), Wisconsin Alumni Research Foundation / University of Wisconsin
- 2012 The Goldmann Award, Glaucoma Research Society, Würzburg, Germany, Sept. 5-8 Lecture: The biology of aqueous humor outflow
- 2013 ARVO Distinguished Service Award – as Editor-in-Chief Emeritus of Investigative Ophthalmology & Visual Science 2008-2012
- 2013 ARVO Joanne G. Angle Service Award, ARVO's highest service honor bestowed to a volunteer professional, recognizing outstanding leaders who have made significant, continuous contributions to ARVO in support of its mission (Member and Chair, Physiology & Pharmacology Section Committee; Glaucoma Section Trustee; Member, ARVO Board of Trustees; ARVO President-Elect, President, Immediate Past President; ARVO Executive Vice President; Editor-in-Chief of IOVS; Member, ARVO Foundation for Eye Research (AFER) Board of Governors)
- 2013 AAO Senior Achievement Award, recognizing lifelong commitment to teaching and contributing knowledge to the next generation

2015 Research to Prevent Blindness Stein Innovation Award
 2017 ARVO Friedenwald Award

Many Years

+ 2002-2015 Listed in “Best Doctors in America” / “America’s Top Doctors”

PROFESSIONAL MEMBERSHIPS

American Academy of Ophthalmology (Fellow)
 American Glaucoma Society
 American Ophthalmological Society
 Association for Research in Vision and Ophthalmology
 Becker Glaucoma Society
 Glaucoma Society of the International Congress of Ophthalmology/Glaucoma Research Society
 International Society for Eye Research
 University of Wisconsin Eye Alumni Association
 Washington University Eye Alumni Association

NATIONAL/ INTERNATIONAL SERVICE

Scientific Advisory Panel

1. Consultant, Retinal and Choroidal Diseases Program Planning Panel (Program Planning Subcommittee, National Advisory Eye Council, National Eye Institute, National Institutes of Health, (NIH-NEI), 1977.
2. Member, Glaucoma Program Planning Panel (Program Planning Subcommittee, National Advisory Eye Council, NIH-NEI), 1980-1983; Consultant, 1990.
3. Member, Site Visit Team, NIH-NEI, 1980 (x1); 1981 (x3); 1982 (x1).
4. Member, Special Study Section/Special Emphasis Panel, NIH-NEI, 1981 (x2), 1982 (x1), 1997 (x1).
5. Contributing Reviewer, United States Pharmacopeia - Dispensing Information, 1981-2000.
6. Member, Medical Advisory Committee, Wisconsin Society to Prevent Blindness, 1979-94.
7. Member, Visual Sciences A1 Study Section, NIH: permanent 1982-85; ad hoc 1987 (x2); 1989 (x2).
8. Member (ad hoc), Vision Research Program/Review Committee, NIH-NEI, 1982 (x1); 1987 (x1); 1990 (x1).
9. Member, Treatment Effects Monitoring and Advisory Committee, Glaucoma Laser Trial, NIH-NEI, 1983-94.
10. Member, Special Study Section on Small Business Innovative Research, NIH, 1984 (x1); declined in 1990 (x1).
11. Chairman, Visual Sciences A2 Study Section (ad hoc M1), NIH, 1988 (x1); declined in 1990 (x1).
12. Consultant, Office of Orphan Products Development, US Food and Drug Administration, 1990-2000.
13. Member, National Advisory Eye Council, NIH, 1991-1994.
14. Member, Grant Review Committee (1995-2001) and Scientific Advisory Board (1992-date), The Glaucoma Foundation, New York, NY.
15. Member, Catalyst Fund Advisory Committee, American Glaucoma Society - Glaucoma Research Foundation, San Francisco, CA, 1992-1997.
16. Member, Data and Safety Monitoring Committee, Early Management of Glaucoma Trial, NIH-NEI and Swedish Medical Research Council, 1993-2005.
17. Member, Merck Institute Board of Scientific Advisors, 1994-1998.
18. Member, Scientific Advisory Committee of the Glaucoma Research Foundation, San Francisco, CA, 1994-2001; Chair, 1998-2001.
19. Member, Scientific Advisory Committee, Alcon Research Institute, Fort Worth, TX, 1995-2000.
20. Member, Scientific Advisory Board, Neurovir, Ltd., Vancouver, BC, Canada, 1995-2000.
21. Member, Lewis Rudin Glaucoma Prize Selection Committee, New York Academy of Medicine, New York, NY, 1995-date.
22. Member, Von Sallmann Prize Committee, International Society for Eye Research, Ridgefield, NJ, 1995-98.
23. Member, International Advisory Board, International Symposium on Ocular Pharmacology & Therapeutics, 1996-2011.
24. Member, Glaucoma Advisory Board, Pfizer/Pharmacia & Upjohn, Inc., Peapack, NJ, 1998-2010.

25. Member, Scientific Advisory Board, Proneuron Biotechnology, Inc., Ness Ziona, Israel, 1997-2007.
26. Member, Scientific Advisory Committee, Gullstrand Foundation, Uppsala, Sweden, 1997-2007.
27. Member, Selection Committee, International Glaucoma Reviews Award, 1999-2005.
28. Member, Working Group on Review of the Molecular, Cellular and Developmental Neuroscience Integrated Review Group, Center for Scientific Review, NIH, 2000.
29. Ad hoc member, Visual Sciences - A Study Section, Center for Scientific Review, NIH, June 15-16, 2000 (in conjunction with # 27).
30. Member/Participant, Glaucoma Research Foundation/American Glaucoma Society/National Eye Institute/Association for Research in Vision & Ophthalmology Catalyst Meeting on the Physician- Scientist in Glaucoma, April 14-16, 2001, Alexandria, VA. Session Moderator: National Eye Institute's Perspective.
31. Member, International Advisory Board, Singapore National Eye Research Institute / First SERI-ARVO Meeting on Research in Vision and Ophthalmology, 2002-2005.
32. Member, Advisory Board, Association of International Glaucoma Societies, 2002-2007.
33. Member, Ad Hoc Scientific Advisory Committee, Research to Prevent Blindness, 2006-date.
34. Co-Organizer/Co-Moderator, NEI/FDA CDER Glaucoma Clinical Drug Trial Design and Endpoints Planning Meeting (November 1, 2007) and Symposium (March 13-14, 2008). NIH, Bethesda, MD.
35. Member, Stage 2 Distinguished Editorial Panel / Neuroscience Panel for NIH Challenge Grants, Center for Scientific Review, NIH, Washington, DC, July 20-12, 2009.
36. Co-Organizer/Co-Moderator, 2010 NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function.
37. Member, International Advisory Board, 8th Hong Kong International Symposium of Ophthalmology, 2012.
38. Research Grants Council / General Research Fund / Early Career Scheme / External Advisor / University of Hong Kong / Hong Kong, China, September 3-4, 2012. Critiques of 20 grant proposals, all biomedical fields 1-on-1 with PIs.
39. Member, Research Grant Review Committee, Research to Prevent Blindness (RPB), New York, NY, September 10, 2012, to review and rank annual RPB grant applications.
40. Member, Special Advisory Committee for Grant Program Review, Research to Prevent Blindness (RPB), New York, NY, September 25, 2013.
41. Member, International Advisory Committee, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China, 2013-2015.
42. Senior Consultant Advisor, Singapore Eye Research Institute, Singapore, 2015-present.
43. International Advisory Committee, Asia ARVO, 2017.

Scientific Referee for NIH, VA, NSF, DFG (Germany), Glaucoma Foundation, Glaucoma Research Foundation, PSI Foundation (Canada), MJ Murdock Charitable Trust, US-Israel Binational Science Foundation, Wellcome Research Trust, John D. and Catherine T. MacArthur Foundation, Fight for Sight Foundation, UK; Canadian Institutes for Health Research, Research Grants Council (Hong Kong), Science & Engineering Research Council - Agency for Science, Technology & Research (Singapore), several universities

*Declined NIH 1981, 1989 and 1990 (x3) and MRC-Canada (1991) site visit/grant review request because of scheduling or other conflict. In addition to 1982-85 Visual Sciences A1 Study Section, 1994-2000 Glaucoma Research Foundation, and 1995-2000 Glaucoma Foundation reviews.

Editorial Responsibilities

Journal Editorial Boards

1980-89	Medstream: The Journal of Medical Therapeutics
1980-94	Current Eye Research
1989-2000	Glaucoma Forum
1990-2000	Focus on Glaucoma
1991-98	Journal of Glaucoma
1999-2009	International Glaucoma Review
2007-12	Investigative Ophthalmology & Visual Science – Editor-in-Chief

2007	Journal of Clinical Investigation – Consulting Editor
2007	Journal of Current Glaucoma Practice – Senior Editorial Advisor
2009	Clinical Pharmacology: Advances and Applications - Honorary Editorial Board
2009	Türkiye Klinikleri Journal of Medical Sciences – Advisory Board
2012	Journal of Glaucoma-Cataract (Turkey) – Advisory Scientific Board
2013-present	Clinical Pharmacology: Advances and Applications – Honorary Editorial Board
2013-present	Cell Health and Cytoskeleton – Honorary Editorial Board

Textbooks – See under Publications

<u>Journal Reviews</u>	<u>Journal</u>	<u>No. of Manuscripts</u>
1972-date*	Investigative Ophthalmology and Visual Science	101
1977-date*	Experimental Eye Research	58
1978-84	Science	1
1979	Glaucoma	1
1981-94, 96*-98*, 00, 15	Current Eye Research	47
1981-94*, 97-00*	American Journal of Ophthalmology	13
1983	Vision Research	3
1985-date*	Archives of Ophthalmology	32
1987-date*	Ophthalmology	24
1987	Archives of Internal Medicine	1
1988	Diabetes	1
1991	Journal of Pharmacology and Experimental Therapeutics	1
1991-date*	Journal of Glaucoma	26
1992	Proceedings of the Society for Experimental Biology and Medicine	1
1993,97, 2012*	British Journal of Ophthalmology	3
1994,97*	New England Journal of Medicine	3
1994,95*	American Journal of Physiology	1
1996, 2007	Survey of Ophthalmology	4
1999	Graefe's Archives of Clinical and Experimental Ophthalmology	1
1999, 2005, 2007, 2009	Proceedings of the National Academy of Sciences	5
2000	Prostaglandins & Lipid Mediators	1
2000, 2005, 2006	Eye	3
2001, 2002*	Gene Therapy	2
2001	Human Gene Therapy	1
2002	Journal of Cataract and Refractive Surgery	1
2002	Molecular Neurobiology	1
2002	European Journal of Ophthalmology	1
2002	Clinical Genetics	1
2003	American Journal of Obstetrics & Gynecology	1
2003, 05, 07	Molecular Vision	6
2004	Ophthalmic Plastic and Reconstructive Surgery	1
2003	Journal of Pharmaceutical Science	1
2004	Ophthalmic and Physiological Optics	1
2004	Cell Motility and Cytoskeleton	1
2005	The FASEB Journal	1
2005	Journal of Refractive Surgery	1
2007	Journal of Neuroscience Research	1
2007	Journal of Clinical Investigation	2
2007	Neuroscience	1
2009	J Ophthalmology	1
2010	Clin Exp Optom	1

2011	Journal of the Royal Society	1
2012	Molecular Neurobiology	1
2014	Proc Nat Acad Sci	1
2015	Biomaterials	1
2016	Advanced Materials	1

*Declined many additional requests because of scheduling conflict.

<u>Outside Reviewer</u>	<u>University</u>	<u>Number</u>
1977	University of Wisconsin-School of Pharmacy	1 ^a
1982,87,91,04,05	City University of New York, Mt. Sinai School of Medicine	5 ^b
1983,84,86,88,92,94	University of California-San Francisco School of Medicine	6 ^b
1984,86,89,95-98,2004,10, 12	University of California-San Diego School of Medicine	11 ^b
1984	University of Pennsylvania School of Medicine	1 ^b
1985,87, 2014	Columbia University College of Physicians and Surgeons	2 ^b
1986	University of South Alabama College of Medicine	1 ^b
1987,98	Yale University School of Medicine	3 ^b
1987,93	University of Louisville School of Medicine	3 ^b
1989	University of Illinois College of Medicine	1 ^b
1989	University of Minnesota School of Medicine	1 ^a
1990	West Virginia University Medical School	1 ^b
1991	University of British Columbia Graduate Faculty	1 ^a
1991	University of Louisville School of Medicine	1 ^c
1992, 98	University of Nebraska School of Medicine	2 ^b
1994	University of Erlangen-Nürnberg	1 ^b
1995	University of Southern California	1 ^b
1995, 2014	Harvard University Medical School	1 ^b
1996	Boston University School of Medicine	1 ^b
1996-2002	Washington University School of Medicine	6 ^b
1997, 2002	University of Texas Health Sci Ctr-San Antonio Medical School	2 ^b
1997, 2002, 03	Mayo Medical School/Foundation/Clinic	3 ^b
1998	Massachusetts Institute of Technology	1 ^b
1998	New York Medical College	1 ^b
1998, 2000	Oregon Health Sciences University	2 ^b
1999, 2003	Stanford University School of Medicine	2 ^b
1999, 2002	University of Michigan School of Medicine	2 ^b
2000, 2005	The Jackson Laboratory	2 ^b
2001	North Carolina State University School of Veterinary Medicine	1 ^d
2001	Faculty of Medicine, Technion-Israel Institute of Technology	1 ^b
2001	Weizmann Institute of Science, Rehovot, Israel	1 ^b
2001	Technion-Israel Institute of Technology/Faculty of Medicine Haifa, Israel	1 ^b
2002	Medical College of Wisconsin, Milwaukee	1 ^b
2002	University of North Carolina-Chapel Hill	1 ^b
2003	University of Sao Paolo	1 ^b
2003	Hebrew University of Jerusalem	1 ^b
2004	University of Toronto	2 ^b
2005	Duke University School of Medicine	1 ^b
2005	University of Maryland School of Medicine	1 ^b
2005	Chinese University of Hong Kong	1 ^b
2005	University of Pennsylvania School of Medicine	1 ^b
2006	Hadassah Medical Center – Dep't of Ophthalmology	1 ^e

2006	University of Michigan School of Medicine	1 ^b
2006	University of Toronto Faculty of Medicine	1 ^b
2008	John Hopkins University School of Medicine	1 ^b
2008	Indiana University School of Medicine	1 ^b
2009	University of Virginia School of Medicine	1 ^{b,c}
2009	Duke University School of Medicine	1 ^b
2009	SUNY Downstate Medical Center	1 ^b
2010	Medical University of South Carolina – Dep't of Ophthalmology & Storm Eye Institute	1 ^e
2011	Ben-Gurion University of the Negev	1 ^b
2011	Emory University School of Medicine	1 ^b
2012	University of Alabama-Birmingham College of Medicine	1 ^b
2015	Stanford University School of Medicine	1 ^b
2016	Duke/NUS Graduate School of Medicine	1 ^b

(a = PhD dissertation, b = Faculty promotion or hire, including Chair, c = Chairman review, d = University research award; e = External institutional review.)

Professional Society Offices

American Academy of Ophthalmology

Associate Councilor for ARVO, 1993-95 (Alternate Associate, 1993-94; Associate, 1994-95)

American Glaucoma Society

Executive Committee, Member, 1994-96

Association for Research in Vision and Ophthalmology (ARVO)

Physiology and Pharmacology Section Committee (Member, 1981-83; Chairman, 1983-84)

Glaucoma Section, Trustee, 1993-1998

Animals in Research Committee, Trustee Member, 1992-95

Executive Vice President Nominating Committee, Chairman, 1994-95

Finance Committee, Member, 1994-96; Chair 1996-99

Corporate Liaison Committee, Member, 1995-99

President Elect, 1996-97; President, 1997-98

Immediate Past President, 1998-99

Co-Chair, Advocacy Planning, 1999-date

Executive Vice President (Chief Executive Officer) – May 2001 - May 2007

Executive Committee, The ARVO Foundation, Member 05/15/02-05/15/07

Board of Governors, The ARVO Foundation for Eye Research, May 2002 – May 2009

Executive Vice President Nominating Committee, 2010

Board of Trustees, May 1993 – May 1999

Editor-in-Chief IOVS Dec 2007 – May 2012

Editors-in-Chief Nominating Committee, 2015

ARVO/American Academy of Ophthalmology

Joint Symposium Program Committee, Member, 1993-96

International Society for Eye Research

Councilor, 1992-95

Travel Fellowship Policy and Selection Committee, Chair, 1992-1993

President-Elect, 1998-2000

Finance Committee, 1998-2003

Long Range Planning Committee, 1998-2003

President, 2000-2003

National Alliance for Eye and Vision Research, Board of Directors, ARVO member, 2002-2007

Charitable Organizations

President and Member, Board of Directors, Ocular Physiology Research and Education Foundation, Inc., Madison, WI, 1989-date

Member, Board of Directors, The Glaucoma Foundation, New York, NY, 2004-date

INSTITUTIONAL SERVICE*UW Hospitals and Clinics Administration*

1975-2004 Director, Glaucoma Service
 1976-1977 Medical Director, General Eye Clinic
 1975-1985 Member and Vice Chairman (1981-85), Pharmacy and Therapeutics Committee*
 1976-1977 Member, Ambulatory Care Committee
 1992 Acting Chief, Ophthalmology Service
 2004-present Chief, Ophthalmology Service
 2004-2012 Member, UWMF Council of Chairs
 2004-present UWHC Medical Board

*Declined Chairmanship in 1982

Department of Ophthalmology Administration

1976-1978 Member, Consultation Practice Plan
 1975-1976 Member, Resident Selection Committee
 1979-1987, 1992 Member, Research and Development Fund Committee
 1980-date Member, Executive Committee
 1982-1992 Member, Long-Range Planning Committee
 1983-1985 Chairman, Full-Time/Part-Time Faculty Liaison Committee
 1987-1992 Member, External Relations Committee
 1987-1993 Member and Chairman (1987-90), Research Committee and Working Group
 1987-1994 Member, Promotion and Compensation Committee (Chairman, 1990-94)
 1987-2007 Member, Finance and Management Committee and Working Group
 1987-1994 Member, Money Purchase Pension Plan Committee
 1990-1994 Member, Construction Committee
 1992 Acting Department Chairman
 1992-1993 Member, Mission Committee
 1992-1994 Member, Basic Science Recruitment Committee
 1992-date Mentoring Committees for junior faculty
 Christopher Murphy, DVM, PhD - School of Veterinary Medicine
 Leonard Levin, MD, PhD – Department of Ophthalmology and Visual Sciences
 Robert Nickells, PhD – Department of Ophthalmology and Visual Sciences
 Bermans Iskander, MD – Department of Neurosurgery
 Andrew Thliveris, MD, PhD – Department of Ophthalmology and Visual Sciences
 1993-date Member, Research Working Group
 1996-date Member, Space Committee
 1999-2004 Co-Chair, Base Salary Adjustment Committee
 2004-2014 Peter A. Duehr Professor and Department Chair

Wisconsin Regional Primate Research Center Administration

1989-98 Member, Board of Studies
 1989-date Director, Ophthalmology Unit

Interdepartmental Training and Administration/Mentoring

1980-1985 Member, Visual Sciences Training Program Committee*
 1988 Member, Ocular Molecular Biology Training Program Committee*

1987-date Member, Neurosciences Training Program Committee*
 1990-date Member, Biology of Aging Training Program Committee*
 1998 Outstanding Mentor, UW Medical School (1 of 50)
 *NIH-supported interdepartmental pre- and postdoctoral research training programs

Campus-Wide Administration

1988-1991 Member, Center for Health Sciences Research Animals Resources Committee
 1988-1990 Member, Primate Research Planning Group
 1991-1993 Member, Primate Facility Subcommittee of the Committee for Planning Animal Research
 Facilities
 1993-1994 Member, Medical School Space Committee and Clinical Space Subcommittee
 1997-2005 Member, Ad Hoc Medical School Animal Care Per Diem Committee
 1998-2005 Member, Animal Care Unit Faculty Advisory Group
 1998 Academic Program Review Committee, Department of Surgical Sciences, School of Veterinary
 Medicine, University of Wisconsin.
 2015- Co-Chair, Forums on Animal Research Ethics (FARE) Committee, UW School of Medicine &
 Public Health and UW Graduate School.

<i>Clinical/Research Preceptor</i>	<i>Type of Trainee</i>	<i>Number</i>
1986-1988	Pre-residency clinical research fellow	1
1979-2015	Post-residency clinical glaucoma fellow	37
1982-85, 88-93, 2003-07	Pre-doctoral (PhD) graduate student	4
1984-87	Post-doctoral (DVM) laboratory research fellow graduate student (MS)	1
1982,88-91, 92-98, 02-04 2007-08	Post-doctoral (MD) laboratory research fellow	8
1978, 82-85, 87, 89-93, 03	Medical student research electees	17
1991, 92, 2003-09	Undergraduate student research electee (1-3 per semester) (Ophthalmology 699, directed study; Zoology 152)	18
1993-98,02-05	Post-doctoral (PhD) laboratory research fellow	3
2001,03	High school student research electee	2

Awards/Honors to Trainees and Research Staff

1982, 86, 87, 92, 96, 02	NEI ARVO Travel Fellowship (K. Erickson, BT Gabelt, K. Crawford, J. Robinson, J. Peterson, S. Wamsley)	6
1984, 92, 98, 00, 02	Pharmacia ISER Travel Fellowship (K. Erickson, J. Robinson, J. Peterson, B. Tian, M.A. Croft, X. Liu)	6
1989	Essilor International Award for Outstanding Research in Presbyopia (K. Crawford, M. Neider)	1
1989-91	NIH Individual National Research Service Award (J. Robinson)	1
1993	UW Medical Student Research Accomplishments Award (M. Oyen)	1
1993	Alexander von Humboldt-Stiftung Research Fellowship (J. Poyer)	1
2000, 03, 04	UW Academic Staff Professional Development Grant (B. Tian, B. Gabelt, C. Rasmussen)	3
2005	Chancellor's Academic Staff Award for Excellence in Research (B. Gabelt)	1
2006	Helen Keller Foundation/Pfizer Ophthalmics Research Award in Glaucoma (Xuyang Liu)	1
2007	UW medical student award – glaucoma & skin cancer research – Soma Ray	1
2010	UW Academic Staff Professional Development Grant (C. Rasmussen)	1

Graduate Degrees Granted

1983, 90, 03, 05, 07, 08	MS, Pharmacology, Veterinary Sciences, Biomedical Engineering, Comparative Biomedical Sciences	6
1985, 92, 93	PhD, Pharmacology - 2; Veterinary Sciences - 1	3

Graduate Students/Fellows in Full-Time Academic Positions

1983-2015	Clinician researchers (BE Klein, JG Feghali, WE Sponsel, JC Robinson, C Kee, CM Hutnik, James Tan, Gillian McLellan)	6
1982-85, 96-98	Basic scientists (K Erickson-Lamy, A. Glasser)	2
1984-87	Veterinary Ophthalmologic Clinicians (JP Pickett)	1
1991, 92, 2003-14	Undergraduate student research electee (1-3 per semester (Ophthalmology 699, directed study; Zoology 152)	24

POSTGRADUATE MEDICAL COURSES (invited)

1. Washington University, St. Louis, MO, December 1, 1979 and April 27, 1980. Lectures: 1) Pre- and postoperative management; 2) Individual surgical instruction. Krupin-Denver Glaucoma Eye Valve Implantation.
2. American Academy of Ophthalmology North Central Regional Update Course, Chicago, IL, April 15, 1988. Lectures: 1) Medical treatment of open angle glaucoma; 2) Neovascular glaucoma; 3) and 4) Panel Discussions - Questions & Answers, I & II.
3. American College of Surgeons, 1988 Clinical Congress, Specialty Program for Ophthalmology, Chicago, IL, October 25, 1988. Lecture: Glaucoma following trauma. Ophthalmic Surgery: Ocular trauma in children and adults.
4. Horizons in Ophthalmology, Second Annual Meeting, University of Illinois-Chicago Eye Center, Chicago, IL, September 14, 1990. Lectures: 1) Physiologic mechanisms underlying the medical therapy of glaucoma; 2) Neovascular glaucoma.
5. Annual Fall Symposium, Current Concepts in Ophthalmology, Department of Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee, WI, November 8-9, 1991. Lectures: 1) Medical therapy of glaucoma: until the millennium; 2) Surgical therapy of glaucoma: until the millennium.
6. Glaucoma, Department of Ophthalmology, University of Indiana, Indianapolis, IN, September 19, 1992 (declined due to scheduling conflict).
7. New Horizons in Glaucoma II: α -Adrenergic Agonists in Glaucoma Therapy. Devers Eye Institute and Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, September 24, 1994. Lecture: Effects on aqueous humor dynamics.
8. Thorny Issues in Ophthalmology: Physiology and Treatment of Myopia. Devers Eye Institute and Legacy Good Samaritan Hospital and Medical Center, Portland, OR, May 31-June 1, 1996. Lectures: 1) Physiological strategies for emmetropia; 2) Presbyopia - a closer look; 3) Aging, accommodation and outflow facility.
9. New Horizons in Glaucoma III. The Optic Nerve in Glaucoma: Structure, Function and Protection. Devers Eye Institute and Legacy Good Samaritan Hospital and Medical Center, Portland, OR, November 7-8, 1997. Lecture: Discussion (moderator): The optic nerve in glaucoma.
10. Winter Glaucoma Symposium. University of Illinois - Chicago Eye Center, Grand Cayman, British West-Indies, February 15-17, 1998. Lectures: 1) Prostaglandins and aqueous humor dynamics; 2) Gene therapy for glaucoma: anterior and posterior segment targets, delivery systems, constraints; 3) Cytoskeletal and cell junctional mechanisms in aqueous outflow; 4) Case presentations.
11. Clinical Day in Ophthalmology. Glaucoma at the Millennium: Modern Approaches to Diagnosis and Therapy. Long Island Jewish Medical Center/North Shore University Hospital/Albert Einstein College of Medicine/New York University School of Medicine, October 21, 1998. Lectures: 1) A perspective on neuroprotection in glaucoma; 2) Gene therapy for glaucoma: anterior and posterior segment targets, delivery systems, constraints.

12. Sixteenth Annual Research Day & First Annual Alumni Day, Department of Ophthalmology, University of British Columbia, Vancouver, BC, Canada, May 12-13, 2000. Lectures: 1) Cytoskeletal and cell junctional modulation of aqueous humor outflow; 2) Prostaglandins and aqueous humor dynamics; 3) Lam DY, To E, Prasad SS, Kaufman PL, Matsubara JA: Identification of a novel anatomical marker for the magnocellular processing stream.
13. Seventy-second Annual Ophthalmology Spring Postgraduate Conference. Glaucoma: Questions and Answers for Your Practice. Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, May 19-20, 2000. Lectures: 1) Prostaglandin mechanisms in aqueous humor dynamics; 2) Cytoskeletal, cell junctional and extracellular matrix mechanisms in aqueous outflow (for the clinician); 3) Panel discussion – questions and answers: Medical management of glaucoma; 4) Normal tension glaucoma; what's it all about?; 5) Case presentations to panel; 6) Panel discussion – questions and answers: surgery; 7) Gene therapy for glaucoma: anterior and posterior segment targets and constraints; 8) Panel discussion – questions and answers: using genetic information in your glaucoma practice.
14. East Coast Glaucoma Symposium: Contemporary Issues in Glaucoma Diagnosis and Therapy, New York Eye and Ear Infirmary/New York Medical College and University of Medicine and Dentistry of New Jersey, New York, NY, June 2-3, 2000. Lectures: 1) Cytoskeletal and cell junctional modulation of aqueous outflow; 2) Gene therapy for glaucoma: Anterior and posterior segment targets and constraints.
15. Nebraska Eye Physicians and Surgeons 2001 Annual Meeting – 2 lectures – Sept. 21-22, 2001, Omaha, Nebraska - declined due to scheduling conflict.
16. Hawaii Ophthalmological Society Midwinter Seminar, Honolulu, Hawaii, February 16-18, 2003. Lectures: 1) Pathophysiology of glaucoma – anterior segment events and the role of IOP; 2) Pathophysiology of glaucoma – posterior segment events; 3) Current pharmacotherapy of glaucoma; 4) Future pharmacotherapy of glaucoma.
17. Tidewater Ophthalmological Society, Norfolk, Virginia, January 29, 2004. Lecture: Medical therapy of glaucoma in the future.
18. Medical College of Virginia/Virginia Commonwealth University/Richmond Ophthalmological Society, Richmond, Virginia, January 28, 2004. Lecture: Medical therapy of glaucoma in the future.
19. Yale Glaucoma Symposium, New Haven, CT, October 1, 2004. Presentations: 1) A closer look at aqueous outflow: trabecular meshwork, cytoskeleton, and cellular contractility; 2) Aqueous outflow targets: uveoscleral outflow, prostaglandins, extracellular matrix; 3) Gene therapy for glaucoma: Where are we, where are we going?
20. Form and Function in Ocular Disease, a multidisciplinary clinical and basic science symposium to commemorate the 25th anniversary of the Eye Care Centre. Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, Canada, October 1-2, 2004. Presentation: Physiology, pharmacology and therapeutics of aqueous humor outflow.
21. Ophthalmology Update: From Front to Back. University of Illinois at Chicago, University of Iowa, Washington University St. Louis, Cancun, Mexico, February 8-10, 2006. Lectures: 1) Central nervous system changes in glaucoma; 2) Gene therapy for glaucoma.
22. Annual Buffalo Glaucoma Symposium, 14th Edition, Dep't of Ophthalmology, University of Buffalo School of Medicine, Buffalo, NY, September 29, 2006. Lectures: 1) Gene therapy for Glaucoma; 2) Uveoscleral outflow – what it is, age and species variations; 3) Prostaglandin analogues – how and why they work; 4) Cytoskeletal drugs for glaucoma; 5) Neuroprotection for glaucoma – where are we?; 6) Brain changes in glaucoma; 7) How our drugs work; 8) Future needs – IOP fluctuation/continuous monitoring, posterior segment drug delivery, watching RGC die in vivo.
23. 31st Annual Midwest Glaucoma Symposium & 16th Annual Gifford/Truhlsen Alumni and Residents Day 2008. University of Nebraska, Omaha, NE, May 16-17, 2008. Presentations: 1) and 2) Medical therapy for glaucoma – the next 20 years; Part I and Part II; 3) Moderator, Current Research in Glaucoma.
24. University of Illinois Eye & Ear Infirmary / Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago, 32nd Annual Alumni Day & 150th Anniversary Celebration, June 20-21, 2008. Presentation: Medical therapy for glaucoma: the next 20 years.

25. University of Florida Department of Ophthalmology / Vision Center, Gainesville, Florida, March 8-9, 2010. Symposium: Development and Delivery of Therapeutic Agents for the Eye. Presentation: 1) A New Ocular Drug; 2) Medical Therapy for Glaucoma in the Future.
26. Mt. Sinai School of Medicine – CUNY Department of Ophthalmology, New York, NY, June 3, 2011. Annual Steven M. Podos, MD, Symposium and Lecture, Innovations in Ophthalmology: Glaucoma & Retina. Presentations: 1) The Glaucoma Treatment Trials – What They Teach Us; 2) Steven M. Podos, MD Lecture: Glaucoma Medical Therapy: Where we Were, Where We Are, Where We Will Be.
27. University of Florida Department of Ophthalmology / Vision Center, Gainesville, Florida, September 19-20, 2011. Symposium: Development Advances in Neuroprotection of the Eye: Presentation: Viral gene transfer for neuroprotections.
28. SUNY Downstate Medical Center Department of Ophthalmology, Brooklyn, New York. Current Concepts in Ophthalmology 2013, Atlantic City, NJ, January 4-5, 2013. Presentations: 1) Drug delivery – beyond eye drops; 2) Gene therapy for glaucoma; 3) Presbyopia – up close; 4) Panel discussion.

VISITING PROFESSORSHIPS (invited)

1. Karolinska Hospital and Institute, Stockholm, Sweden, August 31, 1976. Lecture: New aspects of cholinergic drugs.
2. University of Chicago, Chicago, IL, January 5, 1977. Lecture: Cholinergic drugs: New slants on old friends.
3. University of Illinois Eye and Ear Infirmary, Chicago, IL, March 23, 1977. Lectures: 1) Physiology and pharmacology of aqueous humor drainage I; 2) Physiology and pharmacology of aqueous humor drainage II; 3) Grand Rounds.
4. Mayo Clinic, Rochester, MN, March 28, 1977. Lectures: 1) Echothiophate-induced cataracts in primates; 2) Residents' Conference.
5. Bascom Palmer Eye Institute, University of Miami, Miami, FL, June 15-17, 1977. Lectures: 1) Cholinergic drugs - new slants on old friends; 2) Physiology and pharmacology of aqueous humor drainage.
6. University of Washington, Seattle, WA, October 26-27, 1977. Lectures: 1) Studies of aqueous humor outflow in primates; 2) Ocular hypertension: when to treat.
7. Loyola University, Chicago, IL, April 15, 1981. Lectures: 1) Neovascular glaucoma - current concepts in pathogenesis and management; 2) Dipivefrin; 3) Low tension glaucoma.
8. Medical College of Wisconsin, Milwaukee, WI, May 28, 1981. Lecture: Systemic effects of ocular medications.
9. Medical College of Virginia, Richmond Eye and Ear Hospital Annual Ophthalmological Symposium, Richmond, VA, September 11, 1982 (declined due to scheduling conflict).
10. University of Cincinnati, Cincinnati, OH, May 11, 1983. Lectures: 1) Cholinergic drugs: new slants on old friends; 2) Neovascular glaucoma: diagnosis and management.
11. Cincinnati Ophthalmological Society, Cincinnati, OH, May 11, 1983. Lecture: Low-tension glaucoma.
12. Massachusetts Eye and Ear Infirmary, Harvard University, Boston, MA, September 20-21, 1983. Lecture: Drug mechanisms in the outflow system.
13. Columbia University, New York, NY, February 14-15, 1984. Seminar on Aging: The development of presbyopia and presbyopia in the rhesus monkey. Lecture: Experimental ophthalmic techniques.
14. Annual Meeting of the British Columbia Society of Eye Physicians and Surgeons: The Basis for the Medical Treatment of the Glaucomas. University of British Columbia, Vancouver, British Columbia, Canada, May 10, 1984. Lecture: The current status of the cholinergic agents.
15. Seminar on Future Trends in Ophthalmic Research, Merck Sharp & Dohme-Chibret Inc., Branchburg, NJ, March 18, 1985. Lecture: Glaucoma.
16. Anatomic-Ophthalmologic Colloquium, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, West Germany, July 23, 1986. Lecture: Cholinergic mechanisms of the anterior segment of the eye.
17. Freiburg Ophthalmologists' Evening, Albert-Ludwig University of Freiburg, Freiburg, West Germany, August 1, 1986. Lecture: Cholinergic mechanisms in the anterior segment of the eye.
18. Washington University, St. Louis, MO, February 25-26, 1988. Lectures: (1-3) Clinical physiology of the ciliary muscle and trabecular meshwork I-III; 4) Professor's Rounds; 5) Grand Rounds; (6,7) Residents' Luncheon I, II.

19. St. Louis Ophthalmological Society, St. Louis, MO, February 25, 1988. Lecture: Presbyopia: A closer look.
20. University of Minnesota, Minneapolis, MN, January 30, 1989. Lecture: Clinical physiology of the anterior segment.
21. Georgetown University, Washington, DC, February 22, 1989. Lectures: (1-3) Clinical physiology of the anterior segment I-III; 4) Ciliary muscle aging: pathophysiologic and therapeutic implications for presbyopia, pseudophakia, and glaucoma; 5) Glaucoma following trauma.
22. West Virginia University, Morgantown, WV, May 31, 1989. Lectures: 1) Clinical physiology of the anterior segment; 2) Prostaglandins and aqueous humor dynamics; 3) Accommodation, presbyopia, and primary open angle glaucoma: A closer look.
23. Texas Ophthalmological Society, Austin, TX, October 6, 1989 (declined due to scheduling conflict).
24. Dallas Ophthalmological Society, Dallas, TX, March 21, 1990 (declined due to scheduling conflict).
25. University of Toronto, Toronto, Ontario, Canada, September 6-7, 1989. Lecture: Prostaglandins and aqueous dynamics.
26. Lectures: 1) Prostaglandins and aqueous humor dynamics; 2) Grand Rounds. University of Pittsburgh, Pittsburgh, PA, October 25-26, 1989.
27. District of Columbia Ophthalmological Society, Washington, DC, November 13, 1989 (declined due to scheduling conflict).
28. Massachusetts Eye and Ear Infirmary, Harvard University, Boston, MA, September 7, 1990. Lecture: How and why prostaglandins lower intraocular pressure and increase uveoscleral outflow.
29. Turkish Ophthalmological Society - Turkish National Glaucoma Symposium, Ankara, Turkey, April 10-11, 1992. 1) Lecture: Medical therapy of glaucoma: Physiological principles, current strategies, and outlook until the millennium; 2) Live surgery: Krupin valve implantation in traumatic/neovascular glaucoma.
30. University of California-San Diego, San Diego, CA, December 7, 1992 (declined due to scheduling conflict - may reschedule for 1993).
31. University of Oregon Health Sciences University, Portland, OR, March 4-6, 1993 (declined due to scheduling conflict).
32. Distinguished Vision Scientist Seminar Series, Tufts University, Boston, MA, March 23, 1993. Lecture: Presbyopia and prostaglandins: new roles for the ciliary muscle.
33. University of Chicago, Chicago, IL, April 7, 1993. Lecture: Prostaglandins and aqueous humor dynamics.
34. Duke University, Durham NC, June 3-4, 1993 (declined due to scheduling conflict).
35. Washington University, St. Louis, MO, December 2, 1993. Lectures: 1) Presbyopia: a closer look; 2) Should antimetabolites be used routinely in glaucoma filtration surgery?; 3) The Fourth Bernard Becker Lecture: Prostaglandins and aqueous humor dynamics.
36. University of Florida, Gainesville, FL, December 22-23, 1993. Lecture: Prostaglandins and aqueous humor dynamics.
37. University of California, San Francisco, CA, February 10, 1994. The Second Senju Lecture: Presbyopia and glaucoma: new roles for the ciliary muscle.
38. Schepens Eye Research Institute - Harvard University, Boston, MA, March 17, 1994. The Broadhurst Lecture: Prostaglandins and aqueous humor dynamics.
39. University of British Columbia, Vancouver, BC, Canada, December 8-9, 1994. Lectures: 1) Glaucoma Think Tank: Contractile mechanisms, cytoskeleton, and extracellular matrix in outflow pathways as targets for new glaucoma therapies; 2) Grand Rounds: New ocular hypotensive agents: prostaglandins, α_2 -adrenergic agonists, topical CAIs.
40. Brooke Army Medical Center, Ft. Sam Houston; Wilford Hall Medical Center, Lackland Air Force Base; University of Texas Health Science Center at San Antonio; all at San Antonio, TX, December 15-16, 1994. Lectures: Patient examinations and discussions at BAMC (12/15) and UTHSCA (12/16). Lectures 3): Anterior ocular segment physiology and pharmacology: an integrated basic and clinical approach to understanding function and dysfunction - I, II, III.
41. Mt. Sinai Medical Center - City University of New York, New York, NY, September 15, 1995. The First Irving H. Leopold Lecture: Pharmacologic trabeculocanalotomy: facilitating aqueous outflow by assaulting meshwork cytoskeleton, junctional complexes, and extracellular matrix.

42. University of Washington, Seattle, WA, October 24, 1995. Lectures: 1) Prostaglandins and aqueous humor dynamics; 2) Presbyopia: A closer look; 3) Trusopt® (dorzolamide): Clinical efficacy, safety and tolerability.
43. University of Erlangen-Nürnberg, Erlangen, Germany, January 12, 1996. Lecture: Cytoskeletal control and modulation of aqueous outflow/Pharmacologic trabeculocanalotomy.
44. Tel Aviv University - Ichilov Hospital, Tel Aviv, Israel, March 10, 1996. Lectures: Outflow enhancement in the next decade: 1) Prostaglandins and aqueous humor dynamics; 2) Cytoskeletal drugs.
45. Leeds University/General Infirmary, Leeds, United Kingdom, July 2, 1996. Brian Harcourt Memorial Lecture: Contractile, cytoskeletal, and cell junctional mechanisms in aqueous outflow.
46. University of California, Davis and Sacramento, CA, November 15, 1996. 1) Grand Rounds: Patient presentations and discussions; 2) The Senju Lecture: Pharmacological enhancement of aqueous outflow; 3) Physiology Department Seminar: Cytoskeletal and cell junctional mechanisms in aqueous outflow.
47. University of Missouri, Columbia, MO, January 24-25, 1997. 1) Lecture: Presbyopia: A closer look; 2) Grand Rounds: Patient presentations and discussions; 3) Lecture: Prostaglandins and aqueous humor dynamics; 4) Lecture: Contractile, cytoskeletal and cell junctional mechanisms in aqueous outflow.
48. University of California-San Diego, San Diego, CA, April 3-4, 1997. 1) Lecture: Contractile, cytoskeletal and cell junctional mechanisms in aqueous outflow; 2) Lecture: Prostaglandins and aqueous humor dynamics; 3) Meetings with faculty.
49. Stritch School of Medicine, Loyola University, Chicago, IL, April 9, 1997. 1) Sixth Annual Arthur Light Memorial Glaucoma Lecture: Pharmacologic enhancement of aqueous outflow; 2) Patient presentations and discussion.
50. Emory University School of Medicine, Atlanta, GA, April 1-2, 1999. 1) H. Talmage Dobbs Jr. Lecture: Cytoskeletal and cell junctional modulation of aqueous outflow; 2) Grand Rounds Lecture: Prostaglandins and aqueous humor dynamics.
51. Free University of Berlin, Berlin, Germany, November 22, 1999. Lecture: Glaucoma therapy beyond the millennium.
52. University of Erlangen-Nürnberg, Erlangen, Germany, November 23, 1999. Lecture: Glaucoma therapy beyond the millennium.
53. Scheie Eye Institute-University of Pennsylvania, Philadelphia, PA, January 28-29, 2000. Lectures: 1) Presbyopia a closer look; 2) Glaucoma therapy beyond the millennium; 3) Prostaglandins & aqueous humor dynamics.
54. Canji, Inc., San Diego, CA, January 26-27, 2000. Lecture: Glaucoma and other ocular targets for gene therapy.
55. University of Iowa, Iowa City, IA, February 4, 2000. Lectures: 1) Prostaglandins and aqueous humor dynamics; 2) Glaucoma therapy beyond the millennium; 3) Case discussions.
56. University of Ottawa, Ottawa, Ontario, Canada, November 12, 2000. Lectures: 1) Grand Rounds: Medical therapy of glaucoma in the future; 2) Prostaglandin mechanisms in aqueous humor dynamics; 3) Gene therapy for glaucoma: anterior and posterior segment targets and constraints; 4) Presbyopia – a closer look; 5) Ophthalmic technology student seminar.
57. Tufts University/Tufts Center for Vision Research/New England Eye Center, Boston, MA, January 9, 2001. Lecture: Medical therapy of glaucoma in the future: targets and strategies. Frontiers in Vision Science Seminar Series.
58. Wilmer Distinguished Visiting Lecturer Series, Johns Hopkins University/Wilmer Institute, Baltimore, MD, January 19-20, 2001. Lectures: 1) Medical therapy of glaucoma in the future; 2) Round table discussions with research fellows and faculty.
59. New England College of Optometry, Boston, MA, February 23, 2001. 1) Patient teaching with students; 2) Research Lecture Series. Lecture: Therapy of glaucoma in the future: neuroprotection and gene therapy.
60. Ophthalmology 2000-2001 Saturday A.M. Lecture Series, Washington Hospital Center/Washington National Eye Center, Washington, DC, February 24, 2001. Lectures: 1) Therapy of glaucoma in the future I: cytoskeletal, cell junctional and prostaglandin/extracellular matrix approaches to lowering intraocular pressure; 2) Therapy of glaucoma in the future II: neuroprotection and gene therapy.
61. University of Miami/Bascom Palmer Eye Institute Alumni Association, 37th Annual Residents' Days Meeting Honoring Douglas R. Anderson, MD, Miami, FL, June 21-22, 2001. Special Guest Lecturer, Glaucoma Symposium. Invited Lecture in Honor of Douglas R. Anderson, MD: Neuroprotection in glaucoma: what do we know and what can we do today and tomorrow.

62. Hiroshima University, Hiroshima, Japan, October 16, 2001. Lecture: Medical therapy for glaucoma in the new millennium: concepts.
63. University of Erlangen-Nürnberg, Erlangen, Germany, February 10-13, 2002. Lecture: Viscocanalostomy.
64. Manhattan Eye, Ear & Throat Hospital/Lenox Hill Hospital/New York University, New York, NY, March 26, 2002. Lectures: 1) Prostaglandins, aqueous humor dynamics and glaucoma therapy; 2) The Julius Silver Lecture: Drug mechanisms in glaucoma therapy today and tomorrow.
65. Mt. Sinai School of Medicine, New York, NY, March 27, 2002. Grand Rounds Lecture: Drug mechanisms in glaucoma therapy today and tomorrow.
66. Mayo Clinic/Medical School/Foundation – Molecular Medicine Program, Rochester MN, Nov. 6-7, 2002. Lecture: Molecular therapy of glaucoma – where we are, where we are going.
67. Ophthalmology 2003: What’s Hot and What’s Not! University of California-San Francisco, December 5-6, 2002. Lectures: 1) Prostaglandins, aqueous dynamics and glaucoma; 2) The 2002 Proctor Lecture: Medical therapy of glaucoma in the future.
68. University of Houston College of Optometry 50th Anniversary Symposium. Critical Issues in Optometry and Vision Science, Houston, TX, March 1-3, 2003. Lecture: Mechanisms of accommodation.
69. University of Miami School of Medicine/Bascom Palmer Eye Institute, Miami, FL, September 2-3, 2003. 1) Clinical/Basic Science Lecture: Medical therapy of glaucoma in the future. 2) Meetings with multiple faculty members.
70. East Virginia Medical School, Norfolk, VA, January 29, 2004. Presentations: 1) Grand Rounds – Patient presentations; 2) Lecture: Prostaglandins and aqueous humor dynamics.
71. Allergan, Inc. Irvine, CA, July 16, 2004. Presentation: The Irving H. Leopold Award Lecture: Targeting the trabecular meshwork cytoskeleton, cell adhesion and cell contractility: small molecule and gene transfer strategies for enhancing conventional outflow.
72. Scheie Eye Institute – University of Pennsylvania, 131st Anniversary Meeting, Philadelphia, PA, May 19-21, 2005. Presentations: 1) Medical therapy of glaucoma: The present and the future; 2) Presbyopia: A closer look.
73. Columbia University College of Physicians & Surgeons, New Frontiers in Clinical Glaucoma II, New York, NY, May 11-12, 2005. Presentations: 1) Current and future aqueous outflow enhancers; 2) Presbyopia: a closer look.
74. University of Rochester School of Medicine, Grand Rounds / Bausch & Lomb Visiting Professor Series, Rochester, NY, March 18, 2006. Presentations: 1) Patient presentations / discussion; 2) Medical therapy of glaucoma – what’s next?; 3) Presbyopia – a closer look.
75. University of British Columbia Faculty of Medicine, UBC Department of Ophthalmology and Visual Sciences, 22nd Annual Research Day, Vancouver, BC, Canada, April 21, 2006. Presentations: 1) Medical therapy for glaucoma: the next 20 years; 2) Selection committee for best trainee papers.
76. University of Alabama-Birmingham/Callahan Eye Foundation Hospital, Birmingham, Alabama, May 16-17, 2006. Presentations: 1) Glaucoma Conference with fellows; 2) Rich Distinguished Lecture Series: The future of glaucoma therapy: from drugs to genes; 3) Conference with graduate students/post doctoral fellows; 4) Meetings with faculty.
77. Duke University Eye Center, Durham, NC, November 29, 2006. 1) Duke Dinner Series - Lecture: Drug discovery in glaucoma; 2) Meetings with faculty and trainees.
78. Washington University School of Medicine, St. Louis, MO, February 14, 2007. Presentations: 1) Residents - Career choices, antimetabolites for all patients?; Management of normal tension glaucoma, what would be the role of a neuroprotectant?; 2) Medical therapy of glaucoma – the next 20 years. [Inaugural Michael E. Kass Lecture]
79. Stanford University Medical School, Palo Alto, CA, March 6, 2007. Presentations; 1) Grand Rounds: Medical therapy of glaucoma: where next?; 2) Residents - Antimetabolites for all patients?, management of normal tension glaucoma, what would be the role of a neuroprotectant?
80. University of Toronto, Dep’t of Ophthalmology & Vision Sciences, Toronto, Ontario, Canada, June 15, 2006. 49th Annual Research Day, 26th Clement McCulloch Lecture: Medical Therapy for Glaucoma – the next 20 years.

81. University of Louisville, Louisville, KY, January 18, 2008. Presentations: 1) Grand Rounds Patient Discussions; 2) UL Grand Rounds: Medical therapy of glaucoma - where next? 3) UL Research Seminar: Cytoskeletal drug therapy for glaucoma: from cells to drugs to genes.
82. University of Texas Southwestern Medical School – John R. Lynn, MD Lectureship in Ophthalmology, Dallas, Texas, May 10, 2008. Presentations: 1) Medical Therapy for Glaucoma – The Next 20 Years; 2) Panel Discussion.
83. Kyoto Prefectural University, Dep't of Ophthalmology, August 4, 2008. Lecture: Medical Therapy for Glaucoma – The Next 20 Years.
84. New York Eye & Ear Infirmary / New York Medical College, Dept of Ophthalmology, February 19-20, 2009. Lectures: 1) Medical Therapy for Glaucoma – The Next 20 Years; 2) Grand Rounds: The Pathophysiology of Presbyopia: Fact vs Fiction – A Closer Look.
85. University of Western Ontario, London, Ontario, Canada, March 24-25, 2009. 1) Ophthalmology Grand Rounds – Lecture: Medical Therapy of Glaucoma – The Next 20 Years; 2) Resident Teaching Sessions: Lecture: Presbyopia - Up Close; The Pathophysiology of Presbyopia: Fact vs. Fiction; 3) Resident Teaching Sessions: Case and Assorted Topic Discussions; 4) Lawson Institute Research Day: Poster Judge.
86. Duke University, Distinguished Visiting Speaker, Dept of Ophthalmology & Visual Sciences, Duke Eye Center, Residents' & Fellows' Day, Durham, NC, June 26-27, 2009. Lectures 1) Medical Therapy for Glaucoma – The Next 20 Years; 2) The Pathophysiology of Presbyopia – Fact or Fiction: A Closer Look
87. Aravind Eye Care System, Madurai, Tamil Nadu (simulcast to 4 other hospitals), India, January 13, 2009: Lecture: Medical therapy for glaucoma for glaucoma: the next 20 years.
88. Yale University, New Haven, CT, Department of Ophthalmology & Visual Science, Pfizer MAP Visiting Professorship (competitive national award), September 1-3, 2009. Presentations: 1) Residents Lecture: “Recent developments in understanding the pathophysiology of elevated intraocular pressure”; 2) Research Talk: “The role of actomyosin system in regulating trabecular fluid flow”; 3) Yale Eye Center Clinical Conference: a) Resident case presentations; b) Lecture: “Presbyopia: Up Close”; 3) Individual meetings with faculty and residents/fellows.
89. Tulane University, New Orleans, Louisiana, June 11, 2010. CS O'Brien Professor, Resident Graduation and Resident Research Day. Declined due to conflict with UW Residents' Day.
90. University of Toronto, Toronto, Ontario, Canada, November 18-19, 2010. Presentations: 1) Grand Rounds, discussion of case presentations; 2) Lecture: Future medical therapy for glaucoma; 3) Lecture: Presbyopia – up close.
91. Columbia University / Harkness Eye Institute, New York, NY March 15, 2012: Presentations: 1) Discussant at Residents Quiz and Case Presentation; 2) 15th Annual Ulrich Ollendorff Lecture: Presbyopia – Up Close.
92. Research Grants Council / General Research Fund / Early Career Scheme / External Advisor / University of Hong Kong / Hong Kong, China, September 3-4, 2012. Presentations: 1) Guides on writing grant proposals; 2) Presbyopia – Up Close
93. University of Kentucky Translational Minisymposium Lecture Series, Lexington, Kentucky, April 12, 2012. Presentations: 1) Mechanisms of aging and glaucomatous damage within the trabecular meshwork and ciliary muscle; 2) Why do glaucoma medications reduce IOP? Hint: it is not so that we can treat our patients and not so that drug companies can prosper; 3) Presbyopia – Up close.
94. Vietnam National Institute of Ophthalmology, April 17-18, 2013. Presentations: 1) Anatomy and pathophysiology of aqueous humor outflow and glaucoma; 2) Glaucoma patient presentations by faculty and residents; 3) Presbyopia – up close.
95. University of Regensburg Institute of Human Anatomy and Embryology, Regensburg, Germany, June 3-6, 2014. 1) One-on-one critique of individual graduate student research – 8 students; 2) Group lunch with graduate students; 3) 2014 Vielbert Lecture on Eye Research: The Biological Basis for Medical Therapy of Glaucoma – Today and Tomorrow. 4) Discussions on collaborations with Prof. Dr. Ernst Tamm.
96. Singapore Eye Research Institute / Singapore National Eye Center, Singapore, February 10 & 11, 2015. Presentations: 1) to residents: Getting published: What is the journal editor looking for?; 2) CME seminar: Presbyopia: Up close.
97. National Eye Institute / National Institutes of Health, Bethesda, Maryland April 29, 2015. Concept Group Presentation: Travails of anterior segment gene transfer.

98. National Eye Institute / National Institutes of Health, Bethesda, Maryland May 19, 2015. Clinical Scientist
Lecture Presentation: Presbyopia – Up Close.
99. Albert Einstein College of Medicine / Montefiore Medical Center, June 17, 2015. XXII Annual Paul Henkind Day
& XXXV Annual George. N. Wise Memorial Lecture. Presentation: Presbyopia: Up Close.
100. National Eye Institute / NIH Global Health Interest Group / National Institutes of Health, Bethesda, Maryland,
July 6, 2015: Global Health Vision Lecture - How can gene therapeutics help address global health issues?
101. Singapore Mechanobiology Institute, National University of Singapore, Singapore, August 20, 2015.
Presentation: Aqueous humor drainage from the eye: From passive filter to active mechanosensitive regulator
in 2 generations.
102. Singapore Eye Research Institute / Singapore National Eye Center, Singapore, August 24, 2015. Presentation:
Glaucoma gene therapy.
103. Singapore Eye Research Institute / Singapore National Eye Center, February 20, 2017. Presentation: Why and
how I became a clinician-scientist – lessons learned from a lifetime.

Numerous other invitations declined due to scheduling conflicts.

INTERNATIONAL PRESENTATIONS (* = invited)

1. *Bárány EH, Kaufman PL: Attempts to study the pharmacology of the trabecular meshwork in monkeys.
International Glaucoma Symposium, University of Wurzburg, Wurzburg, West Germany, October 13, 1974.
2. Kaufman PL: Subsensitivity to pilocarpine despite maintenance of maximal cholinergic response in primate
ciliary muscle following topical anticholinesterase treatment. Association for Eye Research, 15th meeting,
Wurzburg, West Germany, October 16, 1974.
3. Bárány EH, Kaufman PL: Pharmacology of the trabecular endothelium in monkey eyes with disconnected ciliary
muscle. Jerusalem Conference on Primatology, Jerusalem, Israel, February 24-26, 1975.
4. Kaufman PL, Bárány EH: Drug effects on outflow facility following ciliary muscle disinsertion and
retrodisplacement in monkeys. Swedish Planning Group for Studies of Circulation and Nutrition of the Eye,
Uppsala, Sweden, June 1975.
5. Kaufman PL, Axelsson U, Bárány EH: Echothiophate cataractogenesis in monkeys. Swedish Planning Group for
Studies of Circulation and Nutrition of the Eye, Uppsala, Sweden, June 1975.
6. Svedbergh B, Bill A, Kaufman P, Lütjen-Drecoll E: Effects of cytochalasin B and EDTA on the anterior ocular
segment. Swedish Ophthalmological Society, Sundsvall, Sweden, September 29, 1978.
7. *Kaufman PL: Presentations: 1) Adrenergic drug effects on outflow facility following ciliary muscle disinsertion
in the Cynomolgus monkey; 2) Update on the use of carbonic anhydrase inhibitors. International Glaucoma
Congress IV, Orlando, FL, March 9-10, 1980.
8. *Kaufman PL: Cell biology of the trabecular meshwork: Introduction. Symposium and Workshop on Cell
Biology of the Trabecular Meshwork, International Society for Eye Research, Fourth International Congress
of Eye Research, New York, NY, September 29, 1980 (Symposium and Workshop organizer/chairman).
9. Bito LZ, Kaufman PL, DeRousseau CJ, Bito JW: Development and aging of the eye: I. Accommodative range,
lenticular growth, development of presbyopia, and occurrence of senile cataracts and ocular hypertension in
rhesus monkeys. International Society for Eye Research, Fourth International Congress of Eye Research,
New York, NY, October 1, 1980.
10. Kaufman PL, Rentzhog L, Bárány EH: Adrenergic drug effects on aqueous outflow facility in monkeys.
International Society for Eye Research, Fourth International Congress of Eye Research, New York, NY,
October 2, 1980.
11. *Kaufman PL: Cytochalasin B and D dose-outflow facility response relationships in the Cynomolgus monkey.
Symposium on Basic Aspects of Glaucoma Research, University of Erlangen-Nürnberg, Erlangen, West
Germany, September 17-19, 1981.
12. *Kaufman PL: Cytochalasins and aqueous outflow. Symposium on Trabecular Meshwork Biology, Fifth Annual
North American Glaucomatologists' Learning Ensemble (ANGLE), Sedona, AZ, March 29-31, 1982.
13. *Kaufman PL: The development of presbyopia. Twelfth Cambridge Ophthalmological Symposium: The Lens,
St. John's College, Cambridge, England, September 9-10, 1982.

14. *Kaufman PL: 1) Biology of the trabecular meshwork: recent advances; 2) Cytochalasins and the trabecular meshwork: current status. Symposium on the Biology of the Trabecular Meshwork, International Society for Eye Research, Fifth International Congress of Eye Research, Eindhoven, The Netherlands, October 4-8, 1982 (Symposium moderator and lead discussant).
15. Bito LZ, Kaufman PL, DeRousseau CJ: Presbyopia: the development and aging of the optical system of the rhesus eye. Symposium on Lens Accommodation and Presbyopia, International Society for Eye Research, Fifth International Congress of Eye Research, Eindhoven, The Netherlands, October 8, 1982.
16. *1) Lütjen-Drecoll E, Kaufman PL: Effects of miotics on the trabecular meshwork; 2) Krupin TH, Kaufman PL, Mandell AI, Ritch R, Terry SA, Podos SM, Becker B: Valve implants in the filtering surgery for eyes with neovascular glaucoma: long term results. Glaucoma Symposium, Glaucoma Society of the International Congress of Ophthalmology, Carmel and San Francisco, CA, October 24-29, 1982.
17. Gonnering RS, Erickson KA, Kaufman PL, Dortzbach RK: The Cynomolgus monkey as a model for orbital research. American Society of Ophthalmic Plastic and Reconstructive Surgery, International Lacrimal Society, International Society for Orbital Diseases. International Symposium on Eyelid, Orbital, and Lacrimal Surgery, San Francisco, CA, October 30, 1982.
18. *Kaufman PL: Presentations: 1) The mechanism of action of cholinergic drugs in the eye; 2) The effects of drugs which influence the washout mechanisms. Glaucoma Pharmacology Symposium, University of British Columbia, Vancouver, British Columbia, July 2-5, 1983.
19. *Kaufman PL: Co-chairman, Session II: Medical Management; Chairman, Session VI: Basic Research in Glaucoma. Presentations: 1) Cholinergic drug effects in the primate anterior segment; 2) Cytochalasins and aqueous humor outflow; (3) Valve implants in neovascular glaucoma. International Symposium on Glaucoma - The 14th International Meeting of the Israel Ophthalmological Society, Hadassah University and Israel Academy of Sciences and Humanities, Jerusalem, Israel, August 28-September 1, 1983.
20. *Kaufman PL: Chairman, Session III: Outflow Pathways in Primary and Secondary Open-Angle Glaucomas. Presentations: 1) Physiologic controls of aqueous outflow; 2) Effect of miotics on aqueous outflow. Seventh International Symposium on Topics in Glaucoma, University of Iowa, Iowa City, IA, September 29-October 1, 1983.
21. *Kaufman PL: Aging and aqueous humor dynamics. International Symposium on the Fundamental Aging Processes in the Eye, Capri Center for Cell Biology and Natural Sciences, Capri, Italy, September 23-26, 1984.
22. *A. Symposium on Ocular Inflammation. Presentation: Kaufman PL, Kulkarni PS: Arachidonic acid metabolism in Cynomolgus and rhesus monkey conjunctiva and lids. B. Symposium on Autonomic Receptors in the Anterior Segment of the Eye. Presentation: Erickson K, Polansky J, Kaufman PL, Zlock D: Cholinergic rx induces alterations in primate ciliary muscle physiology and muscarinic receptor content. C. Symposium on Presbyopia. Presentations: 1) Kaufman PL: Ciliary muscle physiology and pharmacology. 2) Bito LZ, Kaufman PL, Neider MW, Miranda CO: The rhesus monkey eye as a model for the mechanism of accommodation and the etiology of presbyopia and other aspects of ocular aging. Sixth International Congress of Eye Research, International Society for Eye Research, Alicante, Spain, October 1-7, 1984.
23. Erickson KA, Kaufman PL: Reinnervation of the ciliary muscle after ciliary ganglionectomy. Fourteenth Pupil Colloquium, Eye Care Center, University of British Columbia, Vancouver, British Columbia, Canada, May 22-24, 1985.
24. *1) Kaufman PL, Lütjen-Drecoll E: Opposite eyes vs. opposite animals - which control? Some problems with pharmacological studies in small mammals; 2) Lütjen-Drecoll E, Kaufman PL: The effect of timolol and epinephrine on the structure of the ciliary body and the trabecular meshwork. Fifteenth Cambridge Ophthalmological Symposium: The Ciliary Body, St. John's College, Cambridge, England, September 12-13, 1985.
25. Gonnering R, Dortzbach RK, Kaufman PL, Erickson K: The Cynomolgus monkey as a model for orbital research. Fifth International Symposium on Orbital Disorders, Amsterdam, The Netherlands, September, 1985.
26. *Crawford K, Kaufman PL: Prostaglandins and aqueous humor dynamics in the Cynomolgus monkey. Symposium on Prostaglandins, Annual North American Glaucomatologists' Learning Ensemble (ANGLE), Miami Lakes, FL, November 18-20, 1985.

27. *Bito LZ, Kaufman PL, DeRousseau CJ, Koretz JF: Is presbyopia an inevitable consequence of aging? Sixteenth Cambridge Ophthalmological Symposium: The Aging Eye, St. John's College, Cambridge, England, September 4-5, 1986.
28. *Crawford K, Kaufman PL, True B: Effects of exogenous prostaglandins on aqueous humor dynamics, blood-aqueous barrier, and iris and ciliary muscle tone in the Cynomolgus monkey. International Symposium on Prostaglandins and Related Compounds in Ophthalmology, Juntendo University, Tokyo, Japan, October 2-3, 1986.
29. *Kaufman PL: A. Symposium on Aqueous Flow and Glaucoma. Presentation: Recent advances in the physiology and pharmacology of the ciliary muscle in relation to aqueous humor outflow. B. Symposium on Accommodation, Lenticular Aging, and Presbyopia. Presentation: Koretz JF, Kaufman PL, Handelman GH: Aging of the human accommodative mechanism: changes in lens dynamics. Eighth International Congress of Eye Research, International Society for Eye Research, San Francisco, CA, September 4-8, 1988.
30. *Kaufman PL: Current status of medical therapy of glaucoma. Glaucoma Meeting, European Glaucoma Society/Semmelweis University Medical School, Budapest, Hungary, April 13-15, 1989.
31. *Kaufman PL, Erickson-Lamy KA, Rohen JW: The ciliary muscle and nerves after ciliary ganglionectomy. Quadrennial Meetings, Organizing Committee of the Glaucoma Society of the International Congress of Ophthalmology. Closed Meeting, Bali, Indonesia, March 11-13, 1990.; B. Open Meeting, Singapore, March 16-17, 1990. Presentations: 1) Robinson JC, Kaufman PL: Adrenergic/sympathetic mechanisms and interactions in aqueous formation and drainage; 2) Sponsel WE, DePaul KL, Kaufman PL: Correlation of visual function and retinal leukocyte velocity in glaucoma; (3) *Kaufman PL: Physiologic mechanisms underlying the medical therapy of glaucoma.
32. *Kaufman PL: Update - pressure reduction by cholinergic agents. Symposium on Applied Pharmacology of the Glaucomas. University of British Columbia, Vancouver, BC, Canada, May 24-26, 1990.
33. *Kaufman PL: A. Symposium on Models for Ocular Drug Studies. Presentation: Animal models for studies of glaucoma and aqueous humor dynamics. B. Symposium on Outflow: Trabecular Meshwork and Uveoscleral Outflow (Chairman). *Presentation: Why prostaglandins increase uveoscleral outflow. C. Symposium on Ciliary Muscle Accommodation (Chairman). *Presentation: Kaufman PL, Gabelt BT, Crawford K: Aging, accommodation and outflow facility in rhesus monkeys. D. Robinson JC, Kaufman PL: The effect of superior cervical ganglionectomy on aqueous humor production in the Cynomolgus monkey. E. Satellite Symposium on the Ocular Effects of Eicosanoids and Other Lipid Mediators. *Presentations: 1) Robinson JC, Kaufman PL: The effect of topical indomethacin on epinephrine's outflow facility increasing effect in Cynomolgus monkeys. 2) Poyer JF, Gabelt BT, Kaufman PL: The effect of topical PGF_{2a} on uveoscleral outflow and trabecular facility in the rabbit eye. Ninth International Congress of Eye Research, International Society for Eye Research, Helsinki, Finland, July 29-August 6, 1990.
34. *Kaufman PL: Evidence for uveoscleral outflow effects of prostaglandins. Symposium on Uveoscleral Outflow and Related Drugs, Annual North American Glaucomatologists' Learning Ensemble (ANGLE), San Diego, CA, December 12, 1991.
35. *Kaufman PL: Age changes in outflow facility. Symposium on Basic Aspects of Glaucoma Research III: Ageing-Glaucoma, University of Erlangen-Nürnberg, Erlangen, Germany, September 26-28, 1991.
36. *Kaufman PL: Prostanoid receptors in the eye. Symposium on Receptor Biology and Glaucoma, University of British Columbia, Vancouver, BC, Canada; University of Miami, Miami, FL; Alcon Laboratories-International, Ft. Worth, TX. Hamilton, Bermuda, March 26-30, 1992.
37. *Kaufman PL: A. Symposium on New Perspectives in Ocular Antihypertensive Drugs. Presentation: Cholinergic enhancement of aqueous outflow in the next millennium. B. Symposium on Outflow I: Contractility. *Presentation: Robinson JC, Kaufman PL: Cytoskeletal mechanisms in aqueous outflow. Tenth International Congress of Eye Research, International Society for Eye Research, Stresa, Italy, September 20-25, 1992.
38. Sponsel WE, Shoemaker JA, Kaufman PL, Blum F, Brady MA, DePaul KL, Zetlan SR: Timolol vs. betaxolol effects on visual function and ocular hemodynamics. International Perimetric Society, 10th meeting, Kyoto, Japan, October 20-23, 1992.

39. *Symposium on the Optic Nerve, University of British Columbia, Vancouver, BC, Canada; University of Miami, Miami, FL; Alcon Laboratories-International, Fort Worth, TX; Venice, Italy, September 30 - October 3, 1993. No formal presentation.
40. *Kaufman PL: Adrenergic and cholinergic agents: old friends, new mechanisms. The Gullstrand Meeting on Glaucoma - A 100th Anniversary, University of Uppsala, Uppsala, Sweden, May 26-27, 1994.
41. *Kaufman PL: Presbyopia, prostaglandins, and primary open angle glaucoma. Quadrennial Meetings, Glaucoma Society/XVIIth International Congress of Ophthalmology. Closed Meeting, Quebec City, Quebec, Canada, June 23-25, 1994; B. Open Meeting, Toronto, Ontario, Canada, June 26-30, 1994. *Presentations 1) The mechanism of action of antiglaucomatous drugs; 2) Current issues in glaucoma (invited panelist, open discussion symposium).
42. *Kaufman PL: A. Symposium on Ocular Hypotensive Agents. Presentation: Effects of adrenergic drugs and cGMP on aqueous inflow in monkeys: recent observations. B. Symposium on Outflow Facility and the Cytoskeleton and Contractility of the Outflow Pathways. Symposium Co-Chairman and Co-Organizer. *Presentation: Adrenergic and cholinergic effects on aqueous humor drainage in the living primate: recent observations and perspectives. Eleventh International Congress of Eye Research, International Society for Eye Research, New Delhi, India, November 13-18, 1994.
43. *Kaufman PL: Presentations: 1) Contractile and cytoskeletal mechanisms of aqueous outflow; 2) Accommodation, presbyopia and glaucoma. First Sam Rothberg Glaucoma Update Seminar, Maurice and Gabriela Goldschleger Eye Institute, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Itashomer, Herzelia, Israel, February 24, 1995.
44. *Kaufman PL: Presentations: 1) Prostaglandins-the future wonder drug; 2) The control of outflow-the cytoskeleton; (3) What role for gene therapy? Future Directions in the Medical Treatment of Glaucoma, University of British Columbia, Vancouver, BC, Canada, November 10, 1995.
45. *Kaufman PL: A. Symposium on Ion Transport and Ion Channels. *Presentation: Pharmacologic effects on the volumetric rate of aqueous humor flow: end-game of ion transport and ion channels in the ciliary epithelia. B. Symposium on Interaction of Drugs which Affect Aqueous Humor Dynamics. *Presentation: Adrenergic interaction on aqueous humor dynamics in monkeys. C. Symposium on New Views of Hyaluronate's Role in Outflow. *Presentation: Johnson M, Hubbard WC, Gong H, Gabelt BT, Tian B, Peterson JA, Sawhney R, Freddo T, Kaufman PL: GA gases do not affect outflow facility in the primate eye. D. Symposium on Prevention of Blindness. *Presentation: A physiologist's view of blindness prevention. E. Introduction of Endre A. Balazs Prize recipient. XII International Congress of Eye Research, International Society for Eye Research, Yokohama, Japan, September 29-October 4, 1996.
46. *Kaufman PL: Co-Organizer and Presenter. Presentation: Overview of mechanisms and therapies for retinal ganglion cell death, and optic nerve damage in glaucoma. The Gullstrand Foundation Meeting, Apoptosis and Neuroprotection - Do They Play a Crucial Part in Glaucoma, University of Uppsala, Uppsala, Sweden, April 18, 1997.
47. *Kaufman PL: Prostaglandins (PGs) and uveoscleral outflow (Fu). Prostaglandins: An Effective Treatment of Glaucoma. XIth Congress of the European Society of Ophthalmology, Budapest, Hungary, June 1-5, 1997.
48. *Kaufman PL: IOP lowering mechanism of PGF_{2a}. Latanoprost Launch Symposium, University of Amsterdam, Amsterdam, Netherlands, September 27, 1997.
49. *Kaufman PL: A perspective of neuroprotective in the glaucomas. International Symposium on Neuroprotection and Vascular Risk Factors in Glaucoma. University of British Columbia, Vancouver, BC, Canada; Alcon Laboratories- International, Ft. Worth, TX. Naussau, Bahamas, March 6-8, 1998.
50. *Kaufman PL: Presentations: 1) Outflow facility enhancement induced by actin filament disruption in monkeys; *2) Symposium: Prostaglandins in Glaucoma Management: Practical and Philosophical Issues (organizer & moderator); (3) The Sam Rothberg Low Tension Glaucoma Workshop: *Presentations. (a) What about aqueous dynamics in LTG?; (b) Here is what I think is really going on in LTG. Second International Glaucoma Symposium, Jerusalem, Israel, March 15-20, 1998.
51. *Kaufman PL: Co-Organizer and Presenter. Presentation: Physiology and pharmacology of conventional outflow. The Gullstrand Foundation Meeting II - Medical Treatment of Glaucoma - Basic and Applied Pharmacology. University of Uppsala, Sweden, April 25, 1998.

52. Kaufman PL, Peterson JA, Tian B, Gabelt BT, Geiger B: Cytoskeletal, cell junctional and extracellular matrix modulation of aqueous outflow. Quadrennial Meeting, Glaucoma Society/XVIII International Congress of Ophthalmology, closed meeting, Edinburgh, Scotland, June 14-18, 1998. Declined organization of the New Medications session of the open meeting in Amsterdam, Netherlands, June 22-25, 1998.
53. *1) Kaufman PL, Peterson JA, Tian B, Gabelt BT, Geiger B: An actin drug for glaucoma? 2) Peterson JA, Tian B, Gabelt BT, Geiger B, Kaufman PL: Actin disrupting drugs and their effects on anterior segment permeability in monkeys. XIII International Congress of Eye Research, International Society for Eye Research, Paris, France, July 26-31, 1998.
54. *Kaufman PL: Honored Guest. Presentations: 1) Cytoskeletal, cell junctional and extracellular matrix modulation of aqueous outflow. 2) Gene therapy for glaucoma: Anterior and posterior segment targets, delivery system, constraints. Second International Symposium on "The Challenges and Controversies of Ophthalmology and Visual Sciences in the Next Millennium." Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, SARs, China, August 20-23, 1998.
55. *Kaufman PL: Presentations: 1) Gene therapy for glaucoma: Anterior and posterior segment targets, delivery systems constraints. 2) The actin cytoskeleton and aqueous outflow. Closed International Glaucoma Symposium: Pathogenesis and Risk Factors of Glaucoma. Universitäts-Augenklinik, Würzburg, Germany/Chibret Germany. Friedrichsruhe, Germany, September 3-5, 1998.
56. *Kaufman PL: Co-Organizer and Presenter. Presentation: The need for early detection of glaucomatous disease and progression: Medicine or mythology? The Gullstrand Foundation Meeting III - How Do We Monitor Our Glaucoma Patients in the Next Millennium. University of Uppsala, Sweden, April 17, 1999.
57. *Kaufman PL: Symposium Organizer and Moderator. Presentations: 1) Chairman's remarks; 2) Xalatan mechanism of action; 3) Program summary; 4) Meeting wrap-up. Glaucoma Update 99. Pharmacia & Upjohn, Inc., Vancouver, BC, Canada, June 11-13, 1999.
58. *Kaufman PL: Mechanism of action of prostaglandins on aqueous humor dynamics. Latanoprost Launch Symposium - Kanto-Koshinetsu Region Ophthalmology Congress, Tokyo-Osaka-Sendai, Japan, June 19, 1999.
59. *Kaufman PL: Further therapeutic options for outflow. Targeting the Uveoscleral Outflow – The New Approach to IOP Reduction. XIIth Congress of the European Society of Ophthalmology, Stockholm, Sweden, June 28-July 2, 1999.
60. *Kaufman PL: Genetic and other implications. Symposium: New Therapeutic Options in Glaucoma Management. Oxford Ophthalmological Congress, Oxford, England, July 4-7, 1999.
61. *Kaufman PL: Presentations: *1) Where are we at the turn of the millennium? The North American point of view. *2) Where will glaucoma research go? Molecular biology, physiology & pharmacology. International Glaucoma Symposium: Eyes on Tomorrow - Dimensions of Glaucoma Research and Treatment. Pharmacia & Upjohn GmbH, Berlin, Germany, November 19-21, 1999.
62. *Kaufman PL: Cytoskeletal and cell junctional modulation of aqueous outflow. 20th Annual Meeting of the Glaucoma Society of the United Kingdom and Eire, London, England, November 25-26, 1999.
63. *Kaufman PL: New options in the medical management of glaucoma. Belgian Ophthalmological Society, Brussels, Belgium, November 27, 1999.
64. *Kaufman PL: New Findings in prostaglandin mechanism of action. Xalatan Global Expert Meeting, Hong Kong, China, December 14, 1999.
65. *Kaufman PL: 1) Introduce & Moderate Glaucoma Basic Sciences Session; 2) Lecture-Outflow enhancing drugs. Glaucoma in the 21st Century Meeting, Hong Kong, China, December, 15-16, 1999.
66. *Kaufman PL: Presentations: *1) Session Co-Chair - Glaucoma; 2) Keynote Lecture – Targets for future drug development in glaucoma. Third International Symposium on Ocular Pharmacology and Therapeutics – ISOPP, Lisbon, Portugal, February 10-13, 2000.
67. *Glasser A, Kaufman P: Edinger-Westphal stimulated accommodation in rhesus monkeys. 13th Annual Meeting of German Ophthalmic Surgeons, Nürnberg, Germany, June 15-18, 2000.
68. *Kaufman PL: Presentations: 1) High tech glaucomatology in a low-tech environment; 2) Presbyopia: A closer look; 3) Neuroprotection today and tomorrow; 4) Outflow enhancement today and tomorrow. Canadian Ophthalmological Society/Canadian Glaucoma Society, Whistler, BC, Canada, June 17-20, 2000.

69. *Kaufman PL: Poster session on medical treatment. Discussant of 5 posters on ocular hypotensive pharmacologic therapy and 3 posters on neuroprotection. Sixth Congress of the European Glaucoma Society, London, England, June 27-30, 2000.
70. *1) Borrás T, Rowlette LL, Cherwek DH, Caballero M, Gonzalez P, Gabelt BA, Peterson J, Kaufman PL: Trabecular meshwork gene transfer: its effect on intraocular pressure (IOP); *2) Kaufman PL, Liu X, Cai S, Geiger B: Junction dynamics of human trabecular meshwork (HTM) cells treated with cytoskeletal reagents; *3) Tian B, Kaufman PL, Geiger B: Cytoskeletal drugs and outflow resistance regulation. XIV International Congress of Eye Research, International Society for Eye Research, Santa Fe, NM, October 15-20, 2000.
71. *Kaufman PL: Anti-glaucoma therapy - mechanism of action and its relationship to efficacy and side effects. Quebec City Glaucoma Meeting, Quebec City, Canada, November 14, 2000.
72. *Kaufman PL: Presentations: 1) Neuroprotection in glaucoma: what do we know, what can we do today and tomorrow? 2) Medical therapy of glaucoma in the future. Pharmacia 2001 Glaucoma Retreat, Mont Tremblant, Quebec, Canada, January 13, 2001.
73. *Kaufman PL: 1) Chair of session: Surgery I - Non-Penetrating Glaucoma Surgery; 2) Presentation: Kaufman PL, Albert DM, Tamm ER, Carassa R: Outflow facility and morphology after viscocanalostomy in rhesus monkeys. Third International Glaucoma Symposium - I.G.S., Prague, Czech Republic, March 21-25, 2001.
74. *Kaufman PL: Meeting co-organizer; Presentation: Clinical considerations and concerns: topical vs. oral vs. peribulbar vs. intraocular drug delivery. Fourth Gullstrand Glaucoma Symposium: Back to Basics – What is New in Neuroprotection and Apoptosis, Uppsala, Sweden, April 7, 2001.
75. *Kaufman PL: Presentations: 1) Treatment of glaucoma in the future; 2) Neuroprotection in glaucoma; 3) Gene therapy in glaucoma. Royal Australia – New Zealand College of Ophthalmologists (RANZCO) – New Zealand Branch. Ocular Pharmacology & Therapeutics 2001, Wellington, New Zealand, May 10-13, 2001.
76. *Kaufman PL: Presentations: 1) Outflow enhancers or aqueous suppressants – Pros and cons; 2) Session Co-Chair, Concepts in Medical Therapy (II); 3) Panelist, Interactive case presentations & discussion; 4) Panelist, Panel discussion - Future trends. Glaucoma in the 21st Century - Meeting Clinical Challenges, Palma de Mallorca, Spain, May 24-27, 2001.
77. *Kaufman PL: Medical therapy of glaucoma today, and in the future, including neuroprotection. Eye 2 Eye, Niagara-on-the-Lake, Ontario, Canada, June 9, 2001.
78. *Kaufman PL: Presentations: 1) Pathophysiology of increased outflow resistance and potential for new therapeutic interventions; 2) Diagnosis, surgical and medical therapy in the glaucomas. Basic Aspects of Glaucoma Research V, University of Erlangen-Nürnberg, Erlangen, Germany, September 21-22, 2001.
79. *Kaufman PL: Presentations: 1) Keynote Lecture: Medical therapy for glaucoma in the new millennium: concepts; 2) Instruction Course: Medical therapy for glaucoma in the new millennium: a detailed blueprint for how, where and when. The 55th Congress of Clinical Ophthalmology of Japan, Kyoto, Japan, October 11-14, 2001.
80. *Kaufman PL: Presentations: 1) Aqueous humor dynamics; 2) Gene therapy: the pharmacology of the future; 3) The importance of lowering IOP; 4) International Glaucoma Reviews Award Presentation. The 3rd Congress of the Asian-Oceanic Glaucoma Society, Seoul, Korea, October 19-22, 2001.
81. *Kaufman PL: Panel discussant: 1) Is it pressure or not; 2) To be-ta or not to be-ta?; 3) Self-tonometry & tele-glaucoma. Amsterdam Glaucoma Debate, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, December 8, 2001.
82. *Kaufman PL: Presentations: 1) Drug mechanisms in glaucoma; 2) Gene therapy for glaucoma. Fifth Rotterdam Glaucoma Symposium, Rotterdam, The Netherlands, February 9, 2002.
83. *Kaufman PL: Presentations: 1) Moderator, Glaucoma Poster Discussion; 2) Moderator; Glaucoma Drug Development Session; 3) Confronting the algorithm with specific patient cases (patient case discussions); 4) Invited Lecture: From the bench to the patient: finding the path. 4th International Symposium on Ocular Pharmacology and Pharmaceutics – ISOPP, Seville, Spain, February 28-March 3, 2002.
84. *Kaufman PL: Presentation: Designer drugs - changing concepts in drug design. 29th International Congress of Ophthalmology, Sydney, Australia, April 21-25, 2002.
85. *Kaufman PL: Moderator/Chair, Glaucoma 2002 Update, Pharmacia Corp, Montreal, Canada, May 17-19, 2002.

86. *Kaufman PL: Presentations: 1) The importance of lowering intraocular pressure; 2) Rationale for neuroprotection other than IOP lowering. Glaucoma in the 21st Century: A New Standard is Taking Shape. Pharmacia Corp, Istanbul, Turkey, May 25, 2002.
87. *Kaufman PL: Discussant & Co-Moderator, 5th Gullstrand Foundation Meeting, Medical Treatment of Glaucoma – An Update, Uppsala, Sweden, June 1, 2002.
88. *Kaufman PL: Presentations: 1) Glaucoma therapy today and tomorrow – The Dr. Timothy Liu Memorial Lecture; 2) Prostaglandins and aqueous humor dynamics; 3) Co-Moderator, Glaucoma Session I; 4) Glaucoma case presentations, presenter and panelist. The 4th International Symposium of Ophthalmology, Shantou University / The Chinese University of Hong Kong Joint Eye Center, Shantou, The People's Republic of China, June 26-30, 2002.
89. *Kaufman PL: Physiopathology of glaucoma. Therapy in the next decades. Presidential Symposium on Glaucoma, 78th Congress of the Spanish Society of Ophthalmology, Murcia, Spain, September 25-29, 2002.
90. 1) *Kaufman PL: The importance of lowering IOP. The OHTS study; 2) Liu X, Wu Z, Sheibani N, Brandt CR, Polansky JR, Kaufman PL: Latrunculin-A inhibits dexamethasone-induced changes in the actin cytoskeleton and cell adhesive properties of cultured HTM cells (competitive travel fellowship for X Liu); 3) *Croft MA, Glasser A, Gabelt BT, Heatley GAA, Kaufman PL: Functional relationship between ciliary muscle, zonula and lens in young and old monkeys (competitive travel fellowship for MA Croft); 4) *Johnson M, Ethier R, Johnson DH, Kaufman PL, Tamm ET, Epstein DL, Stamer WD: A debate on the generation of aqueous outflow resistance: what controls aqueous outflow: the cells or the ECM? (PLK arguing for JCT, ECM and outflow resistance); 5) *Brandt CR, Huang C-Y, Liu X, Kaufman PL: Gene expression elements for glaucoma gene therapy; 6) Kaufman PL: ISER, its goals and how they are achieved (ICER Opening Session); 7) ISER General Business Meeting; 8) Introduction of the Balazs Prize Lecture; 9) *Faha BA, Heatley GA, Perkins TW, Kiland JA, Seeman J, Maneval D, Kaufman PL, Nickells RW: Adenovirus-mediated antiproliferative p21^{WAF-1/CIP-1} gene therapy to inhibit wound healing following experimental glaucoma filtration surgery. XV International Congress of Eye Research/International Society for Eye Research, Geneva, Switzerland, October 6-10, 2002.
91. *Kaufman PL: The Lecture of the Honorary President: Approaches to basic mechanistic studies of glaucoma surgery. The Second International Congress on Glaucoma Surgery: The New Horizons. Luxor, Egypt, February 6-7, 2003. {PLK was Honorary President of the Congress.}
92. *Kaufman PL: Presentations: 1) Early manifest glaucoma treatment study; 2) New concepts and mechanisms (session moderator); 3) But why not just drug rx for Schlemm's canal? 4th International Glaucoma Symposium – I.G.S., Barcelona, Spain, March 19-22, 2003.
93. *Kaufman PL: Moderator and Discussant – Getting a grip on efficacy and safety. Glaucoma in the 21st century: Setting the Pace, Staying the Course. 3rd Millennium Meeting, Pfizer Ophthalmology, Monte Carlo, Monaco, June 19-21, 2003.
94. *Kaufman PL: Meeting Organizer and Chair: Presentations: 1) The 2003 AG Watson Lecture: Pathophysiology of presbyopia; 2) Prostaglandins and aqueous humor dynamics; 3) Cytoskeletal and cell junctional agents – potential for glaucoma therapy; 4) Ocular hypertension treatment study (OHTS) and the early management of glaucoma trial (EMGT); 5) Gene therapy for glaucoma. The Sally Letson Symposium: Ocular Pharmacology. Physiology and Drug Delivery, Ottawa, Canada, September 11-13, 2003.
95. *Kaufman PL: Presentations: 1) Ocular Hypertension Treatment Study and Early Manifest Glaucoma Trial; 2) Targeting the trabecular meshwork – cell junctional dynamics and aqueous outflow. XIIIth Annual Meeting of the Glaucoma Society of India – Current Opinions in Glaucoma, Tirunelveli, India, September 20-21, 2003.
96. *Kaufman PL: Intraocular fluid dynamics in glaucoma – new knowledge. Czech Ophthalmological Society National Congress of Ophthalmology, Hradec Kralove, Czech Republic, September 25, 2003.
97. *Kaufman PL: Presentations: 1) Plenary Lecture: Challenges and directions in glaucoma basic research in the next decade; 2) Neuroprotection for glaucoma; 3) Prostaglandins and aqueous humor dynamics; 4) Lecture Honoring Dr. Mark T'so: Gene therapy for glaucoma; 5) Co-Moderator, Symposium 15: Glaucoma genetics and basic eye research. Fourth Congress of the Asian-Oceanic Glaucoma Society, in conjunction with Fifth Hong Kong International Symposium of Ophthalmology (HK ISO) and Sixth Asia Pacific Society of Eye Genetics (APSEG) Symposium, Hong Kong, China, October 1-3, 2003.

98. *Kaufman PL: Prostaglandins and aqueous humor dynamics. Shanghai Medical College of Fudan University, Shanghai, People's Republic of China, November 5, 2003.
99. *Kaufman PL: Presentations: 1) Medical therapy of glaucoma in the future; 2) Round table with residents, students and faculty. Xi'an Branch, Chinese Ophthalmological Society, Xi'an, People's Republic of China, November 7-8, 2003.
100. *Kaufman PL: Presentations: 1) Gene therapy for glaucoma; 2) Prostaglandins and aqueous humor dynamics. Third International Congress of Ophthalmology in China, Beijing, People's Republic of China, November 9-12, 2003.
101. *Kaufman PL: Presbyopia: A closer look. Symposium Glaucoma 2004: Basic and Clinical Aspects, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, January 9-10, 2004.
102. *Kaufman PL: Presentations: 1) Co-Moderator, Session on Blood Flow; 2) Gene therapy in glaucoma: will it replace drugs and surgery (session on "Genetics: Basic Concepts for Clinicians"); 3) The efficacy and mechanism of action of prostaglandin analogues (session on "Prostaglandins in the Eye"). Fifth International Symposium on Ocular Pharmacology and Therapeutics (5th ISOPT), Monte Carlo, Monaco, March 11-14, 2004.
103. *Kaufman, PL: Presentations: 1) OHTS, EMGT and other major clinical trials: implications for clinical practice; 2) Mechanisms of non-penetrating surgery and trends for usage in the US. Hellenic Ophthalmological Society – Greek Glaucoma Society, Athens, Greece, March 12-13, 2004.
104. *Kaufman PL: Presentations: 1) Targeting the trabecular meshwork: cytoskeleton, cell contractility, cell junctional dynamics and aqueous outflow; 2) Pathophysiology of presbyopia. Israel Society for Vision and Eye Research (ISVER) 2004, Jerusalem, Israel, March 18-19, 2004.
105. *Kaufman PL: Presentation: Gene therapy for glaucoma. Invited keynote speaker, European Glaucoma Society, 7th Quadrennial Congress, Florence, Italy, May 30-June 4, 2004.
106. *Kaufman PL, Tian B, Sabanay I, Okka M, Gabelt BT, Geiger B: Functional and structural effects of latrunculin B on the monkey aqueous outflow pathway and cornea. XVI International Congress of Eye Research/International Society for Eye Research, Sydney, Australia, August 29-September 3, 2004.
107. *Ver Hoeve JN, Kim CBY, Kaufman PL, Heatley GA, Nickells RW, Nork TM: Ganglion cell functional changes in response to ocular hypertension. XVI International Congress of Eye Research/International Society for Eye Research, Sydney, Australia, August 29-September 3, 2004.
108. *ARVO/NEI US-India Workshop on Collaborative Research Opportunities, Hyderabad, Madurai and Chennai, India, February 9-15, 2005. 1) Main conference co-organizer; 2) Moderator, sessions on Translational Physiology; 3) Presentation: Kaufman PL, Biswas J: Translational physiology: Bedside to bench to bedside
109. *2nd SERI/ARVO Meeting on Research in Vision and Ophthalmology, Singapore, February 16-20, 2005. Invited Presentations: 1) Plenary Lecture 3 - Glaucoma: Medical therapy for glaucoma - yesterday, today, and tomorrow; 2) Symposium 4 - Cataract/Lens: Kaufman PL, Croft MA, James R, McDonald JP, Tamm E, Lütjen-Dreccoil E. Studies of accommodation and presbyopia in non-human primates; 3) Symposium 3 - Hot Topics in Eyes and Vision Research (ARVO): Gene therapy for glaucoma; 4) Glaucoma Symposium 6 – Glaucoma (I): CNS changes in glaucoma.
110. *Fifth International Glaucoma Symposium, Cape Town, South Africa, March 30-April 2, 2005. 1) Targeting therapy to the trabecular meshwork: biological and biomechanical approaches; 2) Session Co-Moderator: Trabecular Meshwork, Cornea and Ciliary Body in Pathogenesis and Therapy of Glaucoma.
111. *World Glaucoma Congress – Association of International Glaucoma Societies, Vienna, Austria July 6-9, 2005. 1) Is gene therapy coming? (Plenary); 2) Mechanisms of action of glaucoma medications (Plenary); 3) Why are drugs not always effective? (Course); 4) Gupta N, Zhang Q, Weinreb RN, Kaufman PL, Rasmussen CA, Yucel YH: Dendritic pathology in lateral geniculate nucleus of the brain occurs early in glaucoma (Poster, nominated, special attention); 5) Lu W, Mitchell C, Rasmussen CA, Gabelt BA, Hennes EA, Kaufman PL, Laties AM: Elevation of primate IOP is associated with a fall in EAAT1 but not EAAT2 expression (Poster, nominated, special attention); 6) Nork TM, Kim CBY, Lucarelli MJ, Levin LA, Kaufman PL, Heatley GA, Verhoeve JN: Multifocal electroretinographic (MFERG) evidence for persistent but reversible outer retinal injury in chronic ocular hypertension in non-human primates (Poster, nominated, special attention); 7) Rasmussen CA, Peterson JC, Hennes BA, Gabelt BT, Kaufman PL: Nerve fiber layer measurements using the GDx VCC in monkeys (Poster, nominated, special attention).

112. Okka M, Gabelt BT, Dean TR, Kaufman PL: Aqueous humor dynamics after topical R-DOI. Turkish Ophthalmological Society, Antalya, Turkey, October 9-13, 2005.
113. *European Association for Vision and Eye Research, Vilamoura, Portugal, October 5-8, 2005. Presentations: Kaufman PL: 1) Navigating problems and pitfalls of collaborating with US researchers [ARVO Session]; 2) medical therapy of glaucoma in the future: from cell culture to clinic [keynote lecture].
114. *World Ophthalmology Congress, Sao Paulo, Brazil, February 19-24, 2006. Presentations: 1) Kaufman PL: Gene therapy for glaucoma (ARVO symposium); 2) Kaufman PL: The prospect of genetic therapy for glaucoma (AGS symposium).
115. *Mapping the Future of Glaucoma, Beijing, China, March 23-25, 2006, Global Glaucoma Summit, Pfizer, Inc. Presentation: Ultrastucture and physiology of the anterior segment: lessons from non-human primates.
116. *Sixth International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), Berlin, Germany, March 30-April 2, 2006. Presentations: 1) Gene therapy for glaucoma; 2) Moderator, Symposium on Improving IOP Control.
117. *Ten year Xalatan Jubilee, Uppsala, Sweden, May 12, 2006. Presentations: 1) Importance of Xalatan treatment worldwide; 2) Glaucoma treatment in the future.
118. *Bausch & Lomb Scientific Advisory Board Meeting, Baltimore, MD, May 17-19, 2006.
119. *Glaucoma Research Society, Vancouver, BC, Canada, June 28-July 1, 2006. Presentations: 1) Kaufman PL: Caldesmon – a new target for gene therapy in glaucoma; 2) Podos SM, Kaufman PL (Co-Chairs, Organizers, Moderators, 2-hr Symposium): Pharmacologic treatment – worldwide issues.
120. *International Ocular Neuroprotection Symposium, University of Toronto, Toronto, Ontario, Canada, October 14, 2006. Presentation: Ocular drug delivery: molecules, cells, and genes.
121. *XVII International Congress of Eye Research/International Society for Eye Research, Buenos Aires, Argentina, October 29-November 3, 2006. Presentations: 1) Gene therapy for glaucoma: science or fiction?; 2) What controls outflow resistance? My hypothesis is that outflow resistance is actively controlled and regulated, in response to physical, humoral and perhaps neuronal stimuli, via cellular contractility-relaxation, the cytoskeleton, and consequent overall tissue architecture in the JCT & IW.; 3) {Gabelt BT, Kaufman PL, Rasmussen CA, Tian BT: Animal Studies of Aqueous Humor Outflow or Talking to the Animals; 4) Interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail. The Ernst H. Barany Prize Lecture.
122. *Tenth Rotterdam Glaucoma Symposium, The Eye Hospital, Rotterdam, The Netherlands, January 27, 2006. Presentations: 1) Latanoprost – 10 years after; 2) Current status of neuroprotection in glaucoma; 3) Medical therapy for glaucoma: the next 20 years.
123. Sixth International Glaucoma Symposium – I.G.S., Athens, Greece, March 28-31, 2007. Presentations: 1) Cytoskeletal and aqueous outflow drugs: where do we stand?; 2) Drug delivery to the back of the eye – today and tomorrow?; 3) Session Co-Chairperson: Glaucoma and the Brain – Neuroprotection
124. *XIVth Afro-Asian Congress of Ophthalmology XXIIth Congress of the Moroccan Ophthalmological Society, Marrakesh, Morocco, June 20-25, 2007 Presentations: 1) Antifibrotic therapy: indications and methods; 2) Panel discussion: glaucoma treatment update (organizer and moderator); 3) Medical therapy of glaucoma: the next 20 years (key note lecture).
125. *2nd Biennial World Glaucoma Congress, Singapore, July 18-21, 2007. Presentations: 1) Global Assembly; Advocacy (with R. Hitchings); 2) Course 8, Chair – The Art of Written and Oral Presentations; Presentation: The art of writing a research paper; 3); Basic and Clinical Science Session 1 – What Do We Really Know About IOP? Presentation: How does the eye regulate IOP?; 4) Didactic Morning Session 2, Pathophysiology of POAG, NPG, ACG and Secondary OAG. Chair; 5) Symposium 5 – Advocacy, Co-Chair; Presentation: Glaucoma Advocacy; what have we learned in the United States?; 6) Combined Didactic Morning and Basic & Clinical Science Session 7 + 8 - Medical Treatment. Presentation: From drugs to genes; 6) Closing Symposium. Presentation: The future of glaucoma drops: the ongoing problem of administering eye drops.
126. *7th International Symposium on Ocular Pharmacology & Therapeutics, International Society of Ocular Pharmacology & Therapeutics, Budapest, Hungary February 28-March 2, 2007. Presentations: 1) Increasing outflow facility committee – today and tomorrow.

127. World Ophthalmology Congress 2008 (XXXI International Congress of Ophthalmology, XXII Congress of Asia-Pacific Academy of Ophthalmology, XIII Congress of Chinese Ophthalmological Society, XX Hong Kong Ophthalmological Symposium), Hong Kong, China, June 28-July 2, 2008. Presentations: *1) Kaufman PL: How shall we deliver therapeutic molecules to targets within the eye? In Nanomedicine half-day workshop: Intersection of Nanotechnology in Medicine, Hong Kong University Li Ka Shing Faculty of Medicine; *2) Kaufman PL: Novel ways of controlling IOP. In: Glaucoma Therapy-What's under development for the Future; 3) Yu M, Chen X, Wang N, Cai S, Li N, Brandt C, Kaufman P, Liu X: H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes.
128. *Kaufman PL: Medical Therapy of Glaucoma: The Next 20 Years. Brazilian Research Association of Vision and Ophthalmology (BRAVO), Aguas de Lindoia, Brazil, August 21-25, 2008.
129. *Kaufman PL, Rasmussen CA, Gabelt BT: Regulators of the actin cytoskeleton. International Congress of Eye Research (ICER-ISER) XVIII, Beijing, China Sept 24-29, 2008.
130. *Kaufman PL, Gabelt BT: Gene therapy for glaucoma. SEAGIG/AACGC (Southeast Asia Glaucoma Interest Group/Asian Angle-Closure Glaucoma Club). Seoul, Korea, Sept 25-27, 2008.
131. Lee E, Gabelt B, Rasmussen C, Peters D, Brandt C, Kaufman P: PGF synthase transgene expression in human ciliary muscle cells and its effect on intraocular pressure in monkey eyes in vivo. SEAGIG/AACGC 5th Congress of South East Asia Glaucoma Interest Group & 6th Meeting of Asian Angle-Closure Glaucoma Club. Sept 25-27, 2008, Seoul, Korea.
132. Lee E, Gabelt B, Peters D, Brandt C, Bhattacharya S, Kaufman P: Coch transgene expression by adenovirus in cultured human trabecular meshwork cells and its effect on outflow facility in organ cultured monkey anterior segments. SEAGIG/AACGC 5th Congress of South East Asia Glaucoma Interest Group & 6th Meeting of Asian Angle-Closure Glaucoma Club. Sept 25-27, 2008 Seoul, Korea
133. *Asia ARVO, Hyderabad, India, January 15-18, 2009. Invited oral presentations:
Symposium: Medical Management of Glaucoma: Kaufman PL: Future medical therapy for glaucoma
Keynote Lecture: Kaufman PL, Croft MA, Lütjen-Drecoll E: The Pathophysiology of presbyopia: fact vs fiction - a closer look. Special Interest Symposium on Restoring Accommodation: Kaufman PL: Measurements in the presbyopic eye.
134. *10th National Congress of Ocular Pharmacology and Research Advances in Ophthalmology, February 3-5, 2009, Cattania, Italy. Presentation: Lettura Mgaistrale: Medical therapy of glaucoma: the next 20 years.
135. *The Meeting of the Blood Flow in Glaucoma Discussion Group, Los Angeles, California, March 27, 2009. Participant/discussant. Discussion co-Leader, session on Pharmacologic effects on optic nerve blood flow.
136. *World Glaucoma Congress, World Glaucoma Association, Boston, MA July 8-11, 2009. Presentations (all invited): 1) Laudatio/Presentation of the WGA Science Award; 2) Discussion of Quigley Presentation in the session, "Innovative approaches to protecting the retinal ganglion cells"; 3) Chair and moderator of session "New Ideas in Medical Treatment". Presentation: Update on cytoskeletal approaches to glaucoma therapy.
137. *8th International Symposium on Ocular Pharmacology & Therapeutics, December 3-6, Rome, Italy. Presentations: 1) *Organizer and Moderator for Session – Clinical Trials Endpoints: the common and unique characteristics of clinical endpoints across the globe; 2) *Co-Chair for Session – Novel therapeutic approaches for glaucoma. *Presentation: Aqueous outflow biology and therapeutics: what's new?
138. *11th Japan Glaucoma Council, Tokyo, Japan, Decmber 12, 2009. Presentation: Future medical therapy for glaucoma.
139. *Meeting of the Japan Glaucoma Society, Fukuoka, Japan, September 24-26, 2010. Presentation: Special Lecture. Declined due to NEI/FDA Glaucoma Clinical Endpoints Meeting.
140. *Glaucoma Research Society, April 1-3, 2010. Kyoto, Japan 2010. Presentation: Long-lasting glaucoma drug-therapy - What research is needed to produce long-lasting IOP-lowering?
141. *XIX International Congress of Eye Research/International Society for Eye Research, Montreal, Canada, July 19-23, 2010. *Presentations: Rasmussen C., Kaufman P: Optic nerve degeneration in glaucoma; 2) *Kaufman PL: Introduction of the Ernst H. Bányi Prize award to Martin B. Wax; 3) *Kaufman P: Afferent/efferent cytoskeletal regulation of aqueous humor outflow.
142. *25th Asia-Pacific Academy of Ophthalmology Congress – Joint Meeting with American Academy of Ophthalmology / 15th Congress of the Chinese Ophthalmological Society, Beijing, China, September 16-20,

2010. *Presentations: 1) Genes targeting the trabecular meshwork to raise or lower IOP; 2) Medical therapy for glaucoma in the future.
143. *Korean Ophthalmological Society, Fall Meeting, Seoul, Korea, November 5-7, 2010. 1) Presentation: Lecture: Future medical therapy for glaucoma; 2) Lunch with young Korean academic glaucoma specialists; 3) Dinner with young and mid-career Korean clinician scientist glaucoma faculty whom we trained in Madison. 4) Introduction to Taejoon Pharma Executives.
144. *International Society of Ocular Pharmacology and Therapeutics – Asia (ISOPT-Asia), Macau, China, December 9-11, 2010. Presentations: *1) Trabecular meshwork outflow / gene therapy / cochlin update; *2) NEI and FDA hold second glaucoma endpoints meeting; 3) Moderator, session on "Endpoints in Clinical Trials".
145. *Association for Vision & Ophthalmology – 5th Asia ARVO Meeting on research in Vision and Ophthalmology / Singapore National Eye Center 21st Anniversary Meetings, Singapore, January 20-23, 2011. Presentations: 1) SNEC Continuing Medical Education Speaker: Future medical therapy for glaucoma; 2) Judge for Asia-ARVO Young Investigator Awards; 3) Presentation in Symposium 14 / Glaucoma session 1: Gene therapy for glaucoma – current status; 4) Co-Chair, Symposium 14 / Glaucoma session 2.
146. *4th World Glaucoma Congress, World Glaucoma Association, Paris, France, June 29-July 2, 2011. Presentations: 1) Gene therapy for glaucoma; 2) Primate models of optic nerve injury-strength and weaknesses; 3) TM and CM outflow-setting the stage; 4) Genetic manipulation of outflow, both pathways. 5) Chair and Organizer, Symposium 16, Conventional and Unconventional Outflow.
147. *BIT's 9th Annual Congress of International Drug Discovery Science and Technology, Shenzhen, China, November 3-6, 2011. Presentation: Gene therapy for glaucoma: insights into the pharmacology of the future.
148. *International Symposium of Ocular Pharmacology and Therapeutics (ISOPT *Clinical*), Vienna, Austria, December 2-4, 2011. 1) Co-Chair Session: Intraocular Pressure and Glaucoma; 2) Chair Session: Regulation of Ophthalmic Products Around the World: Differences and Similarities; 3) Presentation: Endpoints in glaucoma; 4) Manipulation of the TM cytoskeleton to enhance aqueous outflow.
149. *Moorfields International Glaucoma Symposium, Royal College of Physicians, London, England, January 28-29, 2012. Presentations: 1) Manipulating aqueous humor outflow; 2) BAK and glaucoma.
150. *World Ophthalmology Congress, Abu Dhabi, UAE, February 16-20, 2012. Session Chair: Ocular gene therapy and emerging therapies; Session Chair: New therapeutic approaches in glaucoma; Presentation: Gene therapy and aqueous outflow; Presentation: Rho kinase inhibitors and other treatments in the glaucoma pipeline.
151. *Asia-Pacific Academy of Ophthalmology, 27th Congress (jointly with the European Society of Ophthalmology; hosted by the Korean Ophthalmological Society), Busan, Korea, April 13-16, 2012. Presentations: 1) Medical therapy for glaucoma: where are we today?; 2) Session Co-Chair, Laboratory Eye Research – Drugs and Therapeutics, Session 6, Symposium, Traditional Medicine for Eye Diseases.
152. *8th ARVO/Pfizer Ophthalmics Research Institute Conference, Aqueous humor outflow: dynamics and disease, Fort Lauderdale, FL, May 4-5, 2012. *Presentation: Anatomy and physiology of aqueous humor outflow.
153. *Association for Research in Vision and Ophthalmology, Annual Meeting, Fort Lauderdale, FL, May 6-10, 2012. *Workshop – Getting published: advice from editors, May 9, 2012.
154. * The 10th Anniversary of the Joint Shantou International Eye Center of Shantou University / Chinese University of Hong Kong, Shantou, The People's Republic of China, May 26, 2012. Kaufman PL: (1) 10th Anniversary Lecture: Presbyopia: Up Close. (2) Symposium lecture: Future Medical Therapy for Glaucoma.
155. *Kaufman PL: Rho kinase modulation of aqueous outflow: what is the real target? XX Biennial Meeting, International Society for Eye Research, Berlin, Germany, July 21-26, 2012.
156. *Glaucoma Research Society, Biennial Meeting, Freiberg, Germany, September 5-8, 2012. *Presentations 1) Goldman Award Lecture: The biology of aqueous outflow – regulation and manipulation; 2) Discussant for Section III: Targeting aqueous outflow in glaucoma (4 invited speakers + discussion).
157. * Beijing-Tongren Eye Center 10th Anniversary Symposium, Capital Medical University, Beijing, China, September 21-23, 2012. Presentation: *Future medical therapy for glaucoma
158. *Turkish Ophthalmological Society 46th Annual Congress, Konya-Antalya, Turkey, October 17-21, 2012. Presentations: 1) Future medical therapy for glaucoma; 2) Presbyopia – up close.
159. *8th International Symposium of Ophthalmology – Hong Kong (8th ISO-HK), Hong Kong, China, December 16, 2012. Presentations: 1) Dr. Timothy KC Liu Lecture – Presbyopia – up close; 2) Future medical therapy for glaucoma; 3) Gene therapy for glaucoma.

160. *5th World Glaucoma Congress, Vancouver, BC, Canada, July 18-20. Podium Presentations (all invited): *1) Symposium 38 Targeting Aqueous Outflow (CoChair); *2) Molecular signaling in the outflow pathways; *3) New approaches to trabecular outflow; *4) What is the journal editor looking for? Poster presentation: P.L Kaufman, T. Ong, B. Scassellati Sforzolini, J.L. Vittitow: Reduction of intraday intraocular pressure (IOP) by latanoprostene bunod 0.024% ophthalmic solution compared to latanoprost 0.005% in subjects with glaucoma or ocular hypertension.
161. *International Society for Eye Research, 2013 ISER Sarasota Symposium, Molecular Mechanisms in Glaucoma, Sarasota, Florida September 29-October 2, 2013. 1) *Co-moderator, Platform Session VI: Growth Factors; 2) *Presentation in Platform Session VIII: Molecular mechanisms in the regulation of intraocular pressure.
162. *Asia ARVO 2013, New Delhi, India, October 28-31, 2013. 1) *Mini-symposium 2 - glaucoma management: understanding glaucoma, Co-Chairperson. Presentations: 2) *Current status of cytoskeletal drugs for glaucoma therapy; 3) *Current status of gene therapy for glaucoma.
163. *Dr. Schroff Charity Eye Hospital, New Delhi, India, October 30, 2013. Presentation: *The pathophysiology of presbyopia.
164. *China State Key Laboratory of Ophthalmology – Zongshan Ophthalmic Center International Research Symposium, Guangzhou, China, November 8, 2013. Presentation: *UW DOVS: Who we are, what we do.
165. *9th International Symposium of Ophthalmology – Hong Kong (9th ISO-HK), Guangzhou, China, November 8-11, 2013. Presentations: *1) The possible application of novel drug delivery systems in areas of limited resources; *2) Gene therapy for glaucoma; *3) [Zongshan Ophthalmic Center, Clinical Research Center, Clinical Research Study Symposium] What is the journal editor looking for; *4) Trabecular meshwork cytoskeleton – a regulatory mechanism and therapeutic target; *5) Presbyopia – up close; *6) Session Co-Chair: *1) Updates on glaucoma management 1; *2) APAO symposium: advances in our understanding of glaucoma; *3) Updates and latest developments in presbyopia and its treatments.
166. *University of Toronto, Department of Ophthalmology & Visual Sciences, 53rd Annual Walter Wright Day, Glaucoma Management Review Course, Toronto, Ontario, Canada, December 6-7, 2013. *Presentations: *1) New glaucoma drugs in the pipeline; *2) Session Co-Moderator: Glaucoma under pressure – surgical incision indecisions? The new kids on the block; *3) 53rd Walter Wright Day Lecture: 5 Exciting directions in glaucoma – a sneak preview.
167. *World Ophthalmology Congress, Tokyo, Japan, April 2-6 Presentation: Thursday, April 3, 2014 - 1) Trabecular Meshwork and Novel Outflow Compounds; 2) Getting Published: What is the Journal Editor Looking For?; ARVO Session Workshop Chair: How to Succeed in Scientific Article Publication – I and II.
168. *Association for Research in Vision and Ophthalmology, Annual Meeting, Orlando, FL, May 4-8, 2014. *Session presenter: Where, how and why NO affects aqueous humor outflow. Session Title: New insights into the role of nitric oxide signaling in glaucoma: Number 137. May 4, 2014.
169. *11th European Glaucoma Society Congress, Nice, France, June 7-11, 2014.
*1) Invited participant in Think Tank Meeting: Basic mechanisms in glaucoma surgery; *2) Co-Chair June 8 Main Session: Biomarkers and Clinical Markers; *3) Main Session Presentation: Biomarkers from non-human primates; *4) Course Co-Chair: Uveolymphatic, uveoscleral and conventional outflow; *5) Course Presentation: Uveoscleral outflow *6) Course Presentation: What's new in conventional and uveoscleral outflow; 7) Poster Presentation: Aktas Z, Slauson S, Gabelt BT, Rao H, Dietz J, Kaufman PL, Brandt CR: Effect of proteasome inhibition on lentiviral vector transduction in human trabecular meshwork cells and monkey organ-cultured anterior segments; 7) Poster Presentation: Kaufman PL, Aktas Z, Tian B, McDonald J, Yamamoto R, Larsen C, Kiland JA, Rassmusen CA: Canaloplasty for glaucoma gene therapy.
170. *International Society of Ocular Pharmacology & Therapeutics, 11th ISOPT Clinical, Reykjavik, Iceland, June 19-22, 2014. 1) Outflow drugs: What does the future hold; 2) David L. Epstein, MD, in memoriam.
171. *Glaucoma Research Society, Jackson Hole, Wyoming, USA, August 27-30, 2014. *1) Co-Moderator with E. Tamm, Session 4, Trabecular Meshwork and Optic Nerve Head Pathology – a common link?; 2) Session 12, Is visual improvement in advanced glaucoma a realistic goal? *Presentation: Strategies to improve vision in glaucoma.
172. *2nd Asia-Pacific Glaucoma Congress / 10th International Symposium of Ophthalmology – Hong Kong, Hong Kong, China, September 26-28, 2014. Presentations: 1) *ISO-HK Lecture: Gene Therapy for Glaucoma

- targets, strategies, constraints, update; 2) *Current concepts in aqueous humour outflow and assessment; 3) *Medical Treatment for Glaucoma: what's in store.....
173. 2015 Asia ARVO, Yokohama, Japan, February 16-19, 2015. Presentations: *1) Co-Moderator with Yoshiaki Kiuchi, Glaucoma 2 Symposium; 2) Presentation: Kaufman PL, Kiland J, Heatley GA, Nork TM, McDonald J, Katz A, Lutjen-Drecoll E, Croft MA: Accommodative movements in the anterior and posterior segment: implications for presbyopia and glaucoma.
174. *30th Asia-Pacific Academy of Ophthalmology Congress / 20th Congress of the Chinese Ophthalmological Society, Guangzhou, China, March 31-April 4, 2015. Presentations: 1) March 31 Glaucoma Subspecialty Day, EGS/AGS/APAO Symposium: New insights into glaucoma pathophysiology, populations and patient care. *Presentation: Rethinking the Conventional Outflow Pathway; 2) Drugs and therapeutics: Targeting diseases of the anterior segment. *Presentation: Cytoskeleton drugs to reduce IOP.
175. *6th World Glaucoma Congress, World Glaucoma Association, Hong Kong, China, June 6-9, 2015. Presentations: 1) Imaging of the trabecular meshwork; 2) Old and new outflow pathways; 3) MIGS as delivery devices for drugs and biological agents; 4) IOP regulation and Rho GTPase signaling; 5) Session Co-Chair, Plenary Session, Translational Glaucoma; 6) Session Co-Chair, Rho kinase inhibitors as a new glaucoma medication.
176. *31st Asia-Pacific Academy of Ophthalmology Congress / 57th Annual Meeting of the Ophthalmological Society of Chinese Taipei. [Dates?] *Presentations: 1) Nitric oxide and adenosine A1 receptor agonist I therapy for the trabecular meshwork; 2) Co-Chair, GL-SS06, New Glaucoma Medications; 3) Co-Chair, MI-SS02, AAPPO Symposium: All you need to know about international publishing; 4) Why should a paper be published?
177. *Singapore National Eye Center / Singapore Eye Research Institute, Resident Lecture – Visiting Professor, Singapore, April 8, 2016. Presentation: Medical therapy for glaucoma: yesterday, today, tomorrow.
178. *3rd Asia-Pacific Glaucoma Congress, Chiang Mai, Thailand, July 14-16, 2016. Presentations (all invited): 1) Medical Therapy for glaucoma going forward (plenary lecture); 2) Trabecular meshwork & ciliary muscle gene therapy for glaucoma; 3) Update on gene and stem therapy for glaucoma.
179. *International Society for Eye Research, XXIst Biennial International Congress of Eye Research, Tokyo, Japan, September 25-29, 2016. Co-Moderator: Status of Glaucoma Gene and Stem Cell Therapy, Presentation: Trabecular Meshwork and Ciliary Muscle Gene Therapy for Glaucoma.
180. *13th International Society of Ocular Pharmacology & Therapeutics - Clinical, Rome, Italy, December 1-3, 2016. Presentations: 1) Future of Stem Cell Therapy in Glaucoma; 2) Genetic Therapies for Glaucoma.
181. ARVO Asia 2017, Brisbane, Australia, February 4-8, 2017. Presentations: 1) [Translational Vision Summit – Feb. 4] Glaucoma gene therapy via Schlemm's canal; 2) (Kaufman PL, Lutjen-Drecoll E, Croft MA.) Biomechanical properties of the ciliary body in aging and the effects on the optic nerve.
182. *32nd Asia Pacific Academy of Ophthalmology Congress, Singapore, March 1-5, 2017. *Presentation: Gene and Stem Cell Therapy for Glaucoma: Where Do We Stand?
183. 7th World Glaucoma Congress, Helsinki, Finland, June 28 – July 1, 2017: Presentations 1) Wang N, Liu X, Kaufman PL et al: Lentiviral mediated exoenzyme C3 transferase expression. 2) Kaufman PL, Croft MA, Lütjen-Drecoll E: Biomechanics of presbyopia and relevance to glaucoma; 3) Session Co-Chair: What's new in IOP?]
184. International Society for Eye Research / BrightFocus Foundation: Basic Science Catalyzing Treatments for Glaucoma. ISER / BrightFocus 2017 Glaucoma Symposium, Emory Conference Center, Atlanta, Georgia, October 5-8, 2017. Presentations: 1) PL Kaufman, E Lütjen-Drecoll, MA Croft: The Link Between Accommodation, Presbyopia and Glaucoma; 2) Co-Moderator (with Rachel Kuchty): Platform Session II: Clinical and Translational Studies
185. 2nd Dr.Hajar Afsar Lajevardi (HAL) International Memorial Conference. Tehran, Iran. October 26-27, 2017. Presentation: Kaufman PL, Lutjen-Drecoll E, Croft MA: The link between accommodation, presbyopia and glaucoma.

NATIONAL PRESENTATIONS (* = invited)

1. Kaufman PL, Podos SM: Origin of subretinal fluid in primary rhegmatogenous retinal detachment: pseudo-cholinesterase studies. Association for Research in Vision and Ophthalmology (ARVO), annual spring national meeting, Sarasota, FL, April 25, 1972.
2. Kaufman PL, Podos SM: Subretinal fluid butryl-cholinesterase in re-operated rhegmatogenous detachments. ARVO, Sarasota, FL, May 7, 1973.
3. Philipson B, Fagerholm P, Kaufman PL, Axelsson U, Bárány E: Microradiography and morphology of echothiophate cataracts in monkeys. ARVO, Sarasota, FL, April 26, 1976.
4. Kaufman PL, Bárány EH: Subsensitivity to pilocarpine of the aqueous outflow system in monkey eyes following topical anticholinesterase treatment. ARVO, Sarasota, FL, April 27, 1976.
5. *1) Kaufman PL, Bill A, Bárány EH: Effect of cytochalasin B on drainage of aqueous humor in monkeys; 2) Kaufman PL, Bárány EH: Recent observations concerning the effects of cholinergic drugs on outflow facility in monkeys. Symposium on the Ocular and Cerebrospinal Fluids, Fogarty International Center, National Institutes of Health, Bethesda, MD, May 3-6, 1976.
6. Kaufman PL, Bárány EH: Cytochalasin B reversibly increases outflow facility in the eye of the Cynomolgus monkey. ARVO, Central Section, Lexington, Kentucky, November 12, 1976.
7. Kaufman PL, Axelsson U, Bárány EH: Atropine inhibits echothiophate cataractogenesis in vervet and Cynomolgus monkeys. ARVO, Central Section, Lexington, Kentucky, November 12, 1976.
8. Kaufman PL: Anticholinesterase-induced cholinergic subsensitivity in primate accommodative mechanism. ARVO, Sarasota, FL, April 26, 1977.
9. Lütjen-Drecoll E, Svedbergh B, Kaufman PL: Cytochalasin B-induced structural changes in the aqueous humor pathways. ARVO, Sarasota, FL, April 26, 1977.
10. *Kaufman PL: Cholinesterase inhibitor cataracts in monkeys. National Symposium on Drug-Induced Ocular Side Effects and Ocular Toxicology, ARVO and University of Arkansas, Little Rock, AR, September 8-10, 1977.
11. Wilensky J, Herschler J, Kass M, Kaufman PL, Ritch R: Gonioscopy. ARVO, Sarasota, FL, May 1, 1978.
12. Kaufman PL, Rohen JW, Bárány EH: Hyperopia and accommodation loss after ciliary muscle retrodisplacement in monkeys. ARVO, Sarasota, FL, May 2, 1978.
13. Lütjen-Drecoll E, Kaufman PL: Echothiophate-induced structural changes in monkey anterior chamber angle. ARVO, Sarasota, FL, May 2, 1978.
14. Kaufman PL: Aqueous humor dynamics after total iridectomy in Cynomolgus monkeys. ARVO, Sarasota, FL, April 30, 1979.
15. Kaufman PL, Bárány EH: Adrenergic drug effects on aqueous outflow following ciliary muscle retrodisplacement in the Cynomolgus monkey. ARVO, Orlando, FL, May 5, 1980.
16. *Kaufman PL: Cholinergic drug effects on the primate anterior ocular segment. Eighth Conference on Biochemistry of the Eye, Oakland University, Rochester, MI, October 14-17, 1980.
17. *Kaufman PL: The influence of systemic anti-hypertensive therapy on visual field loss in glaucoma patients. Seminar on the Ocular Response to Clonidine, Boehringer-Ingelheim Ltd., San Francisco, CA, January 15-16, 1981.
18. DeRousseau CJ, Bito JW, Kaufman PL: Development of presbyopia, degenerative disk disease and other predictable age-dependent afflictions in rhesus monkeys. American Association of Physical Anthropologists, Fiftieth Annual Meeting, Detroit, MI, April 23, 1981.
19. Erickson KA, Kaufman PL: Comparative effects of three ocular perfusates on outflow facility in Cynomolgus monkeys. ARVO, Sarasota, FL, April 28, 1981.
20. Kaufman PL, Erickson KA, Bárány EH: Effect of repeated anterior chamber perfusion on total outflow facility in monkeys. ARVO, Sarasota, FL, April 28, 1981.
21. Neider MW, Kaufman PL, Erickson KA: Echothiophate cataractogenesis in monkeys: accommodation plays no role. ARVO, Sarasota, FL, May 6, 1982.
22. Kaufman PL, Bárány EH, Erickson KA: Effect of serotonin, histamine, and bradykinin on outflow facility following ciliary muscle retrodisplacement in the Cynomolgus monkey. ARVO, Sarasota, FL, May 7, 1982.
23. Erickson KA, Kaufman PL: Cytochalasin B and D dose-outflow facility response relationships in the Cynomolgus monkey. ARVO, Sarasota, FL, May 7, 1982.

24. DeRousseau CJ, Kaufman PL, Bito LZ, Neider MW: The rhesus monkey as a model for (age related) ocular disorders: occurrence of senile cataracts, presbyopia, ocular hypertension, and glaucoma. ARVO, Sarasota, FL, May 7, 1982.
25. Erickson KA, McDermott ML, France NK, Kaufman PL: Comparative anesthetic effects on aqueous humor dynamics in Cynomolgus monkeys. ARVO, Sarasota, FL, May 2, 1983.
26. Zlock D, Erickson K, Kaufman PL, Brasier A, Polansky J: Cholinergic rx results in a decreased content of muscarinic receptors in ciliary muscle. ARVO, Annual Spring National Meeting, Sarasota, FL, May 5, 1983.
27. DeRousseau CJ, Bito LZ, Kaufman PL: Age-dependent impairment of the rhesus visual and musculoskeletal systems and possible behavioral consequences. American Society of Primatologists, Fifth Annual Meeting, East Lansing, MI, August 7-10, 1983.
28. Hultsch E, Kaufman PL: Aqueous humor dynamics in owl monkeys (*Aotus trivirgatus*). ARVO, Sarasota, FL, May 1, 1984.
29. Kaufman P, Koretz J, Neider M, Bito L: Accommodation, presbyopia, and lens curvatures in rhesus monkeys. ARVO, Sarasota, FL, May 1, 1984.
30. *Kaufman PL: Remarks on presentation of the Friedenwald Memorial Award to Professor Anders Bill. ARVO annual spring national meeting, Sarasota, FL, May 2, 1984.
31. Betaxolol Study Group (Allen RC, Kaufman PL, et al): Betaxolol in the treatment of glaucoma: multiclinic trials. American Academy of Ophthalmology, Annual Meeting, Atlanta, GA, November 11-15, 1984.
32. *Kaufman PL: Cholinergic physiology and pharmacology of the aqueous outflow apparatus. Second Annual Awards Symposium, Alcon Research Institute, Ft. Worth, TX, April 25-26, 1985.
33. Kulkarni PS, Srinivasan BD, Kaufman PL: Comparison of cyclooxygenase and lipoxygenase pathways in rabbit and monkey ocular tissues. ARVO, Sarasota, FL, May 9, 1985.
34. Crawford K, Gabelt BT, Kaufman PL: Topical prostaglandin effects on aqueous humor dynamics in Cynomolgus monkeys. ARVO, Sarasota, FL, May 9, 1985.
35. Erickson-Lamy KA, Polansky JR, Kaufman PL, Gabelt BT: Dissociation of ciliary muscle cholinergic sensitivity and muscarinic receptor content following ciliary ganglionectomy in Cynomolgus monkeys. ARVO, Sarasota, FL, May 9, 1985.
36. *Kaufman PL: Presentations: 1) IOP effects; 2) Mechanism of ocular hypotensive effect; (3) Clinical aspects. Symposium on the Ocular Effects of Prostaglandins and Other Eicosanoids, Pharmacia, Inc, Sarasota, FL, May 10-11, 1985.
37. *1) Lütjen-Drecoll E, Kaufman PL: Effects of long-term timolol and epinephrine treatment on the ciliary processes in Cynomolgus monkeys; 2) Kaufman PL, Erickson-Lamy KA: Effects of anesthesia on fluorophotometrically determined aqueous flow in Cynomolgus monkeys; 3) Kaufman PL: Organizer and moderator of session on clinical aspects of aqueous humor inflow. Meeting on Aqueous Humor Inflow, Oakland University, Rochester, MI, October 8-11, 1985.
38. Baroody RA, Bito LZ, DeRousseau CJ, Kaufman PL, Koester CJ: Ocular development and aging. 1. Corneal endothelial cell density and morphology in cats and in free-ranging and caged rhesus monkeys. ARVO, Sarasota, FL, April 28, 1986.
39. Neider MW, Crawford K, Gabelt BT, Kaufman PL, Bito LZ: Functional studies of accommodation and presbyopia in rhesus monkeys. ARVO, Sarasota, FL, April 29, 1986.
40. Miranda OC, Bito LZ, Kaufman PL, DeRousseau CJ, Raley SE: Ocular development and aging. 2. Different basic patterns of lenticular growth in cats and rhesus monkeys (RhMs) and the lack of discernible effect of sunlight on lenticular aging in RhMs. ARVO, Sarasota, FL, May 1, 1986.
41. Gabelt BT, Crawford K, Kaufman PL, Wallow IHL, Polansky JR: Intraocular parasympathetic denervation following pan-retinal photocoagulation. ARVO, Sarasota, FL, May 1, 1986.
42. Koretz JF, Bertasso AM, Neider MW, Kaufman PL, Bito LZ: Comparison of human and rhesus crystalline lens parameters as functions of accommodative state and age. ARVO, Sarasota, FL, May 1, 1986.
43. Erickson-Lamy KA, Kaufman PL: Cholinergic reinnervation of the ciliary muscle following ciliary ganglionectomy in the Cynomolgus monkey. ARVO, Sarasota, FL, May 2, 1986.
44. Crawford K, Gabelt BT, Kaufman PL, Bito LZ: Effects of various anesthetic and autonomic drugs on refraction and accommodation in monkeys. ARVO, Sarasota, FL, May 2, 1986.

45. Feghali JG, Kaufman PL, Radius RL, Mandell AI: A comparison of betaxolol and timolol in open angle glaucoma. American Academy of Ophthalmology, Annual Meeting, New Orleans, LA, November 9-13, 1986.
46. Tumminia SJ, Koretz JF, Landau JV, Bailey RO, Kaufman PL: Comparison of increased hydrostatic pressure effects on native thick filaments from human and rhesus skeletal muscle. Biophysical Society, 31st Annual meeting, New Orleans, LA, February 22-26, 1987.
47. *Kaufman PL: Aqueous humor dynamics: current concepts regarding inflow and outflow. Glaucoma Symposium, Alcon Educational Fund/Alcon Laboratories, Inc./The Adjuvant Group, Tarpon Springs, FL, March 12-14, 1987.
48. Crawford K, Kaufman PL, Gabelt BT: Pilocarpine antagonizes PGF_{2a}-induced ocular hypotension: evidence for enhancement of uveoscleral outflow by PGF_{2a}. ARVO, Sarasota, FL, May 4, 1987.
49. Gabelt BT, Polansky JR, Kaufman PL: Ciliary muscle muscarinic receptor content and affinity for QNB in young and old rhesus monkeys. ARVO, Sarasota, FL, May 4, 1987.
50. Koretz JF, Rotolante TL, Neider MW, Kaufman PL: Age-related reduction in the human lens refractive index: a resolution of Brown's lens paradox. ARVO, Sarasota, FL, May 4, 1987.
51. Lütjen-Drecoll E, Tamm E, Kaufman PL: Functional morphology of rhesus ciliary muscle during ageing. ARVO, Sarasota, FL, May 4, 1987.
52. Bito LZ, Kaufman PL, Neider M, Miranda OC, Antal P: The dynamics of accommodation (ciliary muscle contraction, zonular relaxation and lenticular deformation) as a function of stimulus strength and age in iridectomized rhesus eyes. ARVO, Sarasota, FL, May 7, 1987.
53. Kaufman PL, Gabelt BT, Wallow IHL: Retinal photocoagulation-induced intraocular parasympathetic denervation: role of the long posterior ciliary nerves. ARVO, Sarasota, FL, May 8, 1987.
54. *1) Crawford K, Kaufman PL: Ocular hypotensive effects of PGs in animals; 2) Kaufman PL: The effects of PGs on outflow facility. Symposium on the Ocular Effects of Eicosanoids. Prostaglandins as a New Approach to the Medical Management of Glaucoma. Pharmacia Ophthalmics AB, Sarasota, FL, May 8-10, 1987.
55. *Kaufman PL: Prostaglandins and aqueous humor dynamics. American Glaucoma Society, First Scientific Meeting, University of Iowa, Iowa City, IA, June 11-13, 1987.
56. *Bito LZ, Kaufman PL, Miranda OC: Accommodation and its age-dependent loss in rhesus monkeys. Symposium on Vision and Normal Aging, Section on Visual Science, American Academy of Optometry, Annual Meeting, Denver, CO, December 5-8, 1987.
57. Koretz JF, Bertasso AM, Neider MW, Kaufman PL, Goeckner PA: Preliminary characterization of human crystalline lens geometry as a function of accommodation and age. Optical Society of America/American Academy of Optometry, Fourth Topical Meeting on Noninvasive Assessment of the Visual System, Incline Village, NV, February 16-18, 1988.
58. Sponsel W, Bowes H, Olander K, DePaul K, Kaufman PL: Clinical evaluation of a new portable non-contact tonometer. ARVO, Sarasota, FL, May 2, 1988.
59. Miranda OC, Bito LZ, Kaufman PL: Ocular aging and presbyopia: comparison of the functional aging of iridial and ciliary muscles. ARVO, Sarasota, FL, May 2, 1988.
60. Kaufman PL, Rohen JW, Goeckner PA, Eichhorn M, Bito LZ: Functional morphology of accommodation in the raccoon. ARVO, Sarasota, FL, May 2, 1988.
61. Crawford K, Kaufman PL, Bito LZ: The role of the iris in accommodation dynamics of rhesus monkeys. ARVO, Sarasota, FL, May 2, 1988.
62. Gabelt BT, Kaufman PL, Goeckner PA: Direct measurement of increased uveoscleral outflow following PGF_{2a} using two methods. ARVO, Sarasota, FL, May 3, 1988.
63. Neider MW, Goeckner PA, Koretz JF, Kaufman PL: Changes in human crystalline lens geometry during accommodation and aging. ARVO, Sarasota, FL, May 3, 1988.
64. Goeckner P, Sponsel W, Strinden T, DePaul K, Kaufman PL: A direct manometric comparison of the Keeler Pulsair with the Goldmann applanation tonometer in post-mortem human eyes. ARVO, Sarasota, FL, May 4, 1988.
65. *Kaufman PL: Presentations: 1) Cytochalasins and chelators; 2) Ciliary muscle aging. Second Trabecular Meshwork/Aqueous Outflow Workshop, University of California/Allergan Pharmaceuticals, Inc., San Francisco, CA, September 9-10, 1988.

66. *Kaufman PL: Prostaglandin F_{2a} and apraclonidine: new approaches to pharmacotherapy of glaucoma. (Discussion of two papers.). Annual Meeting, American Academy of Ophthalmology, Las Vegas, NV, October 8-12, 1988.
67. Kaufman PL, Lütjen-Drecoll E, Bito LZ, Crawford K, Neider MW: Age-related alterations in ciliary muscle structure and function: pathophysiologic and therapeutic implications for glaucoma. American Glaucoma Society, Second Scientific Meeting, Miami Lakes, FL, December 2-3, 1988.
68. DePaul K, Sponsel WE, Kaufman PL: The correlation of visual field and retinal blood flow asymmetry in glaucoma patients and ocular hypertensives. Optical Society of America/American Academy of Optometry, Fifth Topical Meeting on Non-invasive Assessment of the Visual System, Santa Fe, NM, February 13-15, 1989.
69. Crawford K, Kaufman PL, Majors LJ: Dose-response relationships between PGF_{2a}-IE and IOP, refraction and pupil diameter in Cynomolgus monkeys. ARVO, Sarasota, FL, April 30, 1989.
70. Sponsel WE, DePaul KL, Kaufman PL: Correlations of visual field, leukocyte velocity and IOP in glaucomatous and ocular hypertensive eyes. ARVO, Sarasota, FL, May 1, 1989.
71. Gabelt BT, Kaufman PL: True outflow facility remains unchanged following PGF_{2a} in Cynomolgus monkeys. ARVO, Sarasota, FL, May 1, 1989.
72. Koretz JF, Kaufman PL: Physiological strategies for emmetropia. ARVO, Sarasota, FL, May 1, 1989.
73. Callahan EC, Kaufman PL, Tulunay-Keeseey Ü: Spatio-temporal contrast sensitivity in glaucoma. ARVO, Sarasota, FL, May 2, 1989.
74. Robinson JC, Kaufman PL, Wallow IHL: The effect of superior cervical ganglionectomy on anterior segment physiology in the Cynomolgus monkey. ARVO, Sarasota, FL, May 4, 1989.
75. Kaufman PL, Robinson JC: Epinephrine, norepinephrine and timolol effects on outflow facility in the Cynomolgus monkey. ARVO, Sarasota, FL, May 5, 1989.
76. Olander K, Stewart R, Silverstone D, Lenartz H, Burk L, Kaufman PL, Lewis R, Taylor R: Efficacy of safety of Iopidine in controlling the post-laser IOP rise after Nd: YAG posterior capsulotomy: a multi-center trial. American Society of Cataract and Refractive Surgery, Washington, DC, April 27, 1989.
77. *Avorn JL, Kaufman PL, Koppel T, Martin T, Quigley HA, Schoene RB, Smith CW Jr, Van Buskirk EM, Weinreb RN, Wood AJJ. Common Ground: An Interspecialty Approach to the Glaucoma Patient. A nationwide interactive videoconference. Hospital Satellite Network and Ted Koppel Productions, Washington, DC, September 28, 1989.
78. *Kaufman PL: Presentations: 1) How do prostaglandins work: physiology; 2) Epinephrine - cytochalasin interactions on outflow facility. Third Trabecular Meshwork Study Club Meeting, Oakland University, Rochester, MI, October 11-13, 1989.
79. *Kaufman PL: Presentations: 1) Current understanding of outflow mechanisms; 2) Presbyopia and primary open angle glaucoma - a common pathophysiology? Advances in Ophthalmic Research and Beyond, University of Louisville/Kentucky Lions Eye Research Institute, Louisville, KY, October 5-7, 1989.
80. *Kaufman PL: Current status of the medical therapy of glaucoma. Fourteenth Annual Midwest Glaucoma Symposium, University of Louisville/Kentucky Lions Eye Research Institute, Louisville, KY, October 6-8, 1989.
81. *Kaufman PL: Special Feature Seminar. Presentation: Current concepts of presbyopia. American Society of Contemporary Ophthalmology, 25th Annual Meeting, Phoenix, Arizona, March 29-April 1, 1990.
82. Poyer JF, Gabelt BT, Kaufman PL: Topical PGF_{2a} increases uveoscleral outflow in the rabbit eye. ARVO, Sarasota, FL, April 30, 1990.
83. Robinson JC, Kaufman PL: Cytochalasin B potentiates the outflow facility increasing effect of intracameral epinephrine in the Cynomolgus monkey. ARVO, Sarasota, FL, May 1, 1990.
84. Crawford K, Gabelt BT, Kaufman PL: Age-related decline in outflow facility and facility response to pilocarpine in rhesus monkeys. ARVO, Sarasota, FL, May 2, 1990.
85. Koretz JF, Cook CA, Kaufman PL: Age-dependent development of the zones of discontinuity in the human crystalline lens. ARVO, Sarasota, FL, May 2, 1990.
86. Cook CA, Koretz JF, Kaufman PL: Age-dependent and accommodation dependent increases in sharpness of human crystalline lens curvatures. ARVO, Sarasota, FL, May 2, 1990.

87. Brady MA, Sponsel WE, DePaul KL, Kaufman PL: Correlations of the asymmetry of visual function and retinal leukocyte velocity in treated glaucoma patients and untreated glaucoma suspects. ARVO, Sarasota, FL, May 3, 1990.
88. Glaucoma Laser Trial Study Group (Beckman H): Glaucoma Laser Trial - Results. American Academy of Ophthalmology and National Society to Prevent Blindness, Atlanta, GA, October 30, 1990.
89. Koretz JF, Kaufman PL: Scheimpflug slit-lamp photographic characterization of the aging of the human crystalline lens and the development of presbyopia. Optical Society of America/American Academy of Optometry. Sixth Topical Meeting on Non-invasive Assessment of the Visual System, Incline Village, NV, February 5-8, 1990.
90. Crawford KS, Heideman W, Robinson JC, Kaufman PL: Stimulation of cyclic AMP formation in monkey iris, ciliary processes, ciliary muscle and trabecular meshwork. ARVO, Sarasota, FL, April 29, 1991.
91. Robinson JC, Kaufman PL: Superior cervical ganglionectomy: effects on aqueous humor flow in the Cynomolgus monkey. ARVO, Sarasota, FL, April 29, 1991.
92. de Kater AW, Shahsafaei A, Epstein DL, Gabelt BT, Kaufman PL: Colocalization of smooth muscle specific contractile proteins and neuron-specific enolase in the monkey outflow system. ARVO, Sarasota, FL, April 29, 1991.
93. Croft MA, Kaufman PL, Erickson-Lamy K, Polansky JR: Accommodation and ciliary muscle muscarinic receptors after echothiophate. ARVO, Sarasota, FL, April 29, 1991.
94. Hubbard WC, Robinson JC, Kaufman PL: Inhibition of epinephrine's outflow facility increasing effect by indomethacin in the Cynomolgus monkey. ARVO, Sarasota, FL, April 30, 1991.
95. Gabelt BT, Kaufman PL: Muscarinic receptor subtype antagonist inhibition of pilocarpine-stimulated outflow facility, accommodation and pupil constriction in rhesus monkeys. ARVO, Sarasota, FL, May 3, 1991.
96. Kaufman PL: Parasympathetic denervation of the ciliary muscle following retinal photocoagulation. American Ophthalmological Society, 127th Annual Meeting, Pebble Beach, CA, May 19-22, 1991.
97. *Kaufman PL: Presentations: 1) Antimetabolites should be used in conjunction with all glaucoma filtration surgery: Pro; 2) Antimetabolites should be used in conjunction with all glaucoma filtration surgery: Pro (rebuttal). Controversial Issues in Glaucoma Today: A Debate. National Society to Prevent Blindness/American Glaucoma Society cosponsored symposium at the joint meeting of the American Academy of Ophthalmology/Pan-American Association of Ophthalmology, Anaheim, CA, October 15, 1991.
98. Wilensky JT, Kaufman PL, Frolichstein D, Gieser DK, Kass MA, Ritch R, Anderson R: Natural history of angle-closure glaucoma suspects. American Academy of Ophthalmology, 95th Annual Meeting/Pan-American Association of Ophthalmology, XVIIIth Congress, Anaheim, CA, October 15, 1991.
99. Folts JD, Levine RL, Kaufman PL: Cyclic flow reductions in stenosed monkey carotid arteries due to acute platelet thrombus formation: inhibited with aspirin but renewed with epinephrine. American Heart Association, 64th Scientific Sessions, Anaheim, CA, November 11-14, 1991.
100. *Seventeenth Annual Midwest Glaucoma Symposium, Wayne State University, Detroit, MI, March 26-28, 1992 (declined due to scheduling conflict).
101. *Kaufman PL: Physiologic and pharmacologic basis underlying medical therapy for glaucoma. American Society of Contemporary Ophthalmology, Twenty-seventh Annual Meeting/Sixteenth International Glaucoma Congress, Chicago, IL, April 14, 1992.
102. *Kaufman PL: The role of the ciliary muscle in presbyopia. Presbyopia: Causes and Treatment. Special Sunday Symposium, Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, FL, May 3, 1992.
103. Ménage MJ, Robinson JC, Kaufman PL, Sponsel WE: Retinal blood flow after superior cervical ganglionectomy: A laser Doppler velocimeter study in the Cynomolgus monkey. ARVO, Sarasota, FL, May 4, 1992.
104. Poyer JF, Kaufman PL: Pharmacology of the isolated rhesus monkey ciliary muscle. ARVO, Sarasota, FL, May 6, 1992.
105. Crawford KS, Hubbard WC, Kaufman PL: Prostaglandin EP₃ and DP agonist effects on IOP, pupil and refraction in monkeys. ARVO, Sarasota, FL, May 6, 1992.
106. Croft MA, Tamm E, Jungkunz W, Lütjen-Drecoll E, Kaufman PL: Age-related loss of ciliary muscle mobility in the rhesus monkey. Role of the choroid. ARVO, Sarasota, FL, May 6, 1992.

107. Shoemaker JA, Sponsel WE, Kaufman PL, Blum F, Brady MA, DePaul KL, Zetlan SR, Curran JA: Correlation of the asymmetry of visual function and retinal leukocyte velocity in glaucoma; observed differences between timolol- and betaxolol-treated patients. ARVO, Sarasota, FL, May 6, 1992.
108. Çardakli UF, Smythe BA, Kaufman PL: Effects of chronic apraclonidine treatment on IOP in advanced glaucoma. ARVO, Sarasota, FL, May 6, 1992.
109. Robinson JC, Kaufman PL: Phalloidin inhibits the outflow facility increasing effect of cytochalasin B and epinephrine. ARVO, Sarasota, FL, May 6, 1992.
110. Gabelt BT, Robinson JC, Kaufman PL, Peterson CM: Alpha₂-agonist effects on IOP, pulse and aqueous flow in monkeys. Role of systemic blood pressure and ocular sympathetic innervation. AVRO, Sarasota, FL, May 7, 1992.
111. Hubbard WC, Robinson JC, Kaufman PL: Dose-dependent suppression of aqueous humor formation by timolol in the Cynomolgus monkey. ARVO, Sarasota, FL, May 8, 1992.
112. Kemnitz J, Baum S, Elson D, Roecker E, Weindruch R, Barden H, Kaufman P, Crawford K, Ershler W: Caloric restriction and aging in rhesus macaques. FASEB, Anaheim, CA, April 8, 1992.
113. *Kaufman PL: PhXA41 and uveoscleral outflow - discussion (Yablonski ME, Toris CB, Camras CB: Effects of a new PGF_{2a} analog on aqueous humor dynamics in human eyes). Annual Meeting, American Academy of Ophthalmology, Dallas, TX, November 9, 1992.
114. Krupin T, Ruderman JM, Rosenberg LF, Feitl ME, Wax MB, Kass MA, Kolker AE, Camras CB, Liebmann JF, Ritch R, Serle JB, Schumer RA, Podos SM, Kaufman PL, Perkins TW: Krupin eye valve with disk for filtration surgery. Annual Meeting, American Academy of Ophthalmology, Dallas, TX, November 10, 1992.
115. *Kaufman PL: Presbyopia: a closer look. Ophthalmic and Visual Optics: Third Topical Meeting. Optical Society of America, Monterey, CA, February 19-20, 1993.
116. Perkins TW, Çardakli UF, Heatley GA, Promersberger ME, Kaufman PL, Eisele JR: Adjunctive use of intraoperative mitomycin in Molteno implant surgery for glaucoma. ARVO, Sarasota, FL, May 3, 1993.
117. Oyen MJ, Gange SJ, Croft MA, Fisher MR, Kaufman PL: Aging effects on accommodation and outflow facility and their response to pilocarpine in humans. ARVO, Sarasota, FL, May 3, 1993.
118. Poyer JF, Kaufman PL: Effect of muscarinic agonists and receptor subtype-specific antagonists on the contractile responses of the isolated rhesus monkey ciliary muscle. ARVO, Sarasota, FL, May 3, 1993.
119. Gabelt BT, Kaufman PL: Muscarinic receptor subtype antagonist inhibition of aceclidine stimulated outflow facility and accommodation and miosis in rhesus monkeys. ARVO, Sarasota, FL, May 4, 1993.
120. Croft MA, Hubbard WC, Kaufman PL: Effect of ethacrynic acid on aqueous outflow dynamics. ARVO, Sarasota, FL, May 4, 1993.
121. Kee C, Dueker DK, Alvarado JA, Kaufman PL, Pickett JP: Argon laser trabeculoplasty (ALT) in the Cynomolgus monkey. ARVO, Sarasota, FL, May 6, 1993.
122. Koretz JF, Cook C, Kaufman PL: Changes in adult human accommodation with age: crystalline lens dynamics. ARVO, Sarasota, FL, May 6, 1993.
123. Hubbard WC, Erickson KA, Lütjen-Drecoll E, Kaufman PL: Trabecular obstruction by polyacrylamide microgels. ARVO, Sarasota, FL, May 7, 1993.
124. *Kaufman PL: Ocular aging. First Annual Workshop on Dietary Restriction and Aging in Primates. National Institute on Aging and University of Wisconsin Institute on Aging, Merrimac, WI, June 17-20, 1993.
125. *Glaucoma Research Catalyst Seminar I. Potential New Drug Therapies of the Trabecular Meshwork. Glaucoma Research Catalyst Program of the American Glaucoma Society and the Foundation for Glaucoma Research. Chatham, MA, June 23-26, 1993. Roundtable discussions - no formal presentations.
126. Kaufman PL, Lütjen-Drecoll E, Erickson KA, Hubbard WC, Schroeder-Bodenkamp A: Crosslinked polyacrylamide microgels obstruct aqueous humor outflow in monkey and human eyes. Annual Meeting, American Academy of Ophthalmology, Chicago, IL, November 14-18, 1993.
127. *Kaufman PL: Presbyopia: a closer look. Annual Meeting, American Academy of Optometry, Boston, MA, December 10, 1993.
128. *Kaufman PL: Ciliary muscle aging. Basic Science Symposium: Nutrition, Environment and the Eye. Annual Meeting, Contact Lens Association of Ophthalmologists, Las Vegas, NV, January 12, 1994.

129. *Glaucoma Research Catalyst Seminar II. Does Lowering Intraocular Pressure Benefit the Glaucoma Patient? Glaucoma Research Catalyst Program of the American Glaucoma Society and the Foundation for Glaucoma Research, Baltimore, MD, March 10-13, 1994. Roundtable discussions - no formal presentations.
130. Millar JC, Kaufman PL: PGF_{2a} and its isopropylester decrease IOP without inhibiting accommodative response to pilocarpine in the Cynomolgus monkey eye. ARVO, Sarasota, FL, May 2, 1994.
131. Weber AJ, Kaufman PL, Hubbard WC, Stanford LR: Glaucoma-related neuronal degeneration in the primate retina and lateral geniculate nucleus (LGN). ARVO, Sarasota, FL, May 3, 1994.
132. Kaufman PL, Ménage M, Croft MA, Landay S: Intraocular pressure measurement after penetrating keratoplasty: minified Goldmann applanation tonometer, Pneumatonometer and Tono-pen versus manometry. ARVO, Sarasota, FL, May 4, 1994.
133. Kee C, Pelzek CD, Kaufman PL: Mitomycin C suppression of aqueous humor flow in Cynomolgus monkeys. ARVO, Sarasota, FL, May 5, 1994.
134. Gabelt BT, Kee C, Kaufman PL: Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. ARVO, Sarasota, FL, May 5, 1994.
135. Hubbard WH, Croft MA, Kaufman PL: Effect of daily topical ethacrynic acid (ECA) on aqueous dynamics in monkeys. ARVO, Sarasota, FL, May 5, 1994.
136. Croft MA, Kaufman PL: Effect of acepromazine maleate (Promace®) as aqueous humor dynamics. ARVO, Sarasota, FL, May 5, 1994.
137. *Kaufman PL: Organizer, Co-Moderator, Summary Discussion. Animals in Research Committee Symposium. *In Vitro*, Live Animal and Human Methodologies in Vision Research: Competitive or Complementary Approaches. Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, FL, May 4, 1994
138. Weber AJ, Kaufman PL, Hubbard WS, Stanford LR: Neuronal degeneration in the primate dorsal lateral geniculate nucleus (LGN) following elevation of intraocular pressure. Annual Meeting, Society for Neuroscience, Miami Beach, FL, November 17, 1994.
139. *Kaufman PL: Miotics: new understanding, new therapies. Under Pressure: Glaucoma 1994. American Glaucoma Society/American Academy of Ophthalmology Joint Symposium, American Academy of Ophthalmology, 96th Annual Meeting, San Francisco, CA, October 29, 1994.
140. Camras CB, Wax M, Ritch R, Weinreb RN, Robin AL, Higginbotham EJ, USA Latanoprost Study Group. Latanoprost. A potent ocular hypotensive prostaglandin analog, increases pigmentation in peripherally hypopigmented irides. Annual Meeting, American Academy of Ophthalmology, San Francisco, CA, October 30-November 3, 1994.
141. *Kaufman PL: The biomechanics of accommodation and presbyopia. Myopia and Presbyopia: New Insights Regarding Pathogenesis. Association for Research in Vision and Ophthalmology/American Academy of Ophthalmology Combined Meeting, American Academy of Ophthalmology, 96th Annual Meeting, San Francisco, CA, November 3, 1994.
142. Peterson JA, Kiland JA, Croft MA, Aref A, Pelzek C, Kaufman PL: Intraocular pressure measurement in Cynomolgus monkeys: Fluorescein vs. creamer. Tonopen vs. manometry. ARVO, Ft. Lauderdale, FL, May 14, 1995.
143. Millar JC, Poyer JF, Peterson JA, Kaufman PL: Effects of endothelins and prostaglandin F_{2α} on isolated monkey ciliary muscle. ARVO, Ft. Lauderdale, FL, May 14, 1995.
144. *Kaufman PL: Overview of present theories, Session I - Mechanism of Accommodation. Accommodation and Presbyopia, ARVO Special Interest Group Meeting, Ft. Lauderdale, FL, May 15-16, 1995.
145. Hernandez MR, Hanninen L, Hubbard WC, Kaufman PL, Weber AJ: Astrocyte responses in the lamina cribrosa in pressure-dependent glaucomatous optic neuropathy in monkeys. ARVO, Ft. Lauderdale, FL, May 17, 1995.
146. Kiland JA, Gabelt BT, Wagle N, Brubaker RF, Kaufman PL: Effect of timolol on ascorbate levels and aqueous humor flow in rhesus monkeys. ARVO, Ft. Lauderdale, FL, May 17, 1995.
147. Croft MA, Kiland J, Peterson J, Hubbard WC, Kaufman PL: Effects of promazine hydrochloride on aqueous humor dynamics in monkeys. ARVO, Ft. Lauderdale, FL, May 17, 1995.
148. Tian B, Gabelt BT, Crosson CE, Kaufman PL: Effects of adenosine agonists on IOP and aqueous humor dynamics in Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, May 17, 1995.

149. Kee C, Gabelt BT, Croft MA, Gange SJ, Ménage MJ, Kaufman PL: Effects of autologous serum and α -aminocaproic acid on resistance washout and outflow facility in monkeys. ARVO, Ft. Lauderdale, FL, May 17, 1995.
150. Koretz JF, Rogot A, Kaufman PL: Physiological strategies for emmetropia. Annual Meeting, American Ophthalmological Society, Hot Springs, VA, May 23, 1995.
151. Camras CB, Alm A, Watson PG, USA, Scandinavia and UK Latanoprost Study Groups: Glaucoma treatment for one year with latanoprost, a prostaglandin analog, in the USA, Scandinavia and UK. Annual Meeting, American Academy of Ophthalmology, Atlanta, GA, October 30, 1995.
152. Kaufman PL: The future: neuroprotection and reversal of visual loss. Current Concepts in Refractive Surgery, Glaucoma, and Cataract Surgery: The 175th Anniversary Conference. The New York Eye and Ear Infirmary, New York, NY, December 1-2, 1995.
153. *Kaufman PL: Organizer and moderator, Leading Scientists Meeting. Trabecular Meshwork and Optic Nerve. Glaucoma Research Foundation, Tempe, AZ, March 1-3, 1996.
154. Chen Z, Gu Q, Kaufman PL, Cynader MS: The localization of nitric oxide synthase (NOS) in human and monkey eye. ARVO, Ft. Lauderdale, FL, April 22, 1996.
155. Kaufman PL, Jia WW-G, Tan J, Booth V, Tufaro F, Cynader M: Lac z expression in ciliary muscle and trabecular meshwork of the living cat eye following anterior chamber injection of replication-deficient HSV-1. ARVO, Ft. Lauderdale, FL, April 23, 1996.
156. Tian B, Kaufman PL, Geiger B, Volberg T, Gabelt BT: The protein kinase inhibitor H-7 increase outflow facility and inhibits miotic but not accommodative responses to pilocarpine in monkeys. ARVO, Ft. Lauderdale, FL, April 22, 1996.
157. Kiland JA, Croft MA, Kaufman PL: Atropine reduces but does not eliminate the age-related decline in perfusion outflow in monkeys. ARVO, Ft. Lauderdale, FL, April 24, 1996.
158. Peterson JA, Tian B, Kiland JA, Gabelt BT, Bershinsky A, Geiger B, Kaufman PL: Latrunculin (Lat)-A and staurosporin, but not swinholide (Swin)-A, increase outflow facility in the Cynomolgus monkey. ARVO, Ft. Lauderdale, FL, April 24, 1996.
159. Millar C, Kiland JA, Peterson J, Hubbard WC, Osborne NN, Kaufman PL: Serotonergic and endothelin (ET)-1 effects on aqueous humor dynamics in monkeys. ARVO, Ft. Lauderdale, FL, April 24, 1996.
160. Croft MA, Neider MW, Crawford KS, Carino OB, Bito LZ, Kaufman PL: Lenticular and ciliary body dynamics in aging rhesus monkeys. ARVO, Ft. Lauderdale, FL, April 24, 1996.
161. Gabelt BT, Kiland JA, Peterson JA, Kaufman PL: Effects of the NA/K/2C1 co-transport inhibitor bumetanide on aqueous humor formation and outflow facility in monkeys. ARVO, Ft. Lauderdale, FL, April 22, 1996.
162. Hubbard WC, Johnson M, Gong H, Gabelt BT, Tian B, Peterson JA, Sawhney R, Freddo T, Kaufman PL: IOP and outflow facility are unchanged following acute and chronic intracameral chondroitinase and hyaluronidase in monkeys. ARVO, Ft. Lauderdale, FL, April 24, 1996.
163. Coloma FM, Croft MA, Ethier CR, Gangnon R, Ladd B, Kaufman PL: Study of ECA effects on inner wall pores in living monkeys. ARVO, Ft. Lauderdale, FL, April 24, 1996.
164. *Kaufman PL: Presentation: Potential applications of neuroprotectants to glaucoma. Moderator: Discussion session on lazardoids and anti-death gene expression in retinal ganglion cells. Think Tank on Optic Nerve Rescue and Restoration. The Glaucoma Foundation, New York, NY, June 6-7, 1996.
165. *Kaufman PL: Enhancing the outflow. 100 Years of Progress in Glaucoma: Celebrating our Heritage and Looking to the Future. American Glaucoma Society/American Academy of Ophthalmology Joint Symposium, American Academy of Ophthalmology, Centennial Annual Meeting, Chicago, IL, October 26, 1996.
166. *Kaufman PL: Overview of symposium: founding and early history of ARVO. Symposium Organizer and Chairperson, Glaucoma at the Millennium. Association for Research in Vision and Ophthalmology/American Academy of Ophthalmology Combined Meeting, American Academy of Ophthalmology, Centennial Annual Meeting, Chicago, IL, October 30, 1996.
167. *Kaufman PL: Discussion of Drance SM, Crichton A, Mills RP: Comparison of the effect of 0.005% latanoprost and 0.5% timolol on the ocular perfusion pressure in patients with normal tension glaucoma. American Academy of Ophthalmology, Centennial Annual Meeting, Chicago, IL, October 30, 1996.

168. *Kaufman PL: Effects of marijuana on glaucoma. Workshop on the Medical Utility of Marijuana. National Institutes of Health, Bethesda, MD, February 19-20, 1997.
169. Koretz JF, Cook CA, Kaufman PL: Aging changes in the human accommodative process. Optical Society of America/American Academy of Optometry, Vision Science and Its Applications, Santa Fe, NM, January 31-February 3, 1997.
170. Weber AJ, Chen H, Kaufman PL, Hubbard WC: Effects of elevated IOP on cell size, density and number in the primate lateral geniculate nucleus (LGN). ARVO, Ft. Lauderdale, FL, May 11, 1997.
171. Glasser A, Kaufman PL: *In vitro* electrical stimulation of intact enucleated monkey eyes. ARVO, Ft. Lauderdale, FL, May 12, 1997.
172. Peterson JA, Tian B, Geiger B, Spector I, Kaufman PL: In Cynomolgus monkeys Latrunculin (Lat)-A, La-B increase outflow facility, Lat-A decreases intraocular pressure and initially increases aqueous humor formation. ARVO, Ft. Lauderdale, FL, May 12, 1997.
173. Croft MA, Wang RF, Podos SM, Neufeld A, Kaufman PL: Effect of ticrynafen (TI) on aqueous dynamics in monkeys. ARVO, Ft. Lauderdale, FL, May 12, 1997.
174. Vilardo ML, Perkins TW, Kaufman PL, Heatley GA: Early post-operative results of restricted flow implant devices with mitomycin C. ARVO, Ft. Lauderdale, FL, May 12, 1997.
175. To E, Matsubara JA, Cynader M, Kalil RE, Gabelt BT, Nork TM, Kaufman PL: Effects of pan-retinal photocoagulation treatment on central visual pathways in the monkey. ARVO, Ft. Lauderdale, FL, May 13, 1997.
176. Hubbard WC, Gabelt BT, Kaufman PL: Effect of 3 μ , 5 μ -tetrahydrocortisol on total outflow facility in ocular normotensive Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, May 14, 1997.
177. Kiland JA, Peterson JA, Gabelt BT, Kaufman PL: Effect of DMSO and fluid exchange volume on outflow resistance washout and response to pilocarpine during anterior chamber perfusion in monkeys. ARVO, Ft. Lauderdale, FL, May 14, 1997.
178. Gabelt BT, Peterson JA, Tian B, Hubbard WC, Geiger B, Kaufman PL: Latrunculin (Lat)-A causes mydriasis and cycloplegia in the Cynomolgus monkey. ARVO, Ft. Lauderdale, FL, May 14, 1997.
179. Cynader M, Booth V, Nork TM, Gabelt BT, Hubbard WC, Kaufman PL: Ciliary muscle M₃ muscarinic receptors decrease after panretinal photocoagulation in the Cynomolgus monkey. ARVO, Ft. Lauderdale, FL, May 14, 1997.
180. Chen Z, Kia W, Kaufman PL, Cynader M: Herpes simplex virus mediated *Lac-z* gene transfer into rabbit retina. ARVO, Ft. Lauderdale, FL, May 15, 1997.
181. *Kaufman PL: Mechanism and interaction with pilocarpine. Prostaglandin Analogs for Glaucoma Therapy - Facts and Myths. ARVO Special Interest Group Meeting, Ft. Lauderdale, FL, May 12, 1997.
182. *Kaufman PL: Animal models of glaucoma - monkey - polyacrylamide microgels. Moderator: Reports on current research. Fourth Annual Scientific Think Tank on Optic Nerve Rescue and Restoration. The Glaucoma Foundation, New York, NY, June 6-7, 1997.
183. *Kaufman PL: Presentation: Outflow II: physiologic regulation - eye. Moderator: Outflow II: physiologic regulation. Glaucoma - Hydrocephalus Catalyst Meeting. Glaucoma Research Foundation, Val-Morin, Quebec, Canada, June 19-22, 1997.
184. *Kaufman PL: Effects of some novel compounds on fluorophotometrically measured aqueous flow in monkeys. Aqueous Humor Formation and the Development of New Carbonic Anhydrase Inhibitors. Mount Desert Island Biological Laboratory, Salisbury Cove, ME, June 27, 1997.
185. *Kaufman: Cytoskeletal and cell junctional mechanisms in aqueous outflow. 32nd Ophthalmic Biochemistry Conference: Glaucoma Symposium, Oakland University, Rochester, MI, September 25-28, 1997.
186. *Kaufman PL: New thoughts on outflow. Under Pressure: Glaucoma 1997. American Academy of Ophthalmology Subspecialty Day, 101st Annual Meeting, San Francisco, CA, October 25, 1997.
187. *Glasser A, Kaufman PL: The mechanisms of presbyopia (PK invited to present, scheduling conflict precluded, AG presented at PK's suggestion). Reshaping the Future: Refractive Surgery 1997. American Academy of Ophthalmology Subspecialty Day, 101st Annual Meeting, San Francisco, CA, October 24-25, 1997.
188. *Kaufman PL: Marijuana and glaucoma. Workshop on Basic Science and Clinical Perspectives on the Medical Use of Marijuana. Institute of Medicine, National Academy of Sciences, Irvine, CA, December 14-16, 1997.

189. *Kaufman PL: Presentations: 1) Xalatan and its place in glaucoma management; 2) Small Group Session on Risk Factors (moderator). Glaucoma Expert Conference. Pharmacia & Upjohn, New York, NY, December 18-20, 1997.
190. Glasser A and Kaufman PL: Dynamics of refractive changes and lens and ciliary body movements in rhesus monkey eyes during Edinger-Westphal nucleus stimulated accommodation. Vision Science and Its Applications. Optical Society of America, Santa Fe, NM, February 6-9, 1998.
191. Lütjen-Drecoll E, Kaufman PL: Acute and chronic structural effects of pilocarpine on monkey outflow tissues. Annual Meeting, American Ophthalmological Society, Hot Springs, VA, May 17-20, 1998.
192. Glasser A, Kaufman PL: The accommodative mechanism of primate eyes revisited. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
193. Gabelt BT, Tian B, Volberg T, Geiger B, Kaufman PL: Outflow facility effects in monkeys following intracameral 1) H-7 + cytochalasin B; 2) typhostins. ARVO, Lauderdale, FL, May 10-15, 1998.
194. Tian B, Peterson JA, Hubbard WC, Kaufman PL: Effects of topical H-7 on ciliary epithelium and corneal endothelium in monkey eyes. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
195. Hubbard WC, Robinson JC, Schmidt K, Rohen JW, Kaufman PL: Superior cervical ganglionectomy in monkeys: effects on refraction and intraocular pressure. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
196. May CA, Furuioishi M, Furuioishi N, Hayreh SS, Alm A, Kaufman PL, Bloemendal H, Lütjen-Drecoll E: Changes in glial ultrastructure and expression of alphaB-crystallin in glaucomatous optic neuropathy. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
197. Sagara T, Gatton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Prostaglandin F_{2α} alters extracellular matrix collagens in ciliary muscle, iris root and sclera of monkey eyes *in vivo*. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
198. Gatton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Matrix metalloproteinases increases *in vivo* by prostaglandin F_{2α} in iris root, ciliary muscle and adjacent sclera of monkey eyes. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
199. Peterson J, Tian B, Geiger B, Kaufman PL: Reversibility of latrunculin (LAT)-An effect on outflow facility (of) and anterior segment permeability in monkeys. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
200. Kiland JA, Peterson JA, Tian B, Geiger B, Kaufman PL: Effects of latrunculin (LAT)-B on aqueous humor dynamics, aqueous [protein], and corneal thickness in Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL May 10-15, 1998.
201. Lewis R, Perkins TW, Kaufman PL, Heatley GAA, Gangnon R: The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
202. Croft MA, Glasser A, Kaufman PL: The relationship between ciliary muscle function and the lens. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
203. Perkins TW, Glasser A, Gabelt BT, Kaufman PL: Characterization of glaucoma implant devices under pulsatile flow conditions. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
204. Liu X, Glasser A, Croft MA, Polansky JR, Fauss DJ, Kaufman PL: Effect of H-7 on cultured human trabecular meshwork (HTM) cells. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
205. Chen Z, Gu Q, Kaufman PL, Cynader MS: Immunoreactivities of the neurotrophin receptors TrkA and TrkB in human and monkey eyes. ARVO, Ft. Lauderdale, FL, May 10-15, 1998.
206. *Kaufman PL: *In vivo* gene transfer to monkey RGC and RPE. Moderator, Sessions on 1) Research Reports; 2) Extracellular Matrix. Fifth Annual Glaucoma Think Tank on Think Optic Nerve Protection and Restoration, The Glaucoma Foundation, New York, September 25-26, 1998.
207. *Glasser A, Kaufman PL: The mechanism(s) of presbyopia. Refractive Surgery 1998: Reshaping the Future. American Academy of Ophthalmology Subspecialty Day, 102nd Annual Meeting, New Orleans, LA, November 6-7, 1998.
208. *Kaufman PL: Aqueous humor outflow: conventional and unconventional. Glaucoma 1998: Controversies and Update. American Academy of Ophthalmology Subspecialty Day, 102nd Annual Meeting, New Orleans, LA, November 7, 1998.
209. *Kaufman PL: Is glaucoma a medical or surgical disease? EyeNet Audio. American Academy of Ophthalmology Subspecialty Day, 102nd Annual Meeting, New Orleans, LA, November 7, 1998.

210. *Kaufman PL: Current and future drug therapy for glaucoma. Breakfast with the Experts. American Academy of Ophthalmology Subspecialty Day, 102nd Annual Meeting, New Orleans, LA, November 9, 1998.
211. *Kaufman PL: Preclinical pharmacology and physiology. International Glaucoma Meeting. The Use of Docosanoid Derivatives in the Treatment of Glaucoma. CibaVision, Inc., New Orleans, LA, November 8, 1998.
212. *Kaufman PL: Physiology of the trabecular meshwork. Glaucoma Catalyst Meeting IX: Genetics and Cell/Molecular Biology of Glaucoma. Glaucoma Research Foundation, San Juan, PR, December 3-6, 1998.
213. *Kaufman PL: Moderator: Neuroprotection Session. Glaucoma Expert Meeting, Pharmacia & Upjohn, Inc., New York, NY, December 17-19, 1998.
214. *1) Glasser A, Croft MA, Kaufman PL: A morphometric ultrasound biomicroscopic study of the aging rhesus monkey ciliary region; 2) Kaufman PL, Glasser A, Croft MA: The relationship between lens and ciliary process function during accommodation in rhesus monkeys. Vision Science and Its Applications. Optical Society of America, Santa Fe, NM, February 19-22, 1999.
215. Croft MA, Glasser A, Gabelt BT, Ebbert T, Heatley GA, Kaufman PL: Lens and ciliary muscle function in young and old rhesus monkeys. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
216. Kiland JA, Hubbard WC, Kaufman PL: Low doses of pilocarpine do not significantly increase outflow facility in the Cynomolgus monkey. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
217. Yücel YH, Zhang Q, Gupta N, Kaufman PL, and Weinreb RN: Loss of neurons in magno- and parvocellular layers of the lateral geniculate nucleus (LGN) in experimental glaucoma. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
218. Peters DMP, Liu X, Untawale S, Nguyen T, Polansky JR, Fauss DJ, Kaufman PL: Assembly of fibronectin/TIGR matrices in human trabecular meshwork (HTM) cells. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
219. Cai S, Liu X, Glasser A, Croft MA, Polansky JR, Fauss DJ, Kaufman PL: Latrunculin (LAT)-A effects on human trabecular meshwork (HTM) cells. ARVO, Ft. Lauderdale, FL, May 9-14, 1999.
220. Tian B, and Kaufman PL: ML-7, chelerythrine and phorbol ester increase outflow facility in monkeys. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
221. Gabelt BT, Tian B, Sabanay I, Kaufman PL, Geiger B: Effect of H-7 on trabecular meshwork structure and fluid conductance in monkeys. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
222. DeBry PW, Perkins TW, Heatley GA, Kaufman PL: The incidence and outcome of late-onset bleb leaks following trabeculectomy with mitomycin C. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
223. Liu X, Brandt CR, Gabelt BT, Polansky JR, Fauss DJ, Weinreb RN, and Kaufman PL: Herpes simplex virus (HSV)-1 mediated gene transfer to primate ocular tissues. ARVO, Ft. Lauderdale, FL May 9-14, 1999.
224. Leske MC: The Early Manifest Glaucoma Trial: Baseline results. ARVO, Ft. Lauderdale, FL, May 9-14, 1999.
225. Heijl A: The Early Manifest Glaucoma Trial: Study aims and design. ARVO, Ft. Lauderdale, FL, May 9-14, 1999.
226. Weinreb RN, Lindsey JD, Gaton DD, Sagara T, Polansky JR, Gabelt BT: TIGR protein is reduced in the ciliary muscle of prostaglandin-treated monkey eyes. ARVO, Ft. Lauderdale, FL, May 9-14, 1999.
227. *Kaufman PL: Overview of theories of presbyopia. University of Presbyopia Workshop, Bausch & Lomb, Ft. Lauderdale, FL, May 14, 1999.
228. *Kaufman PL: Ocular focusing mechanisms and their aging in subhuman primates. Applications of Vision Science Technical Group Symposium - Accommodation: Experimental and Model Studies. 1999 Optical Society of America Annual Meeting, Santa Clara, CA, September 26-October 1, 1999.
229. Glasser A, Kaufman PL: Edinger-Westphal stimulated accommodation in rhesus and Cynomolgus monkeys. Session on Presbyopia Correction, International Society for Refractive Surgery, Orlando, FL, October 22-23, 1999.
230. *Kaufman PL: New approaches to altering trabecular outflow. Glaucoma 1999: Concepts and Controversies. American Academy of Ophthalmology Subspecialty Day, 103rd Annual Meeting, Orlando, FL, October 23, 1999.
231. *Kaufman PL: Current and future drug therapy for glaucoma. Breakfast with the Experts. American Academy of Ophthalmology Subspecialty Day, 103rd Annual Meeting, Orlando, FL, October 25, 1999.

232. Faha B, Perkins TW, Maneval D, Kaufman PL, Nickells RW: Effect of p21 gene therapy in a rabbit model of glaucoma surgery failure. Keystone Symposium: Gene Therapy - The Next Millennium. Keystone, CO, January 6-12, 2000.
233. Gabelt BT, Kaufman PL: Uveoscleral outflow: monkey vs. man, young vs. old. American Glaucoma Society, 10th Annual Meeting. San Antonio, TX, March 2-4, 2000.
234. Camras CB, Wax MB, Ritch R, Weinreb R, Robim AL, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T, Stjerschantz J, Hedman K and the United States Latanoprost Study Group: Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. American Glaucoma Society, 10th Annual Meeting, San Antonio, TX, March 2-4, 2000.
235. Kaufman PL: What is glaucoma? Moderator: Session II - Aqueous Humor, Myocilin and Outflow; Session V – Translation of Myocilin/TIGR – Effects of Mutations. Glaucoma Research Foundation. Myocilin/TIGR Catalyst meeting. Berkeley, CA, March 30-April 2, 2000.
236. Gabelt BT, Kaufman PL: Uveoscleral outflow decreases in old rhesus monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
237. Seeman JL, Gabelt BT, Kaufman PL, Mittag TW, Podos SM: Effect of 8-iso PGE₂ on IOP and outflow facility in monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
238. Borrás T, Gabelt BA, Rowlette LL, Kaufman PL: Gene transfer to the trabecular meshwork of living monkeys can be followed non-invasively. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
239. Kiland JA, Gabelt BT, Kaufman PL: Timolol + dorzolamide dose-response in the Cynomolgus monkey. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
240. Tian B, Kaufman PL: Effect of the potent inducer of actin polymerization jasplakinolide on outflow facility in monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
241. Yücel YH, Gupta N, Zhang Q, Kaufman PL, Weinreb RN: Loss of blue-on neurons of the lateral geniculate nucleus (LGN) in experimental ocular hypertension. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
242. Croft MA, Glasser A, Gabelt BT, Ebbert T, Heatley GA, Kaufman PL: Ciliary muscle and lens function in young and old monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
243. Perkins TW, Faha B, Kiland JA, Poulsen G, Brumback L, Sinha D, Maneval D, Kaufman PL, Nickells RW: Effect of p21 gene therapy on glaucoma filtering surgery in rabbits. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
244. Lam DY, Kaufman PL, Gabelt BT, Matsubara JA: Cortical consequences of elevated intraocular pressure in a primate model of glaucoma. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
245. Pena JDO, Kaufman PL, Kiland JA, Gabelt BT, Hernandez MR: Elastin expression in the lamina cribrosa in monkeys with experimental glaucoma and with optic nerve transection. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
246. *Kaufman PL: Chronic IOP elevation in the monkey. In mini-symposium: Animal Models for Glaucoma. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
247. *Kaufman PL: Current state of aqueous outflow knowledge: where might TIGR/Myocilin fit? In Special Interest Group #5: TIGR/Myocilin Protein Properties and its Possible Roles in Glaucoma Pathogenesis. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
248. Stamper RL, Kaufman PL: Session moderators: Glaucoma, Pharmacology III. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
249. *Maguire M, Beck R, Ferris F, Kaufman PL: Clinical Trials Course. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2000.
250. *Kaufman PL: Future trends in glaucoma. Glaucoma Update 2000 Meeting, Pharmacia Corporation, Carlsbad, CA, June 9-11, 2000. Meeting Chairman.
251. *Vision for The Future: Moving Glaucoma Research Results into Clinical Practice. Workshop, June 26-27, 2000, Rancho Valencia, CA. The Washington Advisory Group, LLC, Washington, DC. Presentations 1): Glaucoma Pathophysiology and Therapy; 2) Various discussions.
252. *Kaufman PL: Medical therapy of glaucoma in the future: Thinking outside the box. The American Glaucoma Society Subspecialty Day Lecture in Honor of Bernard Becker, MD, AAO/AGS: Subspecialty Day 2000 /

- Glaucoma 2000: Cutting Edge Diagnosis and Therapy. American Academy of Ophthalmology 104th Annual Meeting, Dallas, TX, October 21, 2000.
253. *Kaufman PL: Current and future drug therapy for glaucoma. AAO 2000 Breakfast with the Experts Roundtable Program. American Academy of Ophthalmology 104th Annual Meeting, Dallas, TX, October 23, 2000.
254. *Kaufman PL: Medical therapy to lower intraocular pressure. AAO/Prevent Blindness America Glaucoma Symposium - Glaucoma Management Y2K: Where we are, and where we are going. American Academy of Ophthalmology 104th Annual Meeting, Dallas, TX, October 23, 2000.
255. *Kaufman PL: Brain manifestations of glaucoma. AAO/AAO Program Advisory Committee: Hot Topics Symposium. American Academy of Ophthalmology 104th Annual Meeting, Dallas, TX, October 24, 2000.
256. *Kaufman PL: Future trends in glaucoma treatment. Glaucoma Update 2000 Meeting, Dorado, Puerto Rico, November 3-5, 2000. Meeting Chairman.
257. *Kaufman PL: Viscoanalostomy – Is there a use for it, and how does it work? Chairman, General Glaucoma Section. Glaucoma Specialists Meeting, New York, NY, December 14-16, 2000.
258. *New Orleans Academy of Ophthalmology – Glaucoma. April 2001. Declined due to schedule conflict.
259. *Kaufman PL: Gene therapy for glaucoma: anterior and posterior segment targets and constraints. American Glaucoma Society Basic Science Lecture, Newport Beach, CA, March 1-3, 2001.
260. Croft MA, Glasser A, McDonald JP, Bunch T, Vinje E, Gabelt BT, Ebbert T, Heatley GA, Kaufman PL: Ciliary muscle, lens and zonular interaction in young and old rhesus monkeys. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
261. McDonald JP, Croft MA, Adriansjach P, Vinje E, Bunch T, Gwon A, Laguette SW, Kamerling W, Heatley GA, Kaufman PL: Assessing ciliary muscle (CM), lens, & IOL function during pharmacological or direct electrical stimulation of the CM. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
262. Liu X, Huang C, Cai S, Polansky JR, Kaufman PL, Brandt CR: Activities of viral and human promoters for ectopic TIGR expression in cultured trabecular meshwork cells. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
263. Filla MS, Liu X, Nguyen T, Polansky JR, Kaufman PL, Peters DMP: TIGR/MYOC interaction with trabecular meshwork ECM proteins. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
264. Wilkerson CL, Kim CBY, Kaufman PL, Gabelt BT, Seeman JL, Nork TM, Ver Hoeve JN: Acute elevation of intraocular pressure increases multifocal ERG amplitude. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
265. Ver Hoeve JN, Kim CBY, Heatley GA, Kaufman PL, Kiland JA, Nickells RW, Nork TM: Delay of an early multifocal ERG wave feature in experimental glaucoma. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
266. Firth SI, Kaufman PL, Marshak DW: Innervation of the uvea by galanin and somatostatin immunoreactive axons in macaques and baboons. Invest Ophthalmol Vis Sci 42(4, ARVO Suppl): S210, 2001 (Abstract #1128).
267. Yücel Y, Gupta N, Zhang Q, Kaufman PL, Weinreb RN: Atrophy of surviving neurons in the lateral geniculate nucleus (LGN) in glaucoma increases with optic nerve damage and intraocular pressure. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
268. Gupta N, Zhang Q, Weinreb RN, Kaufman PL, Yücel YH: Degenerative changes in lateral geniculate nucleus (LGN) neurons connected to the unaffected eye in unilateral glaucoma. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
269. Luthra A, Gupta N, Kaufman PL, Weinreb RN, Yücel YH: Evidence of peroxynitrite induced cell injury in the lateral geniculate nucleus (LGN) in glaucoma. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
270. Kim CBY, Ver Hoeve JN, Nickells RW, Kaufman PL, Heatley GA, Kiland JA, Nork TM: Multifocal ERG in experimental glaucoma: Relation to optic nerve transection. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
271. Peters DM, Santas AJ, Liu X, Polansky JR, Kaufman PL, Tamm ER, Johnson D: The Heparan II domain of fibronectin modulates aqueous outflow: Effect on trabecular meshwork (TM) matrix and adhesions. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
272. Agapova OA, Gabelt BT, Levin LA, Lucarelli MJ, Kaufman PL, Hernandez MR: Matrix metalloproteinase (MMP) expression in monkey eyes with experimental glaucoma and with optic nerve transection. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
273. Kiland JA, Gabelt BT, Kaufman PL: Four week treatment with timolol + dorzolamide + PGF2 α reduces outflow facility in the Cynomolgus monkey. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.

274. Seeman JL, Gabelt BT, Kiland JA, Kaufman PL: HU-210 and WIN 55, 212,2 effects on IOP, pupil and refraction in Cynomolgus monkeys. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
275. Rasmussen CA, Gabelt BT, Kiland JA, Russell KR, Potter DE, Kaufman PL: Effect of bremsazocine on IOP, refraction and pupil diameter in Cynomolgus monkeys. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
276. Tian B, Gabelt BT, Sabanay I, Geiger B, Kaufman PL: Effect of fluid conductance on reversibility of H-7 effects on outflow facility in monkeys. ARVO, Ft Lauderdale, FL, April 29-May 4, 2001.
277. *Kaufman PL: The clinician's interface with industry. ARVO Clinician Scientist Forum. ARVO, Ft Lauderdale, FL, May 2, 2001.
278. Nork TM, Lam DY, Kalil RE, Gabelt BT, Hornan DH, Kaufman PL, Matsubara JA: The effects of pan-retinal photocoagulation on the primary visual cortex of the adult monkey. American Ophthalmological Society, 137th Annual Meeting, Hot Springs, Virginia, May 20-23, 2001.
279. Mattison JA, Croft MA, Kaufman PL, Hubbard W, Gabelt BT, Kiland JA, Dahl D, Roth GS, Ingram DK, Lane MA: Calorie restriction does not affect the age-related decline in ocular lens clarity or accommodation in rhesus monkeys. Nonhuman Primate Models of Aging: Evaluating their Current Status and Future Potential; Preconference Symposium to the 30th Annual Meeting of the American Aging Association, Madison, WI, May 31-June 12, 2001.
280. *Croft MA, Gabelt BT, Glasser A, Heatley GA, Kaufman PL: Effects of aging on lens and ciliary muscle function and aqueous humor dynamics. Nonhuman Primate Models of Aging: Evaluating their Current Status and Future Potential; Preconference Symposium to the 30th Annual Meeting of the American Aging Association, Madison, WI, May 31-June 12, 2001.
281. *Kaufman PL: Glaucoma and its potential target tissues. Eighth Annual Glaucoma Foundation Optic Nerve Rescue and Regeneration Think Tank: Gene Therapy. New York, NY, July 20-21, 2001.
282. *2001 American Academy of Ophthalmology, 105th Annual Meeting, New Orleans, LA, November 10-14, 2001. Presentations: 1) Glaucoma Subspecialty Day. Glaucoma 2001: Evolution and Revolution. Moderator, Session on Glaucoma Clinical Challenges. 2) Free Papers: What's New in Glaucoma. Discussant for: Rifkind AW et al: Health Canada Phase I study to determine the effect of scleral expansion band on ocular hypertension and primary open angle glaucoma. 3) Breakfast with the Experts Roundtable. B-223; Present and Future Medical Therapy for Glaucoma. 4) Glaucoma Update (joint AAO/ARVO Symposium) The outflow pathway: how does it function?
283. *Kaufman PL: Glaucoma Therapy: Star Wars. Pharmacia East Coast Glaucoma Summit, Miami, FL, November 30-December 2, 2001.
284. *Kaufman PL: Viscocanalostomy. Pharmacia Glaucoma Specialists Meeting: Latanoprost Clinical Update, New York, NY, December 13-16, 2001.
285. *Kaufman PL: Moderator/Chair. Pharmacia Glaucoma Update Faculty Meeting, St. Martin, F.W.I., March 21-24, 2002.
286. McDonald JP, Croft MA, Mausher I, Larson BL, Kaufman PL: Assessing accommodation after a scleral buckling (SB) procedure. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
287. Bunch T, Croft MA, McDonald JP, Hennes E, Vinje E, Kaufman PL: Effect of isoflurane vs pentobarbital anesthesia on accommodation in rhesus monkeys. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
288. Filla M, Johnson D, David G, Kaufman PL, Peters DM: Localization of Heparan sulfate proteoglycans (syndecans) in the human anterior chamber. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
289. Yücel YH, Yeung J, Zhang Q, Weinreb RN, Kaufman PL, Gupta N: Altered expression of TrkB and TrkC nerve growth factor receptors in the lateral geniculate nucleus in glaucoma. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
290. Kim CBY, Ver Hoeve JN, Kaufman PL, Nork TM: Nonhuman primate species differences in multifocal ERG. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
291. Faha B, Heatley GA, Kiland JA, Seeman J, Maneval D, Kaufman PL, Nickells R. Antiproliferative p21^{WAF-1/Cip-1} gene therapy and trabeculectomy controls IOP and reduces optic nerve damage in a primate model of glaucoma. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
292. Gabelt BT, Seeman JL, Kiland JA, Podos SM, Mittag TW, Kaufman PL: Uveoscleral outflow and trabecular outflow facility after topical 8-ISO PGE₂. ARVO, Ft Lauderdale, FL, May 5-10, 2002.

293. Ver Hoeve JN, Kim CBY, Nickells R, Kaufman PL, Heatley GA, Faha B, Nork TM: Recovery of late multifocal ERG in experimental ocular hypertension following IOP reduction. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
294. Wamsley S, Steffen E, Gabelt BT, Dahl DB, Kaufman PL: Vitreous glutamate concentration in monkeys with experimental glaucoma. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
295. Chen Z, Wen S, Maneval D, Hess M, Nery J, Kaufman PL, Nickells R, Faha B: Biodistribution of an adenovirus encoding human p21^{WAF1/Cip-1} (rAd-p21) following subconjunctival injection in rabbits. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
296. Rasmussen CA, Gabelt BT, Kaufman PL: Effect of WIN 55,212-2 on monkey and dog ciliary muscle *in vitro*. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
297. Seeman JL, Rasmussen CA, Gabelt BT, Kaufman PL: Anesthesia effects on epinephrine-stimulated aqueous humor formation in monkeys. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
298. Hennes EA, Seeman JL, Gabelt BT, Kaufman PL: H-7 Effect on outflow facility after trabecular obstruction following long-term echthiophate treatment in monkeys. ARVO, Ft Lauderdale, FL, May 3-10, 2002.
299. Kiland KA, Ver Hoeve JN, Kim CBY, Dhyanchand RJ, Gabelt BT, Peterson J, Nork TM, Kaufman PL: Effect of H-7 on retinal physiology. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
300. Dhyanchand RJ, Kim CBY, Ver Hoeve JN, Kaufman PL, Lucarelli MJ, Levin LA, Nork TM: Functional relationships between IOP, duration and two features of the mERG waveform in experimental chronic glaucoma. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
301. Tian B, Kaufman PL: Effects of 5% topical H-7 on outflow facility, intraocular pressure and corneal thickness in monkey eyes. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
302. Miller PE, Bentley E, Croft MA, Whiteman AL, Kaufman PL: The effect of 0.005% latanoprost on the canine iridocorneal angle: An ultrasound biomicroscopic study. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
303. Liu X, Brandt CR, Polansky JR, Kaufman PL: Latrunculin-A concentrations subthreshold for increasing outflow facility in monkeys inhibit dexamethasone-induced changes in cytoskeleton and focal adhesions in cultured HTM cells. ARVO, Ft Lauderdale, FL, May 5-10, 2002.
304. *Kaufman PL. What is glaucoma. Clinical Trials Course. ARVO, Ft Lauderdale, FL, May 4, 2002.
305. *Kaufman PL. Funding sources and relationship with industry. Clinician-Scientist Forum. ARVO, Ft Lauderdale, FL, May 8, 2002.
306. *Kaufman PL. Presentations: 1) New frontiers in glaucoma medical therapy; 2) Roundtable II: Contemporary Approaches to Medical Therapy; 3) Clinical applications of glaucoma genetics; 4) Roundtable III: Future Directions in Glaucoma; 5) Mini-Workshop (1) – Glaucoma Diagnostic Pearls. Glaucoma 2002: Contemporary Issues in Diagnosis and Treatment, New York Eye & Ear Infirmary, University of Medicine & Dentistry of New Jersey, and Ophthalmology Times, Plaza Hotel, New York, NY, June 7-8, 2002.
307. *Kaufman PL: Presentations at Refractive Surgery Subspecialty Day – Refractive Surgery - Back to the Future: 1) Presbyopia Luncheon Discussion Group – Moderator; 2) Refractive Surgery in the Young and Old – Keynote Lecture: Accommodation research and testing. Presentation at combined AAO and Prevent Blindness America Symposium “Glaucoma Management 2002: Medical and Surgical State of the Art”: The Robert N. Shaffer Lecture: Medical therapy of glaucoma: where are we going, when will we get there? American Academy of Ophthalmology/Pan-American Association of Ophthalmology 2002 Joint Meeting, Orlando, FL, October 19-23, 2002.
308. Matsubara JA, Jim J, Lam D, To E, Kaufman PL. Neurochemical changes in primary visual cortex induced by chronic vs. transient elevated intraocular pressure in a primate model of glaucoma. Society for Neuroscience, Orlando, FL, November 6, 2002.
309. Ver Hoeve JN, Kim CBY, Kaufman PL, Nork TM. Phototransduction in the cones of monkeys with experimental glaucoma and optic nerve transection: comparison with multifocal ERG. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
310. Croft MA, Glasser A, McDonald JP, Vinje E, Gabelt BT, Heatley GA, Kaufman PL: *In vivo* imaging studies of age related changes of accommodation in the rhesus monkey. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
311. Subramanian R, Cook C, Croft MA, DePaul KL, Neider M, Ferrier NJ, Kaufman PL, Koretz JF: Unilateral real-time scheinplung videography to study accommodation dynamics in human eyes. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.

312. McDonald JP, Croft MA, Vinje E, Glasser A, Heatley GA, Kaufman P, Sarfarazi FM: Sarfarazi elliptical accommodating intraocular lens (EAIOL) in rhesus monkey eyes *in vitro* and *in vivo*. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
313. Nickells RW, Heatley GA, Schlamp CL, Li Y, Kiland J, Faha B, Kaufman P: Characterization of the relationship between the rate of IOP change and glaucomatous damage in non-human primates with ocular hypertension. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
314. Nork TM, Kim CBY, Lucarelli MJ, Levin LA, Kaufman PL, Ver Hoeve JN: Origin of the multifocal electroretinogram (mfERG) N1 waveform: clues from eyes with central retinal artery occlusion (CRAO) and optic nerve transection (ONT). ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
315. Hashimoto K, Aoi S, Gabelt BT, Kaufman PL, Hernandez MR: Activation of c-fos and c-jun in optic nerve head astrocytes of monkeys with unilateral ocular hypertension and in human astrocytes exposed to hydrostatic pressure *in vitro*. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
316. Tian B, Kaufman PL: Effects of the rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
317. Bunch TJ, Tian B, Gabelt BT, Kaufman PL: Intraocular pressure response to repeated ketamine administration. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
318. Rasmussen CA, Gabelt BT, Russell KR, Tian B, Kaufman PL. Blood pressure effects on bremsazocine IOP response; outflow facility in Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
319. *Kaufman PL. Funding sources and relationship with industry. Clinician-Scientist Forum. ARVO, Ft Lauderdale, FL, May 7, 2003.
320. Heijl A, Bengtsson B, Leske MC, Bengtsson B, Bergström A, Åsman P, Early Manifest Glaucoma Trial Group: Comparison of AGIS, CIGTS and EMGT visual field glaucoma progression criteria. A pilot study. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
321. Hyman L, Komaroff E, Heijl A, Bengtsson B, Leske MC, Hussein M, EMGT Group: Vision-related quality of life in early manifest glaucoma trial (EMGT) patients. ARVO, Ft. Lauderdale, FL, May 4-9, 2003.
322. *Chicago Ophthalmological Society, Chicago, IL, June 10, 2003. Declined due to scheduling conflict.
323. *Kaufman PL. Presentations: 1) Meeting Moderator; 2) Patient focused glaucoma management: An evidence-based approach; 3) Patient management goals; 4) Summary. Glaucoma Consultants Meeting, Pfizer, Inc, San Francisco, CA July 25-27, 2003.
324. *Kaufman PL: Presentations: 1) Moderator, Glaucoma Subspecialty Day session on Basic Science Frontiers in Glaucoma Research; 2) AAO/ARVO Joint Symposium on Advances in Gene Therapy (Lecture: Gene therapy for glaucoma); 3) Breakfast with the Experts Roundtable: Current and future medical therapy of glaucoma. American Academy of Ophthalmology, Annual Meeting, Anaheim, CA November 14-18, 2003.
325. *Kaufman PL: Mechanism of action of prostaglandin analogues. Glaucoma Experts Meeting, Pfizer, Inc., New York, NY, December 12-13, 2003.
326. *Kaufman PL: Organizer and Moderator. Presentations: 1) Chairman opening; 2) Key glaucoma trials: what they mean to clinical practice; 3) Future of glaucoma treatment; 4) Closing comments. Glaucoma Advisory Summit, Alcon Laboratories, Las Vegas, NV, February 20-22, 2004.
327. Miller CL, Kiland JA, Kim CBY, Gabelt BT, Peterson J, Nork TM, Kaufman PL: The Effect of latrunculin-B on retinal physiology. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
328. Gabelt BT, Borrás T, Hu Y, Rasmussen CA, Bershady A, Geiger B, Kaufman PL: Outflow facility enhancement by caldesmon gene therapy in organ-cultured human and monkey eyes. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
329. McDonald JP, Croft MA, Vinje E, Gwon A, Laguette SW, Heatley GAA, Kaufman PL: Accommodation in the primate eye following intraocular lens implantation. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
330. Tian B, Sabanay I, Gabelt BT, Geiger B, Kaufman PL: Latrunculin B effects on aqueous outflow and trabecular meshwork and corneal endothelium structure in the monkey eye. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
331. Kim CBY, Ver Hoeve JN, Rasmussen CA, Hennes EA, Kaufman PL, Hare WA, Wheeler LA, Mitchell CH, Laties AM: Effects of memantine on the multifocal ERG in experimentally glaucomatous Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.

332. Schmidt JF, Agapova O, Yang P, Kaufman PL, Rasmussen CA, Hernandez M: Expression of ephrin B1 and ephrin B2 in normal and glaucomatous astrocytes in the optic nerve head and retina of monkeys and human. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
333. Croft MA, Glasser A, McDonald A, Vinje E, James R, Gabelt B, Heatley GAA, Kaufman PL: The accommodative apparatus in the aging rhesus monkey. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
334. *Kaufman PL: Primate glaucoma models. Minisymposium: *In-vitro*, *ex-vivo*, and *in vivo* models of glaucoma. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
335. Ver Hoeve JN, Kim CBY, Nork TM, Hennes EA, Kaufman PL, Whelan HT, Eells JT: Supernormal multifocal ERG after macular grid photocoagulation. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
336. Borrás T, Rasmussen CA, Kaufman PL, Cherwek DH, Rowlette LL, Xue W: Recombinant adeno-associated viruses transduction of the trabecular meshwork. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
337. Vittitow JL, Grosheva I, Bershinsky AD, Geiger B, Kaufman P, Borrás T: Effect of rat non-muscle caldesmon overexpression on the cytoskeleton of human trabecular meshwork cells. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
338. Filla MS, Clark AF, Kaufman PL, Peters DM: Vertices of cross-linked actin networks (CLANs) in human trabecular meshwork (HTM) cells spread on various extracellular matrix proteins contain specific signaling molecules. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
339. Liu X, Filla MS, Brandt CR, Peters DP, Kaufman PL: Exoenzyme c3 transferase gene transfer to cultured human trabecular meshwork cells and ciliary muscle cells--towards glaucoma gene therapy. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
340. James RJ, Croft MA, Rasmussen CA, Kamerling W, Kaufman PL: Effect of centrally stimulated ciliary muscle contraction on outflow facility in young rhesus monkeys. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
341. Rasmussen CA, Gabelt BT, Kaufman PL: Effect of nitric oxide compounds on ciliary muscle *in vitro*. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
342. Hu Y, Gabelt BT, Yao M, Kaufman PL: Outflow facility enhancement and recovery after H-7 in organ-cultured monkey eyes. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
343. Okka M, Gabelt BT, Dean TR, Kaufman PL ARVO, Ft. Lauderdale, FL, April 25-29, 2004. Aqueous humor dynamics in monkeys after topical R (+)-DOI. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
344. Kiland JA, Gabelt BT, Kaufman PL: Effect of age on outflow resistance washout during anterior chamber perfusion in rhesus and Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
345. Bunch TJ, Seeman JL, Gabelt BT, Selén G, Nilsson BM, Svensson M, Lindmark T, Kaufman PL: BVT.28949 as a potential ocular hypotensive agent in monkeys. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
346. *Kaufman PL: Clinician scientists and industry. Clinician Scientist Forum. ARVO, Ft. Lauderdale, FL, April 25-29, 2004.
347. *Kaufman PL: Posterior capsular opacification and capsular-heptic fibrosis in the enabling of accommodating IOL technology. 4th Accommodation Club meeting, Bascom Palmer Eye Institute/University of Miami School of Medicine, Miami, FL, April 30, 2004.
348. *Kaufman PL: The aging eye: Physiology and diseases. AEVR Congressional Briefing, The Aging Eye, U.S. House of Representatives, Washington, DC, May 13, 2004.
349. *Kaufman PL: Presentations: 1) Evidence based medicine; 2) Comparative clinical trials – What do they really tell us? Contemporary Issues in Glaucoma Diagnosis and Therapy, Regional CME Meeting, Ophthalmology Times, Braselton, GA, May 14-15, 2004.
350. *Kaufman PL: Presentations: *1) Kaufman PL: Cytoskeleton, cell adhesion, and cell contractility in the trabecular meshwork as targets for glaucoma therapy. Symposium: Targeted Drug Delivery in Ophthalmology; 2) Okka M, Tian B, Kaufman PL: Effect of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and mitotic and accommodative responses to pilocarpine in monkeys; 3) Nork TM, Kim CBY, Kaufman PL, Ver Hoeve JN: Supranormal multifocal electroretinograms (mfERGs) following acutely elevated intraocular pressure (IOP) in monkeys and in various human retinal disorders. American Ophthalmological Society, Hot Springs, VA, May 23-26, 2004.
351. *Kaufman PL: Presentations: 1) Myth vs. science: what have we learned from 8 years of experience with prostaglandins? 2) Several workshops and panel discussions. Glaucoma Consultants Meeting, Pfizer, Inc., New York, NY, October 8-10, 2004.

352. *Kaufman PL: Breakfast with the Experts Roundtable: Current and future medical therapy of glaucoma. American Academy of Ophthalmology, Annual Meeting, New Orleans, LA, October 24-27, 2004.
353. *Kaufman PL: 1) Outflow mechanisms; 2) Panel discussions. Glaucoma Specialists Forum, Alcon Laboratories, Los Colinas, TX, November 12-14, 2004.
354. *Kaufman PL: Panel discussions. Innovation in Ophthalmology. Pfizer Ophthalmics, New York, NY, December 9-12, 2004.
355. Croft MA, Glasser A, McDonald JP, James RJ, Heatley GA, Kaufman PL: Age-related loss of accommodative ciliary body forward movement in the rhesus monkey. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
356. Filla MS, Kaufman PL, Peters DM: β 1 and β 3 integrins cooperate to induce cross-linked actin networks (clans) in human trabecular meshwork (HTM) cells. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
357. Kompass KS, Agapova OA, Kaufman PL, Rasmussen CA, Gabelt BT, Hernandez MR: Transcriptional changes in the optic nerve head (ONH) in a primate model of ocular hypertension (OHT) determined by oligonucleotide microarrays. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
358. Gupta N, Zhang Q, Weinreb RN, Kaufman PL, Rasmussen CA, Yücel YH: Dendritic pathology in geniculate neurons of the brain occurs early in glaucoma. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
359. Lu W, Mitchell C, Rasmussen CA, Gabelt BT, Hennes EA, Kaufman PL, Laties AM: Elevation of primate iop is associated with a fall in EAAT1 but not EAAT2 expression. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
360. *Kaufman PL: Can the trabecular meshwork be repaired? Minisymposium: Glaucoma - From Repair to Regeneration. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
361. Kim CBY, Ver Hoeve JN, Kaufman PL, Nork TM: Effect of reference electrode location on multifocal electroretinograms in Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
362. Nork TM, Kim CBY, Lucarelli MJ, Levin LA, Kaufman PL, Ver Hoeve JN: Multifocal electroretinographic (mfERG) evidence for persistent outer retinal injury in chronic ocular hypertension in non-human primates. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
363. Rasmussen CA, Peterson JC, Hennes BA, Gabelt BT, Kaufman PL. Nerve fiber layer measurements using the GDx VCC in monkeys. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
364. Maertz NA, Kim CBY, Nork TM, Levin LA, Lucarelli MJ, Kaufman PL, Ver Hoeve JN: Multifocal visual evoked potentials in the anesthetized non-human primate. ARVO, Ft. Lauderdale, FL, May 1-5, 2005.
365. *Kaufman PL: Presentations: 1) Glaucoma clinical management present and into the future. 2) General Recommendations and Final Report: Glaucoma; 3) Various discussion sessions. Eye Diseases in Divergent Populations: Challenges and Opportunities for Preventing and Treating Blindness Washington Advisory Group, San Diego, CA, June 12-14, 2005.
366. *Kaufman PL: Presentations: 1) Kaufman PL: Current and future medical therapy of glaucoma – Breakfast with the Experts; 2) Kaufman PL: How are we to integrate the problems of needing gold-standard data for efficacy with real-world problems of patients going blind despite treatment? Ethical issues, legal issues, communication with patients, documentation; 3) Levin L, Gross RL, Kaufman PL Krupin T, Lesk MR, Ritch R: Neuroprotection and the clinician: practical issues – Instruction Course #456. American Academy of Ophthalmology, 2005 Annual Meeting, Chicago, IL, October 15-18, 2005.
367. *Kaufman PL: Presentations: 1) Is there a role for cytoskeletal agents?; 2) Research and the Future Panel Discussion. 2nd Annual Glaucoma Specialists Forum, Alcon Laboratories, Dallas, Texas, November 18-19, 2005.
368. *Kaufman PL, Tian B, Liu X. Gabelt BT, Faralli JA, Gonzalez JM, Peters DM, Borrás T, Geiger B: The actin cytoskeleton in trabecular outflow regulation. Trabecular Meshwork Society Meeting, University of California – San Francisco, San Francisco, CA, December 10, 2005.
369. *Kaufman PL: ARVO Organization Report. Association of University Professors of Ophthalmology 40th Annual Meeting, Sarasota, Florida, January 26-28, 2006.
370. Heatley GA, Kiland JA, Bunch TJ, Nork TM, Perkins TW, Kaufman PL, Faha B, Nickells RW: Evaluation of presurgical administration of Rad-p21 in preventing wound healing after trabeculectomy in non-human primates: potential for interactions with laser trabeculoplasty. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
371. Bunch TJ, Gabelt BT, Kiland JA, Hennes EA, Kaufman PL: IOP response to topical noladin ether in Cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.

372. Gabelt BT, Hennes EA, Bendel MA, Okka M, Kaufman PL: IOP Lowering comparison in monkeys: PGF_{2a}-ie vs the rest. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
373. Tian B, Kaufman PL: Combined effects of H-7 and pilocarpine on outflow facility, pupil diameter and accommodation in the monkey eye. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
374. Wang H, Liu X, Wang B, Gabelt BT, Lee PY, Podos SM, Wang N, Kaufman PL: MISA A effects on actin of cultured HTM cells, and on structure of rat TM and IOP of rats and monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
375. Yucel Y, Darabie A, Wang S, Kaufman PL, Gupta N: Glutamate NMDA Receptor 1 Subunit Expression Is Increased in the Lateral Geniculate Nucleus of Experimental Glaucoma ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
376. Tan CJ, Kiland JA, Gabelt BT, Kaufman PL: Orthovanadate alters the cytoskeleton of trabecular meshwork cells and increases outflow facility in live monkeys. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
377. Liu X, Guo, L, Park J, Filla MS, Wang N, Kaufman PL: C3 transferase disrupts CLAN formation in DEX treated HTM cells, relevant to glaucoma gene therapy. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
378. Poeschla EM, Loewen N, Rasmussen C, Teo W, Khare P, Kaufman PL: Transduction of nonhuman primate trabecular meshwork with lentiviral vectors. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006
379. Croft MA, Glasser A, McDonald JP, James RJ, Heatley GA, Kaufman PL: Accommodative movements of the ciliary body (CB) and lens in the rhesus monkey. ARVO, Ft. Lauderdale, FL, April 30-May 4, 2006.
380. Peterson JC, Kaufman PL, Rasmussen C: Green Fluorescent Protein Imaging: An Ophthalmology Model, The 6th International Conference on Ophthalmic Photography May 18th – 21st 2006, Plenary Session 3, p10, San Francisco, California U.S.A.
381. *Alcon, Inc. U.S. Advisory Board Meeting, Banff Springs, Alberta, Canada, August 11-13, 2006.
382. *Alcon, Inc. Glaucoma Educators Meeting, Toronto, Ontario, Canada, August 18-20, 2006.
383. American Academy of Ophthalmology / Asia Pacific Academy of Ophthalmology, 2006 Joint Meeting, Las Vegas, Nevada, November 11-14, 2006. Presentations; 1) Instructional Course 744: Neuroprotection and the clinician: practical issues; PK presentation: Ethical, legal, communication, documentation issues; *2) ARVO-AAO Joint Meeting: Developing international research collaborations; PK presentation: Summary and conclusions.
384. Trabecular Meshwork Society, San Diego, California, December 9, 2006. Presentation: Study of cytoskeletal modulation of aqueous humor outflow, including genetic manipulation.
385. *Association for Ocular Pharmacology & Therapeutics, 8th Scientific Meeting, San Diego, California, February 8-11, 2007. Presentation: Latrunculins and outflow resistance.
386. *American Glaucoma Society, San Francisco, California, March 1-4, 2007. XVI American Glaucoma Society Lecture: Medical therapy of glaucoma: where next?
387. Croft MA, Glasser A, McDonald JP, Kaufman PL: Centripetal ciliary body accommodative movements may mitigate age-related loss of forward ciliary body and centripetal lens movement. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
388. Wendt M, Croft MA, McDonald JP, Kaufman PL, Glasser A: Lens diameter changes with age and pharmacologically stimulated accommodation in rhesus monkeys. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
389. Filla MS, Sheibani N, Kaufman PL, Peters DM: β 1 and β 3 Integrins use distinct pathways to regulate cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
390. Buie LK, Rasmussen CA, Samulski RJ, Kaufman PL, Borrás T: Self-complementary adeno-associated viruses (scAAV) transduce anterior segment tissues of living rats and monkeys without detrimental secondary effects. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
391. Gonzalez Jr JM, Hu Y, Gabelt BT, Kaufman PL, Peters DM: Integrin-binding site in HepII domain of fibronectin disrupts actin filaments in human trabecular meshwork TM cells and increases outflow facility (OF) in cultured monkey anterior segments. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
392. Rasmussen CA, Peterson JC, Bunch TJ, Kaufman PL, Nork T: Stratus OCT 3 scanning resolution: fast scans vs normal scans in monkeys. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.

393. McDonald JP, Croft M, Ben-nun J, Heatley GA, Kaufman PL: NuLens experimental accommodating IOL in the primate eye. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
394. Gupta N, Darabie A, Kaufman PL, Yücel Y: Novel NG2 glial cells express NMDA receptors in the optic tract and lateral geniculate nucleus in primate glaucoma. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
395. Lu W, Rasmussen C, Gabelt B, Hennes B, Kaufman P, Laties AM, Mitchell CH: Upregulation of NTPDase 1 in an experimental monkey glaucoma model. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
396. Chiba T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Distribution of aggrecanase-1 and aggrecanase-2 in the primate uveoscleral outflow pathway. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
397. Gabelt BT, Ruiz J, Picciani R, Bhattacharya SK, Kaufman PL: Cochlin expression in MOCAS after TGFbeta2-induced elevated IOP. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
398. *Kaufman PL. Turnarounds. Clinician Scientist Mentor/Mentee Workshop. ARVO, Ft. Lauderdale, FL, May 6-10, 2007.
399. Rasmussen CA, Gabelt BT, Kaufman PL: Aqueous humor dynamics in monkeys in response to the kappa opioid agonist brexazocine. Am Ophthalmol Soc, White Sulphur Springs, WV, May 20-23, 2007.
400. *Kaufman PL: What is glaucoma? Fourteenth Annual Think Tank, The Glaucoma Foundation, New York City, NY, September 28-29, 2007.
401. Optometric Glaucoma Society, Tampa, Florida, October 22, 2007. Presentations: 1) The Aging Eye: Ultrastructure and Physiology of the Anterior Segment; 2) Medical Therapy: Where are we going?; 3) Panel Discussion: The Future of Glaucoma.
402. American Academy of Optometry/Optometric Glaucoma Society Glaucoma Symposium, Tampa, Florida, October 23, 2007. Presentations: 1) The Aging Eye: Ultrastructure and Physiology of the Anterior Segment; 2) Medical Therapy: Where are we going?
403. Trabecular Meshwork Society 2007, Washington, DC, December 1, 2007. Presentation: Update.
404. Glaucoma research update. The Black and White Ball, The Glaucoma Foundation, New York, New York, December 5, 2007.
405. *American Glaucoma Society, Washington DC, March 6-9, 2008. 1) The effect of the A.G.E. crosslink breaker alagebrium on accommodation, outflow facility, tissue morphology, and IOP (Julie A Kiland, MS, B' Ann T Gabelt, MS, Elke Lütjen-Drecoll, MD, PL Kaufman, MD); 2) *Kaufman PL: An important obstacle that I encountered in my early career advancement. Mentoring for Advancement of Physician Scientists program
406. *Kaufman PL: Cytoskeletal approaches to enhancing aqueous humor outflow. US-China networking luncheon. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
407. *Kaufman P: Clinician-Scientist Forum. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
408. Hu Y, Gabelt BT, Peters DM, Kaufman PL: Effects of noladin ether (NE) on the actin cytoskeleton, focal adhesions and cell-cell junctions in human trabecular meshwork (HTM) cells and outflow facility (OF) in monkey organ-cultured anterior segments (MOCAS). ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008
409. Spiga M-G, Buie LK, Li G, Rasmussen CA, Kaufman PL, Borrás T: α B-Crystallin promoter as a novel delivering tool for in vivo targeted gene expression to the trabecular meshwork tissue. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
410. Kiland JA, Gabelt BT, Bunch TJ, Lütjen-Drecoll E, Kaufman PL: The effect of the A.G.E. crosslink breaker ALT-711 on accommodation, outflow facility, IOP, and anterior segment morphology. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
411. Tian B, Jeyalakshmi S, Heatley GA, Haripriya A, Filla MS, Kaufman PL, Muthukkaruppan V: Will cytoskeletal drugs prevent posterior capsule opacification (PCO)? ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008
412. Alarcon-Martinez L, Gupta N, Weinreb R, Kaufman P, Vidal-Sanz M, Yucel Y: Damage to eye movement center neurons of the superior colliculus in experimental primate glaucoma ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
413. Yucel YH, Darabie A, Kaufman PL, Gupta N: Astrocytes and NG-2 glial cells are activated in the optic tract of experimental primate glaucoma. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
414. Chiba T, Lindsey JD, Wright KN, Gabelt BT, Kaufman PL, Weinreb RN: Distribution of aggrecanase-1 and aggrecanase-2 in the primate retina and optic nerve head. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
415. Croft MA, McDonald JP, Kaufman PL: Age related changes of the posterior zonule and the ciliary body at rest and during accommodation. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.

416. Peterson WM, Lampe J, Navratil T, Paran Y, Zvi K, Hennes EA, Gabelt BT, Geiger B, Kaufman PL, Vittitow JL: Topical administration of a novel and potent Rho kinase (ROK) inhibitor INS117548 alters the actin cytoskeleton, effectively lowers IOP, and is well tolerated on the ocular surface. ARVO, Ft. Lauderdale, FL, April 27-May 1, 2008.
417. *Glaucoma research update. The Black and White Ball, Glaucoma Foundation, New York, New York, December 3, 2008.
418. Update on aqueous dynamics. Trabecular Meshwork Society, San Francisco, CA, December 13, 2008.
419. *NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. National Institutes of Health, Washington, DC, March 13-14, 2008. Co-organizers Robert N. Weinreb and Paul L. Kaufman. Presentations: Weinreb RW, *Kaufman PL: 1) Symposium overview and introductory remarks; 2) Meeting summary and next steps. Session topics: 1) Optic Disc and RNFL Parameters as Outcome Measure, 2) Visual Function Parameters as Outcome Measures, 3) Combination of Functional and Structural Tests, 4) IOP Parameters as Outcome Measures, 5) Quality of Life – Parameters and Safety, 5) Design and Endpoints for Glaucoma and Post-Marketing Surveillance.*
420. *American Society of Cataract & Refractive Surgery, San Francisco, CA April 3-8, 2009. Symposium: Refractive Technology. Presentation: Mechanisms of accommodation.
421. Lee E, Gabelt BT, Peters DM, Brandt CR, Bhattacharya SK, Kaufman PL: Effect of cochlin transgene expression by adenovirus on cultured human trabecular meshwork cells and outflow facility in organ cultured anterior segments. ARVO, Ft. Lauderdale, FL, April 28-May 2, 2009.
422. Croft MA, McDonald, JP, Kaufman PL: The posterior vitreous zonule (PVZ) does not stretch during accommodation. ARVO, Ft. Lauderdale, FL, April 28-May 2, 2009.
423. Gabelt BT, Rasmussen CA, Kaufman PL, Katz B: Effect of the ion channel modulator DNB-001 on ciliary muscle contraction. ARVO, Ft. Lauderdale, FL, April 28-May 2, 2009.
424. Schwinn MK, Gonzalez JM Jr, Gabelt BT, Kaufman PL, Peters DM: HepII domain of fibronectin induces an $\alpha 4 \beta 1$ integrin-dependent decrease in contractility in TM cells and morphological changes in MOCAS. ARVO, Ft. Lauderdale, FL, April 28-May 2, 2009.
425. Brandt CR, Sauter MM, Cai S, Gabelt BT, Kaufman PL: IL-6 Induction by HSV and AdV vector challenge of monkey retina. ARVO, Ft. Lauderdale, FL, April 28-May 2, 2009.
426. American Ophthalmological Society, 145th Annual Meeting, Half Moon Bay, CA, May 14-17, 2009. Presentation: Kiland JA, Gabelt BT, Tezel G, Lütjen-Drecoll E, Kaufman PL: Effect of the AGE crosslink breaker alagebrium on anterior segment physiology, morphology and ocular AGE and RAGE.
427. *American Academy of Ophthalmology, October 23-27, 2009, San Francisco, CA. 1) ARVO – AAO Symposium - Translational Research Can Create New Therapeutic Modalities for Challenging Ocular Diseases. Presentation: Glaucoma in the Future; 2) Glaucoma Subspecialty Day, New Findings in Basic Science (Session Moderator).
428. *16th Annual Glaucoma Think Tank, Glaucoma Foundation, New York City, October 2-3, 2009. Exfoliation Syndrome and Exfoliation Glaucoma. Presentation: Glaucoma in 15 minutes.
429. Kaufman PL, Kutuzova GD, Gabelt BT, Kiland JA, DeLuca HF: 1 α ,25-Dihydroxyvitamin D3 reduces intraocular pressure in nonhuman primates. American Glaucoma Society, Annual Meeting. Naples, Florida, March 4-7, 2010.
430. Kiland JA, Elsmo EJ, Hennes EA Kaufman PL, McLellan GJ: Evaluation of rebound and applanation tonometry in cynomolgus monkeys. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
431. McDonald JP, Kaufman PL, Croft M: Accommodative lens thickening vs centripetal movements of the lens equator and movements of the ciliary body. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
432. Gabelt BT, Kutuzova GD, Kiland JA, Hennes-Beann EA, Kim CBY, DeLuca HF, Kaufman PL: Vitamin D effect on intraocular pressure in nonhuman primates. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
433. Seo K, Rasmussen CA, Finch AK, Xiong K, Kaufman PL, McLellan GJ: SD-OCT imaging of the retina and optic nerve in normal and glaucomatous cats. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
434. Kaufman PL, Gabelt BT, Rasmussen CA, Filla MS, Peters DM, Brandt CR, Lee E: Effect of PGF synthase transgene expression on intraocular pressure in monkey eyes in vivo. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.

435. Tian B, Heatley GA, Filla MS, Kaufman PL: Effect of H-7 on secondary cataract after phacoemulsification in the live rabbit eye. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
436. McIntyre KB, Rasmussen CA, Goulding AK, Bantsev V, Ver Hoeve JN, Kaufman PL, Christian BJ, Nork TM: Spectral domain OCT segmentation accuracy in monkeys. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
437. Croft MA, McDonald JP, Kaufman PL: Configuration of the ciliary body: accommodation and presbyopia. ARVO, Ft. Lauderdale, FL, May 2-May 6, 2010.
438. *NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function, National Institutes of Health, Bethesda, Maryland, September 24, 2010. Course Directors/Co-Organizers/Co-Moderators.
439. *17th Annual Glaucoma Think Tank, Glaucoma Foundation, New York City, October 1-2, 2010. Presentation: The aqueous outflow pathway.
440. *Association of University Professors of Ophthalmology (AUPO) 45th Annual Meeting, Scottsdale, AZ, January 27-29, 2011. *Management Symposium: Balancing a Budget in Perilous Times*. Presentation: Revenue Source: Grants and Indirects.
441. *American Glaucoma Society 21st Annual Meeting, Dana Point, CA, March 3-6, 2011. 1) Co-Moderator, Symposium #7, Science of Outflow. 2) Presentation: The uveoscleral outflow pathway – structure and function; 3) Presentation: Outflow and future directions.
442. *New England Ophthalmological Society, 734th Meeting, Boston, MA, April 15, 2011 (Guest of Honor). Presentations: 1) Presbyopia – up close; 2) Guest of Honor Lecture: Medical therapy of glaucoma going forward.
443. *Association for Research in Vision and Ophthalmology, Annual Meeting, Ft. Lauderdale, Florida, April 30-May 5, 2011. *New Insights into Intraocular Pressure and Glaucoma – Minisymposium. Invited Presentation: Aqueous outflow: pathways and opportunities.
444. McDonald JP, Croft MA, Kaufman PL: Effect of scleral buckling (SB) procedure on accommodation. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2011.
445. Gabelt BT, Heyne GH, Kiland JA, Kaufman PL: Effect of nitric oxide on ocular physiology in the cynomolgus monkey. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2011.
446. Croft MA, McDonald JP, Katz AW, Kaufman PL: Extralenticular and lenticular factors in accommodation and presbyopia: human & monkey. ARVO, Ft. Lauderdale, FL, April 30-May 5, 2011.
447. *Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, September 8-9, 2011: Symposium: New Approaches to Understand and Treat Vision Loss. Session: Panel Discussion: Publishing and Patenting: Getting out the message and avoiding conflicts. Presentation: Are the safeguards currently in place to deal with conflicts of interest appropriate; or are they too lax or are they too stringent?
448. American Glaucoma Society 22nd Annual Meeting, New York, NY, March 1-4, 2012: Presentation: Correlation of GDxVCC RNFL measurements with optic nerve axon counts in experimental glaucoma.
449. Association for Research in Vision and Ophthalmology, Annual Meeting, Fort Lauderdale, FL, May 6-10, 2012. (1 and 2) *Ocular lipids: recent advances in analysis and evaluation – Special Interest Group, Moderator, May 7, 2012. *Invited Presentation: Prostaglandins and ocular hypertension – past, present and future. (3) *New Ideas in Glaucoma, Co-Moderator, May 7, 2012. (4) *General business meeting, Remembrance presentation for Joanne Angle, May 8, 2012.
450. 8th Accommodation Club meeting, Bascom Palmer Eye Institute/University of Miami School of Medicine, Miami, FL, May 11, 2012. (1) Croft MA, McDonald J, Katz A, Nork TM, Kaufman PL: The vitreous membrane (anterior hyaloid) bends posteriorly in proportion to accommodative amplitude and lens thickening. (2) Moderator: Accommodation & presbyopia. (3) Beer P, Kaufman P, Croft MA, Katz A, Heatley GA, McDonald JP: Zonular capture haptic.
451. American Ophthalmological Society, 148th Annual Meeting, Charleston, SC, May 17-20, 2012. Presentation: Lee ES, Rasmussen CA, Filla MS, Slauson SR, Peters DM, Brandt CR, Kaufman PL, Gabelt BT: Intraocular pressure reduction following prostaglandin F synthase gene therapy in monkey eyes in vivo.
452. American Academy of Ophthalmology – Asia-Pacific Academy of Ophthalmology Joint Meeting, McCormick Place, Chicago, Illinois, November 10-13, 2012. Presentation: Beer PM, Kaufman PL, Croft MA, Katz A, Heatley GA, McDonald J: Zonular capture haptic.

453. *Glaucoma 2.0: Bench to Bedside, Bascom Palmer Eye Institute / University of Miami Miller School of Medicine. Miami, FL, January 26, 2013. Presentation: ROCK inhibitors: Good for IOP and also good for RGCs?
454. *Association for Research in Vision and Ophthalmology, Annual Meeting, Seattle, WA, May 4-9, 2013. Presentation: Gene Therapy for Glaucoma at the Alcon Research Institute Steven M. Podos Symposium, May 4, 2013.
455. *Helen Keller Prize for Vision Research honoring László Z. Bitó, PhD, 2013 Helen Keller Laureate, Hotel Monaco, Seattle, WA, May 7, 2013. Introduction of László Z. Bitó.
456. Croft MA, Heatley GA, Nork TM, McDonald JP, Katz A, Kiland J, Kaufman PL: Accommodative movements of the lens/capsule in relation to the vitreous face and aging. ARVO, Seattle, WA, May 5-9, 2013.
457. Beer PM, Kaufman PL, Croft MA, Heatley GA, McDonald JP, Katz A: Accommodative-disaccommodative IOL with zonular capture haptics. ARVO, Seattle, WA, May 5-9, 2013.
458. *Kaufman PL: The trabecular meshwork in normal eyes and in exfoliation glaucoma. Twentieth Annual Glaucoma Foundation Optic Nerve Rescue and Restoration Think Tank. Exfoliation syndrome: what do we know and where do we need to go?
459. *36th Annual Midwest Glaucoma Symposium, Setting New Standards in Glaucoma, Pittsburgh, PA September 27-28, 2013. Presentations: 1) Kaufman PL: Interrelatedness of accommodation and outflow in the aging eye; Kaufman PL: 2) Structure/Functions studies in experimental glaucoma.
460. *11th Annual Trabecular Meshwork Study Club / Society Meeting, New Orleans, LA, December 14, 2013. *Presentation: Research update: Benzalkonium chloride and glaucoma; Gene transfer via canaloplasty; Oxygen toxicity in the trabecular meshwork.
461. *American Glaucoma Society 24th Annual Meeting, Washington, DC, February 27-March 2, 2014. *Presentation: Update on rho kinase inhibitors.
462. *6th Ocular Diseases & Drug Discovery Conference, San Diego, CA, March 20-21, 2014. Presentation: Gene therapy for glaucoma.
463. Cleveland Ophthalmological Society, Independence, Ohio, April 8, 2014. Presentations: 1) Presbyopia – Up Close; 2) The Lorand Johnson Lecture: Future Medical Therapy for Glaucoma.
464. *American Academy of Optometry, Denver, Colorado, November 12-15 (13), 2014. Monroe J. Hirsch Research Symposium: Mechanisms of Presbyopia Correction – Beyond Benjamin Franklin. *Presentation: Extralenticular aspects of accommodation and presbyopia.
465. *Trabecular Meshwork Study Club, Ft. Worth, Texas, December 4-6, 2014. Presentation: Kaufman PL, Aktas Z, Brandt CR: Gene Therapy Delivery Methods and Vector Transduction Efficiency.
466. *American Glaucoma Society 25th Annual Meeting, San Diego, California, February 25-March 1, 2015. *Presentations: 1) American Glaucoma Society / North American Neuro-ophthalmological Society Joint Symposium: *What Is Glaucoma: Clinically, Functionally, Pathologically?; 2) *Rethinking Aqueous Outflow Pathways.
467. Croft MA, Nork TM, McDonald JP, Heatley GA, Katz A, Luetjen-Drecoll E, Kaufman PL: Mechanism of accommodation: new findings and the implications for presbyopia. ARVO, Denver, CO, May 3-7, 2015.
468. Brandt CR, Rao H, Gabelt BT, Aktas Z, Slauson SR, Kaufman PL: Genome deficient lentiviral particles improve FIV transduction efficiency of trabecular meshwork. ARVO, Denver, CO, May 3-7, 2015.
469. *Trabecular meshwork and aqueous humor dynamics research group, Case Western Reserve University, Cleveland Ohio, August 7-9, 2015. Presentations: 1) What generates IOP? Outflow resistance, aqueous humor production, uveoscleral outflow. 2) Moderator, open discussion.
470. *Nantucket Glaucoma 2015, University of Pittsburgh, Nantucket, MA, August 26-28, 2015. Presentation: Gene therapy for the trabecular meshwork.
471. *Trabecular Meshwork Study Club, University of Oregon Health Sciences University/University of California-San Francisco, San Diego, CA, December 10-12, 2015. Presentation: Croft MA, Kaufman PL: Age-related ciliary muscle restriction – a link between trabecular meshwork and optic nerve head pathophysiology?
472. Croft MA, Nork TM, McDonald JP, Heatley GA, Lütjen-Drecoll E and Kaufman PL: Accommodative apparatus: movements in phakic and aphakic eyes, interconnections with the vitreous and presbyopia. ARVO, Seattle, WA, May 1-5, 2016.

473. Vittitow JL, Liebmann JM, Kaufman PL, Medeiros FA, Martin KR, Weinreb RN: Long-term efficacy and safety of latanoprostene bunod 0.024% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studies. ARVO, Seattle, WA, May 1-5, 2016.
474. Kaufman PL, Liebmann JM, Vittitow JL, Weinreb RN: Integrated efficacy of latanoprostene bunod 0.024% vs. timolol maleate 0.5% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APPOLLO and LUNAR studies. ARVO, Seattle, WA, May 1-5, 2016.
475. Katz A, Rasmussen C, Kaufman PL, Nork TM, Huang Y: Hemiretinal diathermy axotomy (HEA) in non-human primates: Structural changes by spectral domain optical coherence tomography (sdOCT). ARVO, Seattle, WA, May 1-5, 2016.
476. Kaufman PL: Primate models for XFS. 23rd Annual Glaucoma Think Tank, The Glaucoma Foundation, New York City, NY, June 8-10, 2016.
477. * American Glaucoma Society 27th Annual Meeting, San Diego, California, March 1-5, 2015.*Presentation: Overview of gene-based therapies for glaucoma.
478. Siegfried C, Shui Y-B, Liu Y, Huang A, Kaufman PL: Aqueous humor biomarker of oxidative damage and antioxidant status: Correlations with glaucoma and racial differences. ARVO, Baltimore, MD, May 1-5, 2017.
479. Kaufman PL, Borrás T, Brandt C, Rasmussen C: Help Needed: Why can't we transfect/transduce the TM in live monkeys with transgenes that affect cellular contractility and the cytoskeleton, when we can do so in monkey organ-cultured anterior segments, and when we can do so in live monkeys with GFP using either FIV or scAAV vectors? Trabecular Meshwork Study Club, Portland, Oregon, November 30-December 2, 2017.

REGIONAL AND LOCAL PRESENTATIONS

Three pages of entries omitted for brevity

MISCELLANEOUS TEACHING ACTIVITIES

Biomedical Engineering Design Course Projects selected competitively by the UW BME Program

Modifications of monkey restraint device for administration for topical eye drops (Fall 2003)

Transport cage support for nonhuman primates (Fall 2004)

Glaucoma medication electronic reminder / compliance aid (Fall 2006)

Automated animal board for positioning during ocular imaging and photography (Fall 2006)

Fine control for OCT (Fall 2008, Spring 2009)

Calibrated eye dropper (Spring 2009)

Positioning board for fluorophotometry (Fall 2010)

RESEARCH GRANTS

DIRECT COSTS AWARDED

The Seeing Eye, Inc., Research Fellowship "Pharmacology of the isolated primate trabecular meshwork" Principal Investigator, University of Uppsala 07/01/73-06/30/74	\$10,000
ALZA Corp. Research Fellowship "Pharmacology of the isolated primate trabecular meshwork" Principal Investigator, University of Uppsala	\$2,000

07/01/73-06/30/74	
NIH Special Research Fellowship EY55678-01-02	\$49,750
“Pharmacology of the isolated primate trabecular meshwork”	
Principal Investigator, University of Uppsala	
06/01/74-05/31/76. Accepted for period 06/01/74-09/04/75; TDC \$32,056)	
Fight for Sight, Inc., Research Fellowship	\$2,500
“Pharmacology of the isolated primate trabecular meshwork”	
Principal Investigator, University of Uppsala	
07/01/74-10/30/74 (Could not accept because of concurrent NIH award)	
Medical School Research Committee Research Grant	\$15,000
Subsidiary of NIH Biomedical Research Support Grant 5 S01 RR05435	
“Pharmacology of aqueous outflow”	
Principal Investigator, University of Wisconsin	
09/01/75-08/31/79 (Project highlighted as a demonstration of the fruits of the BRSG program by Dr. James F. Crow, PI of the UW BRSG program, in his report to NIH)	
William Bingham Foundation Glaucoma Research Laboratory Grant	\$33,000
“Physiology and pharmacology of the anterior ocular segment”	
Principal Investigator, University of Wisconsin	
07/01/78-06/30/79	
NIH Research Career Development Award EY00137-01-05	\$180,510
“Physiology and pharmacology of the anterior ocular segment”	
Principal Investigator, University of Wisconsin	
07/01/79-06/30/84	
(01-\$36,000; 02-\$36,000; 03-\$36,000; 04-\$36,090; 05-\$36,420)	
NIH Research Grant R01 EY02698-01-30	\$7,866,298
“Anterior ocular segment physiology and pharmacology”	
Principal Investigator, University of Wisconsin	
07/01/79-08/31/10	
(01-\$63,119; 02-\$48,008; 03-\$58,491; 04-\$92,981; 05-\$102,308; 06-\$145,684;	
07-\$159,188; 08-\$189,546; 09-\$206,919; 10-\$203,981; 11-\$209,245; 12-\$219,334;	
13-\$272,566; 14-\$283,468; 15-\$294,807; 16-\$317,367; 17-\$332,808; 18-\$357,070;	
19-\$408,852; 20-\$386,207; 21-\$401,655; 22-\$417,722; 23-\$430,730; 24-\$443,653;	
25-\$456,962; 26-\$470,672; 27-\$484,792; 28-\$136,055; 29-\$136,054; 30-\$136,054; 31-\$0)	
Fight for Sight, Inc., Research Grant-in-Aid	\$6,980
“Ciliary body circulation in monkeys”	
Principal Investigator, University of Wisconsin	
09/01/79-08/31/81	
Alcon Laboratories, Inc.	\$14,053
“A double-masked comparison of betaxolol and placebo in ocular hypertensives”	
Principal Investigator, University of Wisconsin	
10/07/80-11/30/81	
NIH Research Grant EY03503-01-06	\$96,653
“Natural history of angle closure glaucoma suspects”	
Principal Investigator, University of Wisconsin	
01/01/81-12/31/87 (01-\$18,403; 02-\$11,758; 03-\$13,635; 04-\$18,138;	
05-\$15,231; 06-\$19,488)	
Graduate School Research Committee Research Grant	\$600
“Anterior segment ocular physiology”	
Principal Investigator, University of Wisconsin	
03/01/81-06/30/81	
Wisconsin Psychiatric Research Institute	\$2,600
“The effects of lithium on intraocular pressure and visual accommodation in man”	

Co-Principal Investigator (with JW Jefferson, MD), University of Wisconsin 04/01/81-12/31/81	
Alcon Laboratories, Inc.	\$36,000
“A double-masked comparison of betaxolol and timolol” Principal Investigator, University of Wisconsin 12/01/81-11/30/83	
NIH Research Grant EY04146-01-05	\$354,722
“Presbyopia: the aging process of accommodative mechanisms” Consortium: Columbia University, University of Wisconsin, Rensselaer Polytechnic Institute, New York University Co-Principal Investigator (with Drs. LZ Bitó, JF Koretz, and CJ DeRousseau) (UW TDC: 01-\$43,865; 02-\$53,712; 03-\$66,473; 04-\$70,866; 05-\$119,806) 04/01/82-11/30/88	
The Foundation for Glaucoma Research	\$25,000
“Anterior segment fluorophotometry” Principal Investigator, University of Wisconsin 01/01/84	
William Bingham Foundation	\$6,750
“Anterior segment fluorophotometry” Principal Investigator, University of Wisconsin 01/01/84	
Alcon Research Institute	\$25,000
“1984 Recognition Award for Outstanding Contributions in the Field of Vision Research” 07/01/84	
Squibb Institute for Medical Research - E.R. Squibb & Sons, Inc	\$14,697
“Comparison of oral nadolol and topical timolol in the treatment of open-angle glaucoma” Principal Investigator, University of Wisconsin 01/01/85-12/31/86	
NIH Fogarty International Center	\$19,219
Senior International Fellowship 1 F06 TW01044-01 “Iatrogenic changes in trabecular meshwork/ciliary body” Principal Investigator, University of Wisconsin 08/19/85-08/18/86	
NIH Research Grant EY02195-08-20	\$157,225
“Aging effects on human crystalline lens properties” Consortium: Rensselaer Polytechnic Institute, Univ. of Wisconsin-Madison Co-Principal Investigator (with Dr. JF Koretz) 09/30/85-06/30/97 (UW TDC: 08-\$36,022; 09-\$32,553; 10-\$20,961; 11-\$21,811; 12-\$3,000; 13-\$3,856; 19-\$22,484; 20-\$17,310)	
Alcon Laboratories, Inc.	\$2,115
“Betaxolol vs. Timoptic-IOP effect 3 and 12 hours after dosing” Principal Investigator, University of Wisconsin 06/01/88-03/31/89	
National Glaucoma Research-American Health Assistance Foundation	\$116,890
“Age-related loss of ciliary muscle contractility” Principal Investigator, University of Wisconsin 04/01/89-03/31/94 (01-\$20,000; 02-\$21,965; 03-\$24,982; 04-\$24,957; 05-\$24,986)	
NIH Research Grant AG0783-01-05	\$35,992
“Caloric restriction and aging in nonhuman primates” Co-Investigator, University of Wisconsin (with WB Ershler; figure at right for eye portion only) 06/01/89-05/31/94	

Eye Portion DC 01-\$8,992; 02-\$9,000; 03-\$9,000; 04-\$9,000; 05-\$0	
Allergan Pharmaceuticals, Inc.	\$7,209
“Effect of prostaglandin D ₂ on intraocular pressure in the Cynomolgus monkey”	
Principal Investigator, University of Wisconsin	
11/01/89-10/31/90	
American Cyanamid Company	\$3,466
“Effect of topical methazolamide on aqueous humor formation in Cynomolgus monkeys”	
Principal Investigator, University of Wisconsin	
11/01/89-10/31/90	
NIH Individual National Research Service Award F32 EY06254-01	\$63,000
“Anterior segment physiology after surgical sympathectomy”	
Sponsor, University of Wisconsin (James C. Robinson, awardee)	
11/01/89-10/31/91	
(01-\$30,500; 02-\$32,500)	
Eyegene-Telor Ophthalmic Pharmaceuticals, Inc.	\$64,632
“Effects of ethacrynic acid on aqueous humor dynamics”	
Principal Investigator, University of Wisconsin	
12/01/89-06/30/93	
Allergan Medical Optics	\$24,917
“Accommodation after intraocular lens implant in presbyopic rhesus monkeys”	
Principal Investigator, University of Wisconsin	
02/01/90-01/31/91	
Allergan Pharmaceuticals, Inc.	\$79,552
“Effect of AGN compounds on aqueous dynamics in monkeys”	
Principal Investigator, University of Wisconsin	
01/01/91-12/31/93	
Indiana University	\$7,246
“Retinal blood flow and ocular hydrodynamics”	
Principal Investigator, University of Wisconsin	
01/01/91-12/31/91	
NIH Institutional Research Training Grant T35-DK-07389-10,12	\$1,250
“Short-term research in biomedical sciences”	
Preceptor, University of Wisconsin (R. Holt, L. Fahien, PI)	
06/08/91; 06/08/93	
(10-\$500; 12-\$750)	
Astra-Draco Pharmaceutical Products, Inc.	\$8,200
“A double-blind randomized placebo-controlled multicenter steroid sparing study in patients with chronic steroid dependent asthma; a double-blind randomized placebo-controlled study to determine the relative efficacy of four different doses of Budesonide Turbuhaler® in patients with glucocorticosteroid dependent asthma”	
Co-Investigator, Univ. of Wisconsin-Madison (W. Busse, PI)	
08/01/91-07/31/93 TDC (eye portion only) for entire project \$8,200	
Glaxo, Inc.	\$908
“A randomized double-blind comparative trial of two doses of inhaled fluticasone propionate versus placebo in patients aged 4 to 11 years with mild to moderate chronic asthma.” TDC (eye portion only) - \$908	
Co-Investigator, University of Wisconsin (R. Lemanski, PI)	
01/01/92-12/31/92	
Merck Sharp & Dohme Research Laboratories	\$7,961
“The effects of the prostanoid UF-021 on aqueous humor dynamics in monkeys”	
Principal Investigator, University of Wisconsin	
01/01/92-06/30/92	

Optical Radiation Corporation “Polyacrylamide microgels and aqueous humor dynamics in monkeys” Principal Investigator, University of Wisconsin 01/01/92-06/30/92	\$12,281
Alcon Laboratories, Inc “Short-term use of apraclonidine in patients on maximum tolerated medical therapy for glaucoma” Principal Investigator, University of Wisconsin 07/01/92-06/30/93	\$8,667
Kabi Pharmacia Ophthalmics, Inc. “A 6-month, randomized, double masked, comparison of PhXA41 to timolol in patients with open angle glaucoma or ocular hypertension” Principal Investigator, University of Wisconsin 02/01/93-01/31/94	\$26,888
National Glaucoma Research - American Health Assistance Foundation “Retinal ganglion cell changes in glaucomatous monkeys” Co-Investigator, University of Wisconsin (A. Weber, PI) 04/01/93-03/31/95	\$50,000
Telcor Ophthalmic Pharmaceuticals, Inc. “Effects of Telcor compounds on ocular physiology” Principal Investigator, University of Wisconsin 07/01/93-12/31/95	\$57,188
Kabi Pharmacia Ophthalmics, Inc. “A 6-month open label study with PhXA41 in patients with open angle glaucoma or ocular hypertension. A multicenter study in the United States” Principal Investigator, University of Wisconsin 09/01/93-06/30/94	\$21,613
Alcon Laboratories, Inc. “Effects of Alcon peptides on intraocular pressure, pupil diameter, accommodation and outflow facility in the monkey” Principal Investigator, University of Wisconsin 10/01/93-06/30/94	\$13,530
Euphrasia, Inc. “Eye pigmentation changes as a function of age in rhesus monkeys” Principal Investigator, University of Wisconsin 10/01/93-06/30/94	\$7,299
Alcon Laboratories, Inc. “Glaucoma-related neuronal degeneration in the primate - retina and dorsal lateral geniculate nucleus” Co-Principal Investigator, University of Wisconsin (AJ Weber, Co-PI) (03/01/94-12/31/94)	\$39,674
National Glaucoma Research - American Health Assistance Foundation “Vector-selective contractility in monkey ciliary muscle” Principal Investigator, University of Wisconsin 04/01/94-03/31/96; (01-\$24,996; 02-\$24,995)	\$49,991
NIH-NIA PO1 AG11915 “Dietary restriction and aging in nonhuman primates” Co-Investigator (with R.H. Weindruch), University of Wisconsin 04/20/94-01/99 DC (eye portion)	\$11,051
The Glaucoma Foundation “Structure/function relations of ganglion cells in the glaucomatous retina”	\$11,550

Co-Investigator, University of Wisconsin (AJ Weber, PI) 06/01/94-05/31/95 (01-\$11,550)	
Glaucoma Research Foundation “The role of glycosaminoglycan loss in glaucoma pathophysiology” Principal Investigator, University of Wisconsin Joint project with Massachusetts Institute of Technology and Boston University (M. Johnson, R. Kamm, and T. Freddo, Co-PI's) 07/01/94-06/30/96 (01-\$30,000 (\$15,000 to UW); 02-\$10,000 (\$5,000 to UW))	\$20,000
Amgen, Inc. “Effects of Amgen compounds on intraocular pressure in rabbits and monkeys” Principal Investigator, University of Wisconsin 08/01/94-12/31/95	\$25,797
NIH Research Grant EY10224-01A2-04 “Neuronal changes in the retina and thalamus in glaucoma” Co-Investigator, University of Wisconsin (AJ Weber, Michigan State University, PI) 12/01/94-11/30/98 (UW TDC: 01-\$6,600; 02-\$9,290; 03-\$10,741; 04-\$10,862)	\$37,493
Research to Prevent Blindness Senior Scientific Investigator Award 12/12/94	\$55,000
Glaucoma Research Foundation “Cytoskeletal and cell junctional modulation of aqueous outflow” Principal Investigator, University of Wisconsin Joint project with the Weizmann Institute, Rehovot, Israel, B. Geiger, Co-PI 01/01/95-12/31/97 (UW TDC: 01-\$15,000 (\$25,076. Total TDC for UW and Weizmann = \$80,076)	\$40,076
Argentum Group/VisionX/Kamerling “Electrical stimulation of ciliary muscle to enhance accommodative amplitude and outflow facility in monkeys” Principal Investigator, University of Wisconsin 01/01/95-open Phase 1 - \$5,958; Phase 2 - \$27,462; Phase 3 - \$2,800; Phase 4 - \$19,123; Phase 5 - \$13,168	\$68,511
University of Wisconsin/Weizmann Institute of Science Scientific exchange/collaboration award – “Cytoskeletal mechanisms in aqueous humor outflow” 01/01/95-04/30/96	\$1,500
NIH Research Grant EY10213-01A1-08 “Ciliary muscle aging” Principal Investigator, University of Wisconsin 04/01/96-06/30/05 01-\$152,202; 02-\$139,867; 03-\$145,462; 04-\$200,000; 05-\$200,000 06-\$200,000; 07-\$200,000; 08-\$200,000	\$1,437,531
Biovitrum AB “Intraocular pressure effects of Biovitrum compounds” Principal Investigator, University of Wisconsin 07/01/03-12/31/03 TDC - \$38,003 01/07-12/07 TC = \$29,980; DC=\$20,210	\$58,713

Glaucoma Research Foundation	\$70,000
Shaffer International Research Fellowship	
Sponsor, University of Wisconsin	
07/01/96-06/30/97 (Yan Li awardee) - \$35,000	
07/01/97-06/30/98 (Xuyang Liu, awardee) - \$35,000	
Washington University School of Medicine	\$8,000
“Connective tissue & glial changes in the glaucomatous monkey optic nerve head”	
Principal Investigator, University of Wisconsin (MR Hernandez, PI, WU)	
08/15/96-12/31/98	
Johnson & Johnson, Inc.	\$50,000
“Physiology and pathophysiology of accommodation and presbyopia”	
Principal Investigator, University of Wisconsin	
12/01/96-11/30/97	
Research to Prevent Blindness	\$25,000
Unrestricted Departmental Grant to UW, allocation to Paul Kaufman’s animal care	
1996 - \$9,250; 1997 - \$7,500; 1998 - \$8,250	
Alteon, Inc.	\$45,424
“Effect of Alteon compounds on accommodation and presbyopia in monkeys”	
Principal Investigator, University of Wisconsin	
01/01/97-12/31/98	
Alcon Laboratories, Inc.	\$4,592
“Alcon surgical devices”	
Principal Investigator, University of Wisconsin	
04/01/97-04/30/97	
Columbia University	\$30,000
“Physiology of uveoscleral outflow”	
Principal Investigator, University of Wisconsin	
08/01/97-07/31/98	
Wisconsin Alumni Research Foundation	\$50,000
Mid-Career Award	
1998	
Ciba Vision, Inc.	\$20,304
“Rescula/Xalatan ocular hypotensive mechanisms in primates”	
Principal Investigator, University of Wisconsin	
01/01/98-12/31/98	
Massachusetts Institute of Technology	\$500
“Hydrodynamics of aqueous humor outflow”	
Mark Johnson, PI NIH grant (total direct costs = \$1,103,276);	
PK is Principal Investigator of University of Wisconsin subcontract to	
provide primate ocular tissue) 01/01/98-12/31/01	
Glaucoma Research Foundation	\$75,000
Center of Excellence Award	
Co-Principal Investigator, University of Wisconsin	
06/01/98	
Canji, Inc.	\$133,676
“Effect of rAd-21 gene therapy in controlling wound healing in glaucoma filtration surgery”	
Co-Principal Investigator with R. Nickells, University of Wisconsin	
07/01/98-12/31/04	
(PLK lab portion: TC: \$194,499; DC: \$133,676)	
Glaucoma Research Foundation	\$97,772
“Effects of H-7 and latrunculin on TM and CM cells <i>in vitro</i> ; transfer	
of genes relevant to enhanced outflow to monkey eyes <i>in vivo</i> ”	

Principal Investigator, University of Wisconsin 07/01/98-06/30/00	
01 - \$48,350; 02-\$49,422NIH Research Grant EY06416	\$91,100
“Glaucoma: Connective tissue changes in optic nerve head” (MR Hernandez, Washington University, PI) Principal Investigator, University of Wisconsin subcontract. 04/01/99-03/31/04 (UW TDC: 15-\$17,159; 16-\$17,674; 17-4\$18,204; 18-\$18,750; 19-\$19,313)	
Pharmacia & Upjohn, Inc.	\$54,596
“Comparison of ciliary muscle extracellular matrix remodeling in monkey eyes treated with latanoprost or unoprostone” Principal Investigator, University of Wisconsin 06/01/99-01/31/01	
Bio-Concept Laboratories, Inc.	\$903
“Drug penetration / pupil studies” Principal Investigator, University of Wisconsin 11/01/99-10/31/00	
The Glaucoma Foundation	\$15,359
“Effects of elevated intraocular pressure on the central visual pathways in a primate model of glaucoma – J. Matsubara, Univ. of British Columbia, PI” Principal Investigator, University of Wisconsin subcontract 01/01/00–12/31/00 (UBC/UW combined TDC-\$32,879; UW subcontract=\$15,359)	
Allergan, Inc.	\$50,632
“Accommodative potential of the primate eye following intraocular implantation of a flat silicone disc IOL compared to a SI40NB IOL in the opposite eye” Principal Investigator, University of Wisconsin 01/01/00-06/30/03	
University of Wisconsin Medical School Research Committee	\$10,000
“Ciliary muscle aging” Principal Investigator, University of Wisconsin 01/01/00-06/30/00	
NIA-NIH	\$8,179
“Ocular effects of caloric restriction in aging rhesus monkeys” Principal Investigator, University of Wisconsin 01/01/00-12/31/00	
Allergan, Inc.	\$5,789
“A comparison of the response to pharmacologically induced accommodation by topical and iontophoresis application of carbachol in the phakic and pseudophakic rabbit eye implanted with a flat or angled silicone disc IOL” 03/15/00-02/14/01	
CibaVision, Inc.	\$17,968
“Conventional and uveoscleral outflow determination in rabbits following topical isopropyl unoprostone or latanoprost” Principal Investigator, University of Wisconsin 03/20/00-02/19/01	
NIH/NEI EY10009	\$123,535
“Excitatory amino acids in glaucoma,” (Evan Dreyer/Alan Laties, Univ. of Pennsylvania, PI) Principal Investigator, University of Wisconsin subcontract 07/01/00-06/30/03 (UW TDC: 01-\$39,967; 02-\$41,166; 03-\$42,402)	
Glaucoma Research Foundation	\$48,559
“Adaptation of aqueous humor dynamics techniques for the mouse eye”	

Principal Investigator, University of Wisconsin 07/01/00-06/30/01 (Kaufman Lab \$43,559; Ernst Tamm Lab {Univ. Erlangen-Nürnberg} \$5,000)	
Pharmacia Corp. “Mechanism of viscocanalostomy in monkeys” Principal Investigator, University of Wisconsin 07/01/00-06/30/02 (Kaufman Lab \$23,981, Daniel Albert Lab {UW} \$17,000, Ernst Tamm Lab {Univ. Erlangen-Nürnberg} \$10,000)	\$50,981
QuestVision, Inc. “Studies of accommodating intraocular lens Implants in rhesus monkeys” Principal Investigator, University of Wisconsin 08/15/00-08/15/01	\$32,973
Shenasa Medical “Test of elliptical accommodating intraocular lens in rhesus monkeys” – SBIR/NIH Principal Investigator, University of Wisconsin 01/01/01-07/31/02	\$22,196
Shenasa Medical “Test of elliptical accommodating intraocular lens in rhesus monkeys – STTR/NIH Principal Investigator, University of Wisconsin 03/01/01-07/31/02	\$30,000
NIH/NEI EY12515 “Signaling role of fibronectin in trabecular meshwork” Co-Investigator, (Donna Peters, Univ. of Wisconsin, PI) 04/01/01-03/31/06 (TDC: \$175,000 x 5 = \$875,000; Kaufman lab DC = \$43,308 x 5 = \$216,540)	\$216,540
Research to Prevent Blindness Physician Scientist Award 01/01/02-12/31/02	\$55,000
NIH/NEI EY11906-05-09 “Regulation of outflow facility by gene transfer” (Teresa Borrás, Duke University/ University of North Carolina-Chapel Hill, PI; TDC-\$1,310,511) Principal Investigator, University of Wisconsin subcontract) 04/01/02-03/31/07 UWDC: 05-\$15,452; 06 -\$15,915; 07-\$16,392; 08-\$16,884; 09-\$16,992	\$81,635
Alcon Laboratories, Inc. “Effect of Alcon serotonergic compounds on aqueous humor dynamics in monkeys” Principal Investigator, University of Wisconsin 10/01/02-3/31/04 TDC- \$56,550 (TC - \$82,281)	\$56,550
Allergan, Inc. “Glutamate and Glaucoma in Monkeys” Principal Investigator, University of Wisconsin 10/01/02-open TDC - \$51, 546 (TC - \$75,000)	\$51,546
Synphora AB / Pharmacia Corp “Effect of Synphora compound JB002A on aqueous humor outflow in monkeys” Principal Investigator, University of Wisconsin 10/01/02-09/30/03 TDC-\$70,562 (TC = \$102,667)	\$70,562
Santen, Inc. “Effect of Santen compounds on aqueous humor dynamics”	\$82,478

Principal Investigator, University of Wisconsin 10/01/02-09/30/03 TDC – \$82,478 (TC - \$120,005)	
Defense Advanced Research Projects Agency (DARPA) “Light-emitting diode treatment healing post-retinal LASER injury Principal Investigator, Harry Whelan, Medical College of WI; James Ver Hoeve UW PI 11/13/02-11/12/03 TDC: \$30,619 Kaufman lab portion of DC: \$13,519 N66001 04 8923: “Photobiomodulation for treatment of acute neurologic injury using light-emitting diode (LED). Principal Investigator, Harry Whelan, Medical College of WI; James Ver Hoeve UW PI 8/1/04-8/31/05 TDC: 132,599, Kaufman lab portion of DC: \$18,938	\$32,457
The Glaucoma Foundation “Stem cells in the primate trabecular meshwork” Principal Investigator, University of Wisconsin (Primary PI: E Tamm, University of Erlangen-Nürnberg). 01/01/03-12/31/03 TDC - \$35,000; UWDC - \$22,500	\$22,500
Fight for Sight Competitive Post-Doctoral Research Fellowship “Memantine effects on retinal topography and retinal nerve fiber layer thickness in experimental glaucoma in monkeys” Principal Investigator for Dr. Mehmet Okka, Visiting Scholar in Dr. Kaufman’s Laboratory 9/1/03-8/31/04	\$16,000
Biovitrum AB “Intraocular pressure effects of Biovitrum compounds” Principal Investigator, University of Wisconsin 07/01/03-12/31/03 TDC - \$38,003 01/07-12/07 TC = \$29,980; DC=\$20,210	\$58,713
Laszlo Bito & Olivia Carino Foundation, Inc 2003, Unrestricted grant	\$100,000
University of Wisconsin Medical School Research Committee Award Monitoring the progression of damage in the monkey experimental glaucoma model 10/1/03-9/30/04	\$10,000
Walter H. Helmerich/Retina Research Foundation Chair Department of Ophthalmology, University of Wisconsin 1/1/04-12/31/04 TDC - \$50,000	\$50,000
Department of Ophthalmology and Visual Sciences Clinical Research Award 7/1/04-6/30/05	\$7,370
NIH/NEI 1 U13 EY015437-01 “Workshops on clinical and basic ophthalmology research” Principal Investigator, Association for Research in Vision & Ophthalmology 09/01/04-08/31/05	\$322,800
TDC - \$322,800; TC - \$419,317 Teva Pharmaceuticals, Ltd Feasibility planning: Effect of Copaxone on progression of glaucomatous optic neuropathy in monkeys” Principal Investigator, University of Wisconsin 2003-2004	\$20,097

TDC – 20,097; TC - \$29,241	
Pfizer, Inc.	
“Effect of Pfizer compounds on IOP and aqueous humor dynamics in monkeys”	\$109,517
Principal Investigator, University of Wisconsin	
08/01/04-12/31/05	
(TC = \$159,347; DC= \$109,517)	
Merck	\$76,465
“Effect of Merck compounds on IOP and aqueous humor dynamics in monkeys”	
Principal Investigator, University of Wisconsin	
10/01/04-9/3/05	
(TC = \$111,257; DC = \$76,465)	
Wisconsin Alumni Research Foundation	
“Laboratory Share Distribution – Royalty & Licensing Income	\$52,500
02/24/05 – open ended	
Alcon Research, Ltd	\$30,928
“Effect of COX inhibitor on IOP-lowering by AL-37807”	
4/1/05-12/31/05	
(TC = \$45,000; DC = \$30,928)	
MEMX, Inc	\$47,003
“Glaucoma Shunt Device Using MEMX Filtering Technology”	
7/1/05-7/1/06	
(TC = \$68,390; DC = \$47,003)	
American Health Assistance Foundation	\$89,866
“A.G.E. Crosslink Breakers for Ocular Disorders” Principal Investigator, University of Wisconsin	
04/01/05-03/31/07	
DC & TC - \$44,269 (01) + \$45,597 (02)	
University of Wisconsin Graduate School	\$15,000
“Ciliary muscle aging” insurance vs NIH renewal	
Principal Investigator, University of Wisconsin	
07/01/05-06/30/06	
**NIH/NEI 5 P30 EY001665	**\$851,216
07/01/05-06/30/10 (no cost extension to 6/30/2011)	
Principal Investigator: Curtis Brandt, UW Madison	
TC entire grant = \$2,910,000	
DC entire grant = \$1,999,999	
Animal and Organ Culture Core Director: Paul Kaufman	
DC= 01- \$115,454; 02-\$118,918; 03-\$122,485; 04-\$126,160; 05-129,944	
Kaufman portion DC (\$381,381):	
01=\$71,835; 02=\$73,990; 03=\$76,209; 04=\$78,496; 05=\$80,851	
NuLens, LLC	\$182,365
“Accommodating Intraocular Lenses”	
Principal Investigator, University of Wisconsin	
12/29/05 – 5/31/12	
TC = \$269,132; TDC=\$182,365	
Eyetech	\$257,461
“A 13-Week Exploratory Assessment of Retinal Function in	
Cynomolgus Monkeys following Repeat Intravitreal Injections of Avastin or Macugen”	
Principal Investigator: T. Michael Nork, UW Madison (CORL)	
04/06-12/06	
Entire project: \$369,631	
Kaufman lab: DC\$257,461	
Helen Keller Foundation/Pfizer Ophthalmics Research Award in Glaucoma	\$40,000

<p>“Modulation of Aqueous Humor Outflow by Gene Therapy Targeting Actin” Principal Investigator, Xuyang Liu, University of Wisconsin 03/01/06-02/28/07 (TC & DC: \$40,000; Kaufman lab portion, \$40,000)</p>	
NIH/NEI 1 R01 EY009741-13	
<p>“Adenosine Agonists: Potential Antiglaucoma Agents” Principal Investigator Craig Crosson, Medical Univ South Carolina Principal Investigator UW subcontract: Paul Kaufman 04/01/06-03/31/07 (UW TC=\$70,655; UW DC=\$48,560)</p>	\$48,560
Allergan	\$105,000
Unrestricted grant for research 10/1/05-9/30/08 \$35,000 x 3 = \$105,000	
Inspire Pharmaceuticals, Inc	\$435,329
<p>“Evaluation of cytoskeletal active compounds on intraocular pressure and outflow facility in Cynomolgus monkeys” Principal Investigator, Univ Wisconsin 6/20/06-7/1/09 TC=\$645,073; TDC=\$435,329</p>	
NIH/NEI 1 R21 EY017612-01 (Tian)	\$235,000
Will cytoskeletal drugs prevent PCO? Principal Investigator: Baohe Tian, Univ Wisconsin 9/1/06-8/31/08 TC 01 - \$219,090; 02 - \$178,110 TDC 01 - \$150,000; 02 - \$125,000 UW DC 01- \$122,000; 02-DC \$113,000 TDC Subcontract to India 01+02 = \$40,000	
Lens AR, Inc (aka Frey Research LLC)	\$187,435
Randy Frey LLC Project 10/1/06-ongoing TC = \$287,485; DC=\$187,435	
Cytokinetics, Inc	\$63,343
Effects of Cytokinetic compounds on IOP and outflow facility in monkeys 7/6/07-7/6/08 DC = \$63,343 TC=\$94,113	
Cara Therapeutics, Inc	\$23,116
Effects of Cara Compounds on IOP in Monkeys 3/1/08-4/30/09 DC=\$23,116 TC=\$33,793	
Danube Pharmaceuticals, Inc	\$7,484
Effect of Danube Compounds on IOP and Its Mechanism in Monkeys 4/1/08-3/31/09 DC=\$7,484 TC=\$10,942	
Santen Pharmaceutical Co. Ltd	\$269,005
The Effect of USG-196 on Aqueous Humor Dynamics in Monkeys 4/1/08-3/31/09 DC = \$269,005 TC = \$419,460	

NIH/NEI R21 EY018370-01A2/02 (Kaufman)	\$275,000
Extralenticular aspects of accommodation and presbyopia	
12/1/08-11/30/10	
DC = \$275,000 (yr1=\$150,000; yr2=\$125,000)	
TC= \$392,618	
NIH/NEI R21 EY018370-01A2S1	\$275,000
ARRA Competitive Revision Extralenticular aspects of accommodation and presbyopia	
09/30/2009-09/29/2011	
DC = \$275,000 (yr 1 = \$150,000; yr2 = \$125,000)	
TC = \$389,400	
NIH R01 EY002698 ARRA Grant (144-PRJ26RS)	\$5,000
Anterior Ocular Segment Physiology and Pharmacology: administrative supplement	
for students and science educators under the recovery act	
08/01/09-10/31/09	
UW DC: \$5,000	
UW TC: \$7,425	
NIH-NEI (ARRA) R01 EY018567 (Kaufman)	\$492,485
Aqueous humor dynamics studies in vivo and in vitro	
08/01/2009-07/31/2011 (No-cost extension to 07/31/2012)	
DC: yr 1, \$242,604; yr 2, \$249,881	
TC: yr1, \$360,267; yr 2, \$371,073	
AHAF (133-PRJ27HD)	\$100,000
Vitamin D effects on anterior segment physiology in monkeys	
04/01/2009-03/31/2011	
DC: yr1, \$50,000; yr2, \$50,000	
QLT Plug Delivery, Inc	\$43,365
Primate study to evaluate the IOP lowering effect of latanoprost 0.005% once a day to latanoprost 0.001% given 5	
times per day	
03/01/2010-04/30/2011	
DC: \$43,365	
TC: \$67,650	
Herbert Kaufman	\$2,215
Effect of Aricept on Pupil Diameter in Monkeys	
6/1/2010-8/31/2010	
DC: \$2,215	
TC: \$3,238	
NIH-NEI (Borrás)	\$203,246
Regulation of outflow facility by gene transfer	
9/1/2010-8/31/2012	
DC yr1=\$99,683; yr2=\$103,563 (UW)	
TC yr1=\$146,534; yr2=\$152,238 (UW)	
NIH R01 EY021515 (PI: Carla Siegfried, Washington Univ)	\$361,834
Ocular Oxygen Metabolism and the Etiology of Open Angle Glaucoma	
4/1/2011-4/30/2014 (subcontract)	
DC: yr1=\$139,289; yr2=\$114,397; supplement \$108,148	
TC: yr1=\$206,844; yr2=\$169,879.55; supplement \$160,600 (Kaufman Lab portion)	
UW Graduate School	\$75,000
WARF Named Professorship, Ernst H. Bány Professor of Ocular Pharmacology	
07/01/11-6/30/2016	
Z Lens, LLC	
Principle testing of a Zonular Capture Haptic	
10/01/2011 – 09/30/2012	
	\$40,313

TC: \$60,670 DC: \$40,313	
Merck Sharp & Dohme Corp	\$116,927
Effects of benzalkonium on aqueous humor dynamics in monkeys 10/01/2012-09/30/2013 TC: \$164,183 DC: \$116,927	
NSF SBIR Phase 1A Grant IIP-1248141 (PI: Paul M. Beer, Z Lens, LLC & Albany Med Coll)	\$36,577
SBIR Phase I: A Novel Intraocular Lens Using Zonular Capture Haptics 01/01/2013-06/30/2013 Parent Grant award \$150,000; Supplement \$30,000 = total \$180,000 Subaward to Kaufman Lab: TC \$46,499+\$8,430; DC \$30,963 + \$5,614	
NEI STTR 1 R41 EY022828-01A1 (PI: Paul M. Beer (Z Lens, LLC & Albany Med Coll))	\$73,349
STTR Phase II: A Novel Intraocular Lens Using Zonular Capture Haptics 04/01/2013 – 03/31/2014 UW: TC = \$110,049; DC=\$73,349	
BrightFocus (PI: Curtis R. Brandt)	\$40,212
Enhancement of Gene Expression for Glaucoma Therapy 07/01/13-06/30/15 Parent Grant: \$100,000 DC: yr1=\$20,106; yr2=\$20,106 (Kaufman lab portion)	
Wallace H. Coulter Center for Translational Research (PI: Sanjoy Bhattacharya, Univ of Miami)	\$19,000
New endogenous lipid entities to fulfill unmet needs for glaucoma treatment 11/01/13 – 10/30/14 Parent Grant: DC=\$79,000 UW DC = \$19,000 (no indirect costs allowed)	
136-6005 AlconLaboratories	\$346,163
Alcon Presbyopia Study 08/01/13 – 07/31/14 DC = \$346,163.11 TC = \$520,975.48	
Department of Defense (PI: Sanjoy Bhattacharya, Univ of Miami)	\$78,808
Endogenous Lipid Protectants against Neurodegeneration 07/01/14-06/30/16 DC: \$78,808 TC: \$118,606	
Glaucoma Research Foundation Shaffer Grant	\$40,000
Gene Therapy for Glaucoma Principal Investigator, University of Wisconsin 03/01/2015-02/29/2016 No IC; TC = \$40,000	
VistaOcular FFS (Roholt)	\$30,090
Utilizing the Ciliary Muscles Action Potential to Drive an Accommodating IOL 04/01/2015 – 09/01/2015 DC 30,090.20 IC 15,947.80 (Supplement)	
RegenEye FFS (Peter Reinke)	\$93,489.07
RegenEye Collar Stent Principal Investigator, University of Wisconsin 07/01/2015 – 06/30/2015 DC 93,489.07 IC 49,549.21 (Supplement)	

NIH R01 EY019587-11 (PI-David Piwnica-Worms, MD Anderson Cancer Center, Houston, TX) \$64,521 “Membrane Permeant Peptides for Imaging Cell Function” 09/30/13 – 09/29/2017	
WNPRC Pilot Research Pilot Program Grant (P Kaufman, D Gamm – co - PIs) “Stem cell-derived photoreceptor transplantation in the non-human primate eye: an initial evaluation of delivery, safety, and cellular integration” 01/01/2015 –Parent grant: \$50,000	\$36,570
NSF SBIR Phase II (Z Lens, LLC)) (PI: Paul M Beer, Albany Med Coll) SBIR Phase II: ZLens Axial Shift Device 02/01/2015-12/31/2016 Sub-award to Kaufman Lab: DC \$261,267.01 TC \$327,080	\$261,267
Research to Prevent Blindness Stein Innovation Award MIGS as a delivery method for glaucoma gene transfer Principal Investigator, University of Wisconsin 07/01/2015-06/30/2017 DC 01-\$150,000; 02-\$150,000, No IC	\$300,000
NIH/NEI 1R01EY02359 Extralenticular aspects of accommodation and presbyopia 01/01/2016-12/31-2019 DC 01- \$433,634; 02- \$408,428; 03- \$402,428; 04- \$402,428 = \$1,646,918 TC 01- \$663,459; 02- \$624,894; 03- \$615,714; 04- \$615,714 = \$2,519,781	\$1,646,918
**NIH/NEI 2 P30 EY001665 Core grant for vision research 9/1/16-8/31/21 Principal Investigator: Curtis Brandt, UW Madison TC entire grant = \$2,970,000 DC entire grant = \$2,000,000 Animal Core portion DC: (\$564,410) 01=\$112,882; 02=\$112,882; 03=\$112,882; 04=\$112,882; 05=\$112,882 TC: (\$863,550) 01=\$172,710; 02=\$172,710; 03=\$172,710; 04=\$172,710; 05=\$172,710	**\$863,550
Lions Eye Bank of Wisconsin Title: Schlemm's canal pressure and episcleral venous pressure in monkeys Summary: Development of a minimally invasive reproducible gonioscopic imaging technique for measuring Schlemm's canal pressure (and indirectly episcleral venous pressure) in live non-human primates, based on real-time videography of Schlemm's canal blanching/filling as IOP is precisely manipulated and measured. The ultimate objective is to determine whether the intraocular pressure (IOP) lowering effects of drugs are associated with drug effects on SCP/EV, providing a data-driven description of the pharmacology of SCP/EVP in non-human primates and applying this knowledge to human clinical trials. 07/01/17-06/30-18 TC=DC; no IC	\$55,000
TOTAL DIRECT COST GRANT FUNDS AWARDED	\$22,790,163

PATENTS

Cytoskeletal Active Agents for Glaucoma Therapy; US Patent Numbers 5,798,380 A, 6,110,912 A, 6,586,425 B1; 8/25/1998, 8/29/2000, 7/1/2003 (Expires 2/21/2016); Inventors: Kaufman PL, Geiger B.
Method for Treating Glaucoma (Caldesmon); Patent Number PCT/US2005/005428; US Patent number 7,196,062; 03/27/07; 2/18/2005 (Expires 2/18/2025); Inventors Kaufman PL, Geiger B, Borrás T, Bershinsky AD.

Method for Treating Glaucoma (C3); Patent Number PCT/US2005/005427; 2/18/2005 (Expires 2/18/2025); US Patent Number 7,083,783 B2; 08/01/2006; Inventors Kaufman PL, Liu X.

Vitamin D Compounds and Methods for Reducing Ocular Hypertension (OHT); Pub. No.: US 2011/0059926 A1, 3/10/2011; Inventors: DeLuca HF, Kutuzova GD, Kaufman PL, Gabelt BT.

PUBLICATIONS

Original Articles

1. Wynder EL, Kaufman PL, Lesser RL: A short-term follow-up study on ex-cigarette smokers, with special emphasis on persistent cough and weight gain. *Am Rev Respir Dis* 96:645-655, 1967.
2. Kaufman PL, Podos SM: Subretinal fluid butyrylcholinesterase: I. Source of the enzyme and factors affecting its concentration in subretinal fluid from primary rhegmatogenous retinal detachments. *Am J Ophthalmol* 75:627-636, 1973.
3. Kaufman PL, Podos SM: The subretinal fluid in primary rhegmatogenous retinal detachment. *Surv Ophthalmol* 18:100-116, 1973 (Review).
4. Kaufman PL, Podos SM: Subretinal fluid butyrylcholinesterase: II. Reoperated rhegmatogenous detachments and diabetic traction detachments. *Am J Ophthalmol* 77:19-24, 1974.
5. Kaufman PL, Kolker AE: Ocular findings and corticosteroid responsiveness in parents of children with primary infantile glaucoma. *Invest Ophthalmol* 14:46-49, 1975.
6. Kaufman PL, Bárány EH: Subsensitivity to pilocarpine in primate ciliary muscle following topical anticholinesterase treatment. *Invest Ophthalmol* 14:302-306, 1975.
7. Kaufman PL, Högberg F: Minified Swan-Jacob lens for gonioscopy in small primates. *Invest Ophthalmol* 14:410-411, 1975.
8. Kaufman PL: Prognosis of primary rhegmatogenous retinal detachments: I. Associations between clinical detachment characteristics, subretinal fluid butyrylcholinesterase, and visual outcomes following scleral buckling procedures. *Acta Ophthalmol* 53:660-671, 1975.
9. Kaufman PL, Lütjen-Drecoll E: Total iridectomy in the primate *in vivo*: Surgical technique and postoperative anatomy. *Invest Ophthalmol* 14:766-771, 1975.
10. Kaufman PL, Hahnenberger R: CI-744 anesthesia for ophthalmological examination and surgery in monkeys. *Invest Ophthalmol* 14:788-791, 1975.
11. Kaufman PL, Axelsson U: Induction of subcapsular cataracts in aniridic vervet monkeys by echothiophate. *Invest Ophthalmol* 14:863-866, 1975.
12. Kaufman PL: Prognosis of primary rhegmatogenous retinal detachments: II. Accounting for and predicting final visual acuity in surgically reattached cases. *Acta Ophthalmol* 54:61-74, 1976.
13. Kaufman PL, Bárány EH: Residual pilocarpine effects on outflow facility after ciliary muscle disinsertion in the *Cynomolgus* monkey. *Invest Ophthalmol* 15:558-561, 1976.
14. Kaufman PL, Bárány EH: Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the *Cynomolgus* monkey. *Invest Ophthalmol* 15:793-807, 1976.
15. Kaufman PL, Bárány EH: Subsensitivity to pilocarpine of the aqueous outflow system in monkey eyes after topical anticholinesterase treatment. *Am J Ophthalmol* 82:883-891, 1976.
16. Kaufman PL, Bárány EH: Cytochalasin B reversibly increases outflow facility in the eye of the *Cynomolgus* monkey. *Invest Ophthalmol Vis Sci* 16:47-53, 1977.
17. Kaufman PL, Axelsson U, Bárány EH: Induction of subcapsular cataracts in *Cynomolgus* monkeys by echothiophate. *Arch Ophthalmol* 95:499-504, 1977.
18. Lütjen-Drecoll E, Kaufman PL, Bárány EH: Light and electron microscopy of the anterior chamber angle structures following surgical disinsertion of the ciliary muscle in the *Cynomolgus* monkey. *Invest Ophthalmol Vis Sci* 16:218-225, 1977.
19. Kaufman PL, Bill A, Bárány EH: Formation and drainage of aqueous humor following total iris removal and ciliary muscle disinsertion in the *Cynomolgus* monkey. *Invest Ophthalmol Vis Sci* 16:226-229, 1977.

20. Kaufman PL: Drugs and the trabecular meshwork. *Invest Ophthalmol Vis Sci* 16:475-477, 1977 (Editorial on Recent Advances, by invitation of the editor).
21. Kaufman PL, Axelsson U, Bárány EH: Atropine inhibition of echothiophate cataractogenesis in monkeys. *Arch Ophthalmol* 95:1262-1268, 1977.
22. Kaufman PL, Bill A, Bárány EH: Effect of cytochalasin B on conventional drainage of aqueous humor in the Cynomolgus monkey. *Exp Eye Res* 25(Suppl - in: Bito LZ, Davson H, Fenstermacher JD, eds. The ocular and cerebrospinal fluids. Fogarty International Center Symposium):411-414, 1977.
23. Kaufman PL, Bárány EH: Recent observations concerning the effects of cholinergic drugs on outflow facility in monkeys. *Exp Eye Res* 25(Suppl - in: Bito LZ, Davson H, Fenstermacher JD, eds. The ocular and cerebrospinal fluids. Fogarty International Center Symposium):415-418, 1977.
24. Kaufman PL: Anticholinesterase-induced cholinergic subsensitivity in primate accommodative mechanism. *Am J Ophthalmol* 85:622-631, 1978.
25. Svedbergh B, Lütjen-Drecoll E, Ober M, Kaufman PL: Cytochalasin B-induced structural changes in the anterior ocular segment of the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 17:718-734, 1978.
26. Anderson CJ, Kaufman PL, Sturm RJ: Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. *Am J Ophthalmol* 86:516-519, 1978.
27. Klewin KM, Appen RE, Kaufman PL: Amaurosis and blood loss. *Am J Ophthalmol* 86:669-672, 1978.
28. Philipson B, Kaufman PL, Fagerholm P, Axelsson U, Bárány EH: Echothiophate cataracts in monkeys: Electron microscopy and microradiography. *Arch Ophthalmol* 97:340-346, 1979.
29. Kaufman PL: Pilocarpine update. *Ann Ophthalmol* 11:631-632, 1979 (Glaucoma Editorial, by invitation of the editor).
30. Kaufman PL, Svedbergh B, Lütjen-Drecoll E: Medical trabeculocanalotomy in monkeys with cytochalasin B or EDTA. *Ann Ophthalmol* 11:795-796, 1979 (Glaucoma Editorial, by invitation of the editor).
31. Kaufman PL, Rohen JW, Bárány EH: Hyperopia and loss of accommodation following ciliary muscle disinsertion in the Cynomolgus monkey: Physiologic and scanning electron microscopic studies. *Invest Ophthalmol Vis Sci* 18:665-673, 1979.
32. Kaufman PL: Aqueous humor dynamics following total iridectomy in the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 18:870-875, 1979.
33. Lütjen-Drecoll E, Kaufman PL: Echothiophate-induced structural alterations in the anterior chamber angle of the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 18:918-929, 1979.
34. Kaufman PL, Davis GE: "Minified" Goldmann applanating prism for tonometry in monkeys and humans. *Arch Ophthalmol* 98:542-546, 1980.
35. Krupin T, Kaufman P, Mandell A, Ritch R, Asseff C, Podos SM, Becker B: Filtering valve implant surgery for eyes with neovascular glaucoma. *Am J Ophthalmol* 89:338-343, 1980.
36. Bundy WE III, Kaufman PL, Stainer GA, Prensky JC: Unilateral Rieger's anomaly. *Am J Ophthalmol* 90:725-727, 1980.
37. Kaufman PL, Bundy WE III, Neider MW: Zeiss gonioscopy lens for noncontact biomicroscopic ophthalmoscopy. *Am J Ophthalmol* 90:739-740, 1980.
38. Kaufman PL, Friske HH: Sidewall-holed needle for anterior chamber infusion. *Ophthalmic Surg* 12:108-109, 1981.
39. Kaufman PL, Bárány EH: Adrenergic drug effects on aqueous outflow facility following ciliary muscle retrodisplacement in the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 20:644-651, 1981.
40. Kaufman PL, Rentzhog L: Effect of total iridectomy on outflow facility responses to adrenergic drugs in Cynomolgus monkeys. *Exp Eye Res* 33:65-74, 1981.
41. Kaufman PL, Neider MW, Pankonin WH: Slit lamp mount for Zeiss gonioscopy lens. *Arch Ophthalmol* 99:1455, 1981.
42. Erickson KA, Kaufman PL: Comparative effects of three ocular perfusates on outflow facility in the Cynomolgus monkey. *Curr Eye Res* 1:211-216, 1981.
43. Kaufman PL, Calkins BT, Erickson KA: Ocular biometry of the Cynomolgus monkey. *Curr Eye Res* 1:307-309, 1981.

44. Kaufman PL, Bito LZ: The occurrence of senile cataracts, ocular hypertension, and glaucoma in rhesus monkeys. *Exp Eye Res* 34:287-291, 1982.
45. Bito LZ, DeRousseau CJ, Kaufman PL, Bito JW: Age-dependent loss of accommodative amplitude in rhesus monkeys: An animal model for presbyopia. *Invest Ophthalmol Vis Sci* 23:23-31, 1982.
46. Kaufman PL, Bárány EH, Erickson KA: Effect of serotonin, histamine, and bradykinin on outflow facility following ciliary muscle retrodisplacement in the Cynomolgus monkey. *Exp Eye Res* 35:191-199, 1982.
47. Kaufman PL, Erickson KA: Cytochalasin B and D dose-outflow facility relationships in the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 23:646-650, 1982.
48. Kaufman PL, Bito LZ, DeRousseau CJ: The development of presbyopia in primates. *Trans Ophthalmol Soc UK* 102:323-326, 1983.
49. Kaufman PL, Erickson KA, Neider MW: Echothiophate iodide cataracts in monkeys: Occurrence despite loss of accommodation induced by retrodisplacement of ciliary muscle. *Arch Ophthalmol* 101:125-128, 1983.
50. Kaufman PL, Erickson KA, Bárány EH: Effect of repeated anterior chamber perfusion on intraocular pressure and outflow facility in the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 24:159-164, 1983.
51. Krupin T, Kaufman P, Mandell AI, Terry SA, Ritch R, Podos SM, Becker B: Long term results of valve implants in filtering surgery for eyes with neovascular glaucoma. *Am J Ophthalmol* 95:775-782, 1983.
52. Gonnering RS, Dortzbach RK, Erickson KA, Kaufman PL: The Cynomolgus monkey as a model for orbital research: I. Normal anatomy. *Curr Eye Res* 3:529-540, 1984.
53. Gonnering RS, Dortzbach RK, Erickson KA, Kaufman PL: The Cynomolgus monkey as a model for orbital research: II. Anatomic effects of lateral orbitotomy. *Curr Eye Res* 3:541-555, 1984.
54. Erickson KA, Gonnering RS, Kaufman PL, Dortzbach RK: The Cynomolgus monkey as a model for orbital research: III. Effects on ocular physiology of lateral orbitotomy and isolation of the ciliary ganglion. *Curr Eye Res* 3:557-564, 1984.
55. Jefferson JW, Kaufman P, Ackerman D: Tear lithium concentration. A measurement of dubious clinical value. *J Clin Psychiatr* 45:304-305, 1984.
56. Erickson-Lamy KA, Kaufman PL, McDermott ML, France NK: Comparative anesthetic effects on aqueous humor dynamics in the Cynomolgus monkey. *Arch Ophthalmol* 102:1815-1820, 1984.
57. Kaufman PL: On presentation of the Friedenwald Award of the Association for Research in Vision and Ophthalmology to Anders Bill. *Invest Ophthalmol Vis Sci* 26:404-405, 1985 (Invited Presentation).
58. Kaufman PL, Erickson-Lamy KA: Effect of repeated anterior chamber perfusion on aqueous flow in the Cynomolgus monkey. *Invest Ophthalmol Vis Sci* 26:885-886, 1985.
59. Kaufman PL, Wallow IH: Minified diagnostic contact lenses for biomicroscopic examination and photocoagulation of the anterior and posterior segment in small primates. *Exp Eye Res* 40:883-885, 1985.
60. Kaufman PL, Jefferson JW, Ackerman D, Baumgartner S: Ocular effects of oral lithium in humans. *Acta Ophthalmol* 63:327-332, 1985.
61. Kaufman PL: Isoproterenol dose-outflow facility response relationships in the vervet monkey. *Curr Eye Res* 4:877-883, 1985.
62. Kaufman PL, Hultsch E: Aqueous humor dynamics in the owl monkey with comparison to Cynomolgus. *Curr Eye Res* 4:933-940, 1985.
63. Kaufman PL: Aging and aqueous humor dynamics. *Atti Fondazione Giorgio Ronchi* 40:465-470, 1985.
64. Feghali JG, Kaufman PL: Decreased intraocular pressure in the hypertensive human eye with betaxolol, a β_1 adrenergic antagonist. *Am J Ophthalmol* 100:777-782, 1985.
65. Lütjen-Drecoll E, Kaufman PL, Eichhorn M: Long-term timolol and epinephrine in monkeys: I. Functional morphology of the ciliary processes. *Trans Ophthalmol Soc UK* 105:180-195, 1986.
66. Lütjen-Drecoll E, Kaufman PL: Long-term timolol and epinephrine in monkeys: II. Morphological alterations in trabecular meshwork and ciliary muscle. *Trans Ophthalmol Soc UK* 105:196-207, 1986.

67. Kaufman PL: Epinephrine, norepinephrine, and isoproterenol dose-outflow facility response relationships in Cynomolgus monkeys with and without ciliary muscle retrodisplacement. *Acta Ophthalmol* 64:356-363, 1986.
68. Kaufman PL: Total iridectomy does not alter outflow facility responses to cyclic AMP in Cynomolgus monkeys. *Exp Eye Res* 43:441-447, 1986.
69. Feghali JG, Azar DT, Kaufman PL: Comparative aqueous outflow facility measurements by pneumatonography and Schiotz tonography. *Invest Ophthalmol Vis Sci* 27:1776-1780, 1986.
70. Lütjen-Drecoll E, Kaufman PL: Biomechanics of echthiophate-induced anatomic changes in monkey aqueous outflow system. *Graefes Arch Clin Exp Ophthalmol* 224:564-575, 1986.
71. Kaufman PL: Effects of intracamerally infused prostaglandins on outflow facility in Cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle. *Exp Eye Res* 43:819-827, 1986.
72. Erickson-Lamy KA, Polansky JR, Kaufman PL, Zlock DM: Cholinergic drugs alter ciliary muscle response and receptor content. *Invest Ophthalmol Vis Sci* 28:375-383, 1987.
73. Kaufman PL: Non-additivity of maximal pilocarpine and cytochalasin effects on outflow facility. *Exp Eye Res* 44:283-291, 1987.
74. Koretz JF, Neider MW, Kaufman PL, Bertasso AM, DeRousseau CJ, Bito LZ: Slit-lamp studies of the rhesus monkey eye: I. Survey of the anterior segment. *Exp Eye Res* 44:307-318, 1987.
75. Kaufman PL: Adenosine 3',5'-cyclic monophosphate and outflow facility in monkey eyes with intact and retrodisplaced ciliary muscle. *Exp Eye Res* 44:415-423, 1987.
76. Erickson-Lamy KA, Kaufman PL: Reinnervation of primate ciliary muscle following ciliary ganglionectomy. *Invest Ophthalmol Vis Sci* 28:927-933, 1987. [Published erratum in *IOVS* 28(8):1235, 1987]
77. Kulkarni PS, Kaufman PL, Srinivasan BD: Cyclo-oxygenase and lipoxygenase pathways in Cynomolgus and rhesus monkey conjunctiva, anterior uvea and eyelids. *Curr Eye Res* 6:801-808, 1987.
78. Bito LZ, Kaufman PL, DeRousseau CJ, Koretz J: Presbyopia: An animal model and experimental approaches for the study of the mechanism of accommodation and ocular ageing. *Eye (formerly Trans Ophthalmol Soc UK)* 1:222-230, 1987.
79. Crawford K, Kaufman PL: Pilocarpine antagonizes prostaglandin F_{2α}-induced ocular hypotension in monkeys: Evidence for enhancement of uveoscleral outflow by prostaglandin F_{2α}. *Arch Ophthalmol* 105:1112-1116, 1987. [Reprinted in *Classic Papers in Glaucoma*, Ritch R, Caronia R (eds), Kugler, 2000]
80. Crawford K, Kaufman PL, Gabelt BT: Effects of topical PGF_{2α} on aqueous humor dynamics in Cynomolgus monkeys. *Curr Eye Res* 6:1035-1044, 1987.
81. Koretz JF, Bertasso AM, Neider MW, Gabelt BT, Kaufman PL: Slit-lamp studies of the rhesus monkey eye: II. Changes in crystalline lens shape, thickness and position during accommodation and aging. *Exp Eye Res* 45:317-326, 1987.
82. Baroody RA, Bito LZ, DeRousseau CJ, Kaufman PL: Ocular development and aging: I. Corneal endothelial changes in cats and in free-ranging and caged rhesus monkeys. *Exp Eye Res* 45:607-622, 1987.
83. Kulkarni PS, Kaufman PL, Srinivasan BD: Eicosapentaenoic acid metabolism in Cynomolgus and rhesus monkey conjunctiva and eyelid. *J Ocular Pharmacol* 3:349-356, 1987.
84. Erickson-Lamy KA, Kaufman PL: Effect of cholinergic drugs on outflow facility after ciliary ganglionectomy. *Invest Ophthalmol Vis Sci* 29:491-494, 1988.
85. Erickson-Lamy KA, Kaufman PL, Polansky JR: Dissociation of cholinergic supersensitivity from receptor number in ciliary muscle. *Invest Ophthalmol Vis Sci* 29:600-605, 1988.
86. Koretz JF, Bertasso AM, Neider MW, Kaufman PL: Slit-lamp studies of the rhesus monkey eye: III. The zones of discontinuity. *Exp Eye Res* 46:871-880, 1988.
87. Kaufman PL, Gabelt BT, Erickson-Lamy KA: Time-dependence of perfusion outflow facility in the Cynomolgus monkey. *Curr Eye Res* 7:721-726, 1988.
88. Feghali JG, Kaufman PL, Radius RL, Mandell AI: A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. *Acta Ophthalmol* 66:180-186, 1988.

89. Lütjen-Drecoll E, Tamm E, Kaufman PL: Age-related loss of morphologic responses to pilocarpine in rhesus monkey ciliary muscle. *Arch Ophthalmol* 106:1591-1598, 1988.
90. Lütjen-Drecoll E, Tamm E, Kaufman PL: Age changes in rhesus monkey ciliary muscle: Light and electron microscopy. *Exp Eye Res* 47:885-899, 1988.
91. Koretz JF, Bertasso AM, Neider MW, Kaufman PL, Goeckner PA: Preliminary characterization of human crystalline lens geometry as a function of accommodation and age. In: *Non-invasive Assessment of the Visual System*. Washington DC: Optical Society of America, Technical Digest Series 3:130-133, 1988.
92. DePaul K, Sponsel WE, Kaufman PL: The correlation of visual field and retinal blood flow asymmetry in glaucoma patients and ocular hypertensives. In: *Non-invasive Assessment of the Visual System*. Washington DC: Optical Society of America, Technical Digest Series 7: 24-27, 1989.
93. McGetrick JJ, Wilson DG, Dortzbach RK, Kaufman PL, Lemke BN: A search for lymphatic drainage of the monkey orbit. *Arch Ophthalmol* 107:255-260, 1989.
94. Rohen JW, Kaufman PL, Eichhorn M, Goeckner PA, Bito LZ: Functional morphology of accommodation in the raccoon. *Exp Eye Res* 48:523-537, 1989.
95. Koretz JF, Kaufman PL, Neider MW, Goeckner PA: Accommodation and presbyopia in the human eye. I. Evaluation of *in vivo* measurement techniques. *Applied Optics* 28:1097-1102, 1989.
96. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial: I. Acute effects of argon laser trabeculoplasty on intraocular pressure. *Arch Ophthalmol* 107:1135-1142, 1989.
97. Gabelt BT, Kaufman PL: Prostaglandin F_{2α} increases uveoscleral outflow in the Cynomolgus monkey. *Exp Eye Res* 49:389-402, 1989.
98. Kaufman PL: Discussion of Camras C, et al.: Maintained reduction of intraocular pressure by prostaglandin F_{2α} l-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. *Ophthalmology* 96:1336-1337, 1989.
99. Crawford K, Terasawa E, Kaufman PL: Reproducible stimulation of ciliary muscle contraction in the Cynomolgus monkey via a permanent indwelling midbrain electrode. *Brain Res* 503:265-272, 1989.
100. Sponsel WE, Stodtmeister R, DePaul K, Zetlan SR, Kaufman PL: Studies of the relationship between visual function and retinal blood flow in open angle glaucoma. *Res Clin Forums* 112:69-77, 1989.
101. Sponsel WE, Kaufman PL, Strinden TL, DePaul KL, Bowes HN, Olander KW, Barnebey HS: Evaluation of the Keeler Pulsair non-contact tonometer. *Acta Ophthalmol* 67:567-572, 1989.
102. Koretz JF, Kaufman PL, Neider MW, Goeckner PA: Accommodation and presbyopia in the human eye: Aging of the anterior segment. *Vision Res* 29:1685-1692, 1989.
103. Neider MW, Crawford K, Kaufman PL, Bito LZ: *In vivo* videography of the rhesus monkey accommodative apparatus. Age-related loss of ciliary muscle response to central stimulation. *Arch Ophthalmol* 108:69-74, 1990.
104. Sponsel WE, DePaul KL, Kaufman PL: Correlation of visual function and retinal leukocyte velocity in glaucoma. *Am J Ophthalmol* 109:49-54, 1990.
105. Robinson JC, Kaufman PL: Effects and interactions of epinephrine, norepinephrine, timolol and betaxolol on outflow facility in the Cynomolgus monkey. *Am J Ophthalmol* 109:189-194, 1990. [Published erratum in *Am J Ophthalmol* 109:499, 1990]
106. Rohen JW, Eichhorn M, Kaufman PL, Erickson-Lamy KA: Ciliary neuromuscular morphology in Cynomolgus monkeys after ciliary ganglionectomy. *Graefes Arch Clin Exp Ophthalmol* 228:49-54, 1990.
107. Gabelt BT, Kaufman PL: The effect of prostaglandin F_{2α} on trabecular outflow facility in Cynomolgus monkeys. *Exp Eye Res* 51:87-91, 1990.
108. Crawford K, Gabelt BT, Kaufman PL, Bito LZ: Effect of various anesthetic and autonomic drugs on refraction in monkeys. *Curr Eye Res* 9:525-532, 1990.
109. Erickson-Lamy KA, Johnson CD, Gabelt BT, Kaufman PL: Ciliary muscle choline acetyltransferase and acetylcholinesterase after ciliary ganglionectomy. *Exp Eye Res* 51:295-299, 1990.
110. Crawford KS, Kaufman PL, Bito LZ: The role of the iris in accommodation of rhesus monkeys. *Invest Ophthalmol Vis Sci* 31:2185-2190, 1990.

111. The Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): 2. Results of argon laser trabeculoplasty versus topical medicines. *Ophthalmology* 97:1403-1413, 1990.
112. Gabelt BT, Kaufman PL, Polansky JR: Ciliary muscle muscarinic binding sites, choline acetyltransferase and acetylcholinesterase in aging rhesus monkeys. *Invest Ophthalmol Vis Sci* 31:2431-2436, 1990.
113. Kaufman PL: Parasympathetic denervation of the ciliary muscle following retinal photocoagulation. *Trans Am Ophthalmol Soc* 88:513-553, 1990.
114. Koretz JF, Kaufman PL: Scheimpflug slit-lamp photographic characterization of the aging of the human crystalline lens and the development of presbyopia. In: *Non-Invasive Assessment of the Visual System*. Washington DC: Optical Society of America, Technical Digest Series 3:160-163, 1990.
115. Crawford KS, Kaufman PL: Dose-related effects of prostaglandin F_{2α} isopropylester on intraocular pressure, refraction and pupil diameter in monkeys. *Invest Ophthalmol Vis Sci* 32:510-519, 1991. [Published erratum in *Invest Ophthalmol Vis Sci* 32:2665, 1991].
116. Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, Shaw B: New developments in the drug treatment of glaucoma. *Drugs* 41:514-532, 1991 (Invited Review).
117. Robinson JC, Kaufman PL: Cytochalasin B potentiates epinephrine's outflow facility-increasing effect. *Invest Ophthalmol Vis Sci* 32:1614-1618, 1991.
118. Gabelt BT, Crawford K, Kaufman PL: Outflow facility and its response to pilocarpine decline in aging rhesus monkeys. *Arch Ophthalmol* 109:879-882, 1991.
119. Kaufman PL, Rohen JW, Gabelt BT, Eichhorn M, Wallow IHL, Polansky, JR: Parasympathetic denervation of the ciliary muscle following panretinal photocoagulation. *Curr Eye Res* 10:437-455, 1991.
120. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): 3. Design and methods. *Controlled Clin Trials* 12:504-524, 1991.
121. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. *Ophthalmic Surg* 22:324-329, 1991.
122. Croft MA, Kaufman PL, Erickson-Lamy KA, Polansky, JR: Accommodation and ciliary muscle muscarinic receptors after echthiophate. *Invest Ophthalmol Vis Sci* 32:3288-3297, 1991.
123. Kaufman PL: Pharmacologic trabeculocanalotomy: facilitating aqueous outflow by assaulting the meshwork cytoskeleton, junctional complexes, and extracellular matrix. *Arch Ophthalmol* 110:34-36, 1992. (Editorial, by invitation of the editor); also published in *JAMA-India, Supplement: Selections from Arch Ophthalmol*. March-May: 7-9, 1992, selected for inclusion in Special Supplement and in Chinese Language Edition - *Arch Ophthalmol* 4:223-225, 1992, selected for publication in CLEAO by Chinese editor and editorial board.
124. Robinson JC, Kaufman PL: Superior cervical ganglionectomy in monkeys: surgical technique. *Invest Ophthalmol Vis Sci* 33:247-251, 1992.
125. Poyer JF, Gabelt B, Kaufman PL: The effect of topical PGF_{2α} on uveoscleral outflow and outflow facility in the rabbit eye. *Exp Eye Res* 54:277-283, 1992.
126. Tamm E, Croft MA, Jungkunz W, Lütjen-Drecoll E, Kaufman PL: Age-related loss of ciliary muscle mobility in the rhesus monkey. Role of the choroid. *Arch Ophthalmol* 110:871-876, 1992.
127. Crawford KS, Kaufman PL, Hubbard WC, Woodward DF: The DP-receptor agonist SQ27986 raises but does not lower intraocular pressure in ocular normotensive monkeys. *J Glaucoma* 1:94-99, 1992.
128. Robinson JC, Kaufman PL: The effect of 12(R)-hydroxyeicosatetraenoic acid on aqueous humor dynamics in the rabbit and Cynomolgus monkey. *Exp Eye Res* 54:813-815, 1992.
129. Gabelt BT, Kaufman PL: Inhibition of outflow facility, accommodative, and miotic responses to pilocarpine in rhesus monkey eyes by muscarinic receptor subtype antagonists. *J Pharmacol Exp Ther* 263:1133-1139, 1992.
130. Kemnitz JW, Weindruch R, Roecker EB, Crawford K, Kaufman PL, Ershler WB: Dietary restriction of adult male rhesus monkeys: Findings from the first year of study. *J Gerontol (Biol Sci)* 48:B17-B26, 1993.
131. Wilensky JT, Kaufman PL, Frohlichstein D, Gieser DK, Kass MA, Ritch R, Anderson R: Follow-up of angle closure glaucoma suspects. *Am J Ophthalmol* 115:338-346, 1993.

132. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. *Ophthalmic Surg* 24:232-241, 1993.
133. Poyer JF, Kaufman PL, Flügel C: Age does not affect contractile responses of the isolated rhesus monkey ciliary muscle to muscarinic agonists. *Curr Eye Res* 12:413-422, 1993.
134. Kaufman PL: Discussion of Toris CB, Camras CB, Yablonski ME: Effects of PhXA41, a new prostaglandin F₂ analog, on aqueous humor dynamics in human eyes. *Ophthalmology* 100:1304, 1993.
135. Robinson JC, Kaufman PL: Dose-dependent suppression of aqueous humor formation by timolol in the Cynomolgus monkey. *J Glaucoma* 2:251-256, 1993.
136. Çardakli UF, Smythe BA, Eisele JR, Kaufman PL, Perkins TW: Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma. *J Glaucoma* 2:271-278, 1993.
137. Kaufman PL: Presbyopia: A closer look. In: *Ophthalmic and Visual Optics – Non-invasive Assessment of the Visual System*. Washington DC: Optical Society of America, Technical Digest Series 3:2-7, 1993.
138. Lütjen-Drecoll E, Kaufman PL: Morphological changes in primate aqueous humor formation and drainage tissues after long-term treatment with antiglaucomatous drugs. *J Glaucoma* 2:316-328, 1993.
139. Robinson JC, Kaufman PL: Superior cervical ganglionectomy in monkeys. Pilocarpine-induced accommodation and prostaglandin F₂-induced hypotension and mydriasis. In: Lütjen-Drecoll E, ed. *Basic Aspects of Glaucoma Research III*. Stuttgart: Schattauer, pp. 355-363, 1993 (Original Article).
140. Ménage MJ, Robinson JC, Kaufman PL, Sponsel WE: Retinal blood flow after superior cervical ganglionectomy: A laser Doppler study in the Cynomolgus monkey. *Br J Ophthalmol* 78:49-53, 1994.
141. Croft MA, Hubbard WC, Kaufman PL: Effect of ethacrynic acid on aqueous outflow dynamics in monkeys. *Invest Ophthalmol Vis Sci* 35:1167-1175, 1994.
142. The Krupin Eye Valve Filtering Surgery Study Group: Krupin eye valve with disk for filtration surgery. *Ophthalmology* 101:651-658, 1994.
143. Kee C, Kaufman PL, Gabelt BT: Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. *Invest Ophthalmol Vis Sci* 35:2769-2773, 1994.
144. Gabelt BT, Kaufman PL: Inhibition of aceclidine-stimulated outflow facility, accommodation and miosis in rhesus monkeys by muscarinic receptor subtype antagonists. *Exp Eye Res* 58:623-630, 1994.
145. Kee C, Kaufman PL: Profound long-term hypotony without maculopathy after trabeculectomy with antimetabolite. *Acta Ophthalmol* 72:388-390, 1994.
146. Ménage MJ, Kaufman PL, Croft MA, Landay SP: Intraocular pressure measurement after penetrating keratoplasty. Minified Goldmann applanation tonometer, Pneumatonometer and Tono-Pen versus manometry. *Br J Ophthalmol* 78:671-676, 1994.
147. Kaufman PL, Lütjen-Drecoll E, Hubbard WC, Erickson KA: Obstruction of aqueous humor outflow by cross-linked polyacrylamide microgels in bovine, monkey and human eyes. *Ophthalmology* 101:1672-1679, 1994.
148. Cook CA, Koretz JF, Pfahnl A, Hyun J, Kaufman PL: Aging of the human crystalline lens and anterior segment. *Vision Res* 34:2945-2954, 1994.
149. Robinson JC, Kaufman PL: Phalloidin inhibits epinephrine's and cytochalasin B's facilitation of aqueous outflow. *Arch Ophthalmol* 112:1610-1613, 1994.
150. Flügel-Koch C, Kaufman P, Lütjen-Drecoll E: Association of a choroidal ganglion cell plexus with the fovea centralis. *Invest Ophthalmol Vis Sci* 35:4268-4272, 1994.
151. Gabelt BT, Robinson JC, Hubbard WC, Peterson CM, Debink N, Wadhwa A, Kaufman PL: Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. *Exp Eye Res* 59:633-644, 1994.
152. Poyer JF, Gabelt BT, Kaufman PL: The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated rhesus monkey ciliary muscle. *Exp Eye Res* 59:729-736, 1994.

153. Kee C, Pelzek CD, Kaufman PL: Mitomycin C suppresses aqueous humor flow in Cynomolgus monkeys. *Arch Ophthalmol* 113:239-242, 1995; also selected for publication by Spanish editor and editorial board of *Archives of Ophthalmology*. La mitomicina C suprime el flujo de humor acuoso enmonos Cynomolgus. *Arch Ophthalmol (Edición Española)* 6:222-226, 1995.
154. Perkins TW, Çardakli UF, Eisele JR, Kaufman PL, Heatley GA: Adjunctive mitomycin-C in Molteno implant surgery. *Ophthalmology* 102:91-97, 1995.
155. Gabelt BT, Robinson JC, Gange SJ, Kaufman PL: Superior cervical ganglionectomy in monkeys: Aqueous humor dynamics and their responses to drugs. *Exp Eye Res* 60:575-584, 1995.
156. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. *Am J Ophthalmol* 120:10-22, 1995.
157. Ménage MJ, Croft MA, Gange SJ, Kaufman PL: α -Aminocaproic acid does not inhibit outflow resistance washout in monkeys. *Invest Ophthalmol Vis Sci* 36:1745-1749, 1995.
158. Croft MA, Kaufman PL: Effect of daily topical ethacrynic acid on aqueous humor dynamics in monkeys. *Curr Eye Res* 14:777-781, 1995.
159. Kee C, Pickett JP, Dueker DK, Kaufman PL: Argon laser trabeculoplasty and pilocarpine effects on outflow facility in the Cynomolgus monkey. *J Glaucoma* 4:334-343, 1995.
160. Robin AL, Ritch R, Shin DH, Smythe B, Mundorf T, Lehmann RP, and The Apraclonidine Maximum Tolerated Medical Therapy Study Group: Short-term efficacy of apraclonidine hydrochloride when added to maximum-tolerated medical therapy for glaucoma. *Am J Ophthalmol* 120:423-432, 1995.
161. Kaufman PL, Gabelt B: α_2 -Adrenergic agonist effects on aqueous humor dynamics. *J Glaucoma* 4(Suppl 1; New Horizons in Glaucoma II):S8-S14, 1995.
162. Poyer JF, Millar C, Kaufman PL: Prostaglandin $F_{2\alpha}$ effects on isolated rhesus monkey ciliary muscle. *Invest Ophthalmol Vis Sci* 36:2461-2465, 1995.
163. Koretz JF, Rogot A, Kaufman PL: Physiological strategies for emmetropia. *Trans Am Ophthalmol Soc* 93:105-122, 1995.
164. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial and Glaucoma Laser Trial Follow-up Study: 7. Results. *Am J Ophthalmol* 120:718-731, 1995.
165. Millar JC, Kaufman PL: $PGF_{2\alpha}$ /pilocarpine interactions on IOP and accommodation in monkeys. *Exp Eye Res* 61:677-683, 1995.
166. Millar C, Poyer JF, Gabelt BT, Kaufman PL: Endothelin subtypes: Effect on isolated rhesus monkey ciliary muscle. *J Pharmacol Exp Ther* 275:1143-1147, 1995.
167. Camras CB, USA Latanoprost Study Group: Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - A six-month masked multicenter trial in the United States. *Ophthalmology* 103:138-147, 1996.
168. Croft MA, Oyen MJ, Gange SJ, Fisher MR, Kaufman PL: Aging effects on accommodation and outflow facility responses to pilocarpine in humans. *Arch Ophthalmol* 114:586-592, 1996; also published by *Arch Ophthalmol (Indian Edition)* 4:26-32, 1996, selected by Indian editor and editorial board.
169. Peterson JA, Kiland JA, Croft MA, Kaufman PL: Intraocular pressure measurement in Cynomolgus monkeys: Tono-Pen versus manometry. *Invest Ophthalmol Vis Sci* 37:1197-1199, 1996.
170. Crawford KS, Robinson JC, Gabelt BT, Heideman W, Hubbard WC, Kaufman PL: Indomethacin and epinephrine effects on outflow facility and cyclic adenosine monophosphate formation in monkeys. *Invest Ophthalmol Vis Sci* 37:1348-1359, 1996.
171. Kee C, Gabelt BT, Gange SJ, Kaufman PL: Serum effects on aqueous outflow during anterior chamber perfusion in monkeys. *Invest Ophthalmol Vis Sci* 37:1840-1848, 1996.
172. Hubbard WC, Kee C, Kaufman PL: Aceclidine effects on outflow facility after ciliary muscle disinsertion. *Ophthalmologica* 210:303-307, 1996.
173. Camras CB, Alm A, Watson P, Stjernschantz J, Latanoprost Study Groups: Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after 1 year of treatment in 198 patients. *Ophthalmology* 103:1916-1924, 1996.
174. Koretz JF, Cook CA, Kaufman PL: Accommodation and presbyopia in the human eye: Changes in the anterior segment and crystalline lens with focus. *Invest Ophthalmol Vis Sci* 38:569-578, 1997.

175. Sponsel WE, Zetlan SR, Stodtmeister R, Kaufman PL: Retinal capillary hemodynamics and VEP/pressure tolerance: Evidence of retinal microcirculatory compromise in treated glaucomatous eyes. *Ophthalmologica* 211:172-177, 1997.
176. Kiland JA, Croft MA, Gabelt BT, Kaufman PL: Atropine reduces but does not eliminate the age-related decline in perfusion outflow facility in monkey eyes. *Exp Eye Res* 64:831-835, 1997.
177. Sponsel WE, Kaufman PL, Blum FG Jr: Association of retinal capillary perfusion with visual status during chronic glaucoma therapy. *Ophthalmology* 104:1026-1032, 1997.
178. May CA, Hayreh SS, Furuoshi N, Ossoinig K, Kaufman PL, Lütjen-Drecoll E: Choroidal ganglion cell plexus and retinal vasculature in rhesus monkeys with laser-induced glaucoma. *Ophthalmologica* 211:161-171, 1997.
179. Tian B, Gabelt BT, Crosson CE, Kaufman PL: Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in Cynomolgus monkeys. *Exp Eye Res* 64:979-989, 1997.
180. Kaufman PL: Prostaglandins and cholinomimetics. *Arch Ophthalmol* 115:911-913, 1997 (Editorial, by invitation of the editor).
181. Tamm ER, Rohen JW, Schmidt K, Robinson JC, Wallow IHL, Kaufman PL: Superior cervical ganglionectomy in monkeys: Light and electron microscopy of the anterior eye segment. *Exp Eye Res* 65:31-43, 1997.
182. Hubbard WC, Johnson M, Gong H, Gabelt BT, Peterson JA, Sawhney R, Freddo T, Kaufman PL: Intraocular pressure and outflow facility are unchanged following acute and chronic intracameral chondroitinase ABC and hyaluronidase in monkeys. *Exp Eye Res* 65:177-190, 1997.
183. Gabelt BT, Wiederholt M, Clark AF, Kaufman PL: Anterior segment physiology following bumetanide inhibition of Na-K-Cl co-transport. *Invest Ophthalmol Vis Sci* 38:1700-1707, 1997.
184. Kiland JA, Peterson JA, Gabelt BT, Kaufman PL: Effect of DMSO and exchange volume on outflow resistance washout and response to pilocarpine during anterior chamber perfusion in monkeys. *Curr Eye Res* 16:1215-1221, 1997.
185. Croft MA, Kiland J, Gange SJ, Aref A, Pelzek CD, Kaufman PL: Comparison of Goldmann tonometry measurements using creamer vs. fluorescein in Cynomolgus monkeys. In: Lakshminarayanan V, ed. *Basic and Clinical Applications of Vision Science. The Professor Jay M. Enoch Festschrift Volume Documenta Ophthalmologica Proceedings Series. Dordrecht: Kluwer, 60:213-216, 1997 (Original Article).*
186. Koretz JF, Cook CA, Kaufman PL: Aging changes in the human accommodative process. In: *Vision Science and Its Applications. Washington DC: Optical Society of America, Technical Digest Series 1:68-71, 1997.*
187. Glasser A, Kaufman PL: Dynamics of refractive changes and lens and ciliary body movements in rhesus monkey eyes during Edinger-Westphal nucleus stimulated accommodation. In: *Vision Science and its Applications. Washington DC: Optical Society of America, Technical Digest Series 1:172-175, 1998.*
188. Perkins TW, Libby C, Gangnon R, Ladd W, Kaufman PL: Molteno implant with mitomycin: Intermediate-term results. *J Glaucoma* 7:86-92, 1998.
189. Chen Z, Gu Q, Kaufman PL, Cynader MS: Histochemical mapping of NADPH-diaphorase in monkey and human eye. *Curr Eye Res* 17:370-379, 1998.
190. Tian B, Kaufman PL, Volberg T, Gabelt BT, Geiger B: H-7 disrupts the actin cytoskeleton and increases outflow facility. *Arch Ophthalmol* 116:633-643, 1998.
191. Gabelt BT, Kaufman PL: A rational approach to adding glaucoma medications. *Rev Ophthalmol* 5:44-57, 1998; also published in *Vision Times* 61:11-14, 1999 (Translated into Japanese).
192. Tian B, Millar C, Kaufman PL, Bershadsky A, Becker E, Geiger B: H-7 effects on the iris and ciliary muscle in monkeys. *Arch Ophthalmol* 116:1070-1077, 1998.
193. Perkins TW, Gangnon R, Ladd W, Kaufman PL, Heatley GA: Trabeculectomy with mitomycin C: Mid-term results. *J Glaucoma* 7:230-236, 1998.
194. Camras CB, Wax MB, Ritch R, Weinreb R, Robin AL, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T, Stjernschantz J. Latanoprost treatment for glaucoma: Effects of treating for 1 year

- and of switching from timolol. The United States Latanoprost Study Group. *Am J Ophthalmol* 126:390-399, 1998.
195. Weber AJ, Kaufman PL, Hubbard WC: Morphology of single ganglion cells in the glaucomatous primate retina. *Invest Ophthalmol Vis Sci* 39:2304-2320, 1998.
 196. Croft MA, Wang RF, Podos SM, Neufeld AH, Kaufman PL: Effect of ticrynafen on aqueous humor dynamics in monkeys. *Arch Ophthalmol* 116:1481-1488, 1998.
 197. Kaufman PL: Marijuana and glaucoma. *Arch Ophthalmol* 116: 1512-1513, 1998 (Invited Editorial).
 198. Lütjen-Drecoll E, Wiendl H, Kaufman PL: Acute and chronic structural effects of pilocarpine on monkey outflow tissues. *Trans Am Ophthalmol Soc* 96:171-195, 1998.
 199. Lewis R, Perkins TW, Gangnon R, Kaufman PL, Heatley GA: The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. *Ophthalmology* 105:2256-2259, 1998.
 200. Croft MA, Kaufman PL, Crawford KS, Neider MW, Glasser A, Bito LZ: Accommodation dynamics in aging rhesus monkeys. *Am J Physiol – Regulatory, Integrative, and Comparative Physiology* 275(44):R1885-R1897, 1998.
 201. Millar JC, Gabelt BT, Hubbard WC, Kiland JA, Kaufman PL: Endothelin-1 effects on aqueous humor dynamics in monkeys. *Acta Ophthalmologica Scand* 76:663-667, 1998.
 202. Tian B, Gabelt BT, Peterson JA, Kiland JA, Kaufman PL: H-7 increases trabecular facility and facility after ciliary muscle disinsertion on monkeys. *Invest Ophthalmol Vis Sci* 40:239-242, 1999.
 203. Chen Z, Jia W, Kaufman PL, Cynader M: Immunohistochemical localization of dopamine β -hydroxylase in human and monkey eyes. *Curr Eye Res* 18:39-48, 1999.
 204. Peterson JA, Tian B, Geiger B, Kaufman PL: Latrunculin-A causes mydriasis and cycloplegia in the *Cynomolgus* monkey. *Invest Ophthalmol Vis Sci* 40:631-638, 1999.
 205. Peterson JA, Tian B, Bershadsky AD, Volberg T, Gangnon RE, Spector I, Geiger B, Kaufman PL: Latrunculin-A increases outflow facility in the monkey. *Invest Ophthalmol Vis Sci* 40:931-941, 1999.
 206. Tian B, Gabelt BT, Kaufman PL: Effect of staurosporine on outflow facility in monkeys. *Invest Ophthalmol Vis Sci* 40:1009-1011, 1999.
 207. Glasser A, Kaufman PL: The mechanism of accommodation in primates. *Ophthalmology* 106:863-872, 1999.
 208. Kaufman PL: Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans. *Arch Ophthalmol* 117:673-674, 1999 (Invited Editorial).
 209. Hubbard WC, Robinson JC, Schmidt K, Rohen JW, Tamm ER, Kaufman PL: Superior cervical ganglionectomy in monkeys: Effects on refraction and intraocular pressure. *Exp Eye Res* 88:637-639, 1999.
 210. Glasser A, Croft MA, Kaufman PL: A morphometric ultrasound biomicroscopic study of the aging rhesus monkey ciliary region. In: *Vision Science and Its Applications*. Washington, DC: Optical Society of America, Technical Digest Series 1:126-129, 1999.
 211. Kaufman PL, Glasser A, Croft MA: The relationship between lens and ciliary process function during accommodation in rhesus monkeys. In: *Vision Science and Its Applications*. Washington, DC: Optical Society of America, Technical Digest Series 1:130-133, 1999.
 212. Ethier CR, Croft MA, Coloma FM, Gangnon R, Ladd W, Kaufman PL: Ethacrynic acid effects on inner wall pores in living monkeys. *Invest Ophthalmol Vis Sci* 40:1382-1391, 1999.
 213. Tian B, Gabelt BT, Geiger B, Kaufman PL: Combined effects of H-7 and cytochalasin B in outflow facility in monkeys. *Exp Eye Res* 68:649-655, 1999.
 214. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Topical prostaglandin $F_{2\alpha}$ treatment reduces collagens types I, III, and IV in the monkey uveoscleral outflow pathway. *Arch Ophthalmol* 117:794-801, 1999.
 215. Altuna JC, Greenfield DS, Wand M, Liebmann JM, Camras C, Taglia DP, Kaufman P, Cioffi GA, Lee DA, Robin A, Crichton A, Costa V, Ritch R: Latanoprost in glaucoma associated with Sturge-Weber Syndrome: Benefits and side-effects. *J Glaucoma* 8:199-203, 1999.

216. Kaufman PL, Gabelt BT, Cynader M: Introductory comments on neuroprotection. *Surv Ophthalmol* 43(S1):S89-S90, 1999.
217. Kaufman PL, Jia WW-G, Tan J, Chen Z, Gabelt BT, Booth V, Tufaro F, Cynader M: A perspective of gene therapy in the glaucomas. *Surv Ophthalmol* 43(S1):S91-S97, 1999.
218. Kaufman PL: Nitric-oxide synthase and neurodegeneration/neuroprotection. *Proc Natl Acad Sci USA* 96:9455-9456, 1999.
219. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Collagen type I is reduced in the ciliary muscle of inflamed monkey eyes. *Invest Ophthalmol Vis Sci* 40:2568-2576, 1999.
220. Liu X, Brandt CR, Gabelt BT, Bryar PJ, Smith ME, Kaufman PL: Herpes simplex virus mediated gene transfer to primate ocular tissues. *Exp Eye Res* 69:385-395, 1999.
221. Leske MC, Heijl A, Hyman L, Bengtsson B, EMGT Group: Early manifest glaucoma trial: Design and baseline data. *Ophthalmology* 106:2144-2153, 1999.
222. Tian B, Geiger B, Epstein DL, Kaufman PL: Cytoskeletal involvement in the regulation of aqueous humor outflow. *Invest Ophthalmol Vis Sci* 41:619-623, 2000 (New Developments article-invited/peer reviewed).
223. Yücel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN: Loss of neurons in magno- and parvocellular layers of the lateral geniculate nucleus in glaucoma. *Arch Ophthalmol* 118:378-384, 2000.
224. Peterson JA, Tian B, Geiger B, Kaufman PL: Effect of latrunculin-B on outflow facility in monkeys. *Exp Eye Res* 70:307-313, 2000.
225. Weber AJ, Chen H, Hubbard WC, Kaufman PL: Experimental glaucoma and cell size, density, and number in the primate dorsal lateral geniculate nucleus. *Invest Ophthalmol Vis Sci* 41:1370-1379, 2000.
226. Kiland JA, Hubbard WC, Kaufman PL: Low doses of pilocarpine do not significantly increase outflow facility in the Cynomolgus monkey. *Exp Eye Res* 70:603-609, 2000.
227. Peterson JA, Tian B, McLaren JW, Hubbard WC, Geiger B, Kaufman PL: Latrunculin's effects on intraocular pressure, aqueous humor flow, and corneal endothelium. *Invest Ophthalmol Vis Sci* 41:1749-1758, 2000.
228. Sabanay I, Gabelt BT, Tian B, Kaufman PL, Geiger B: H-7 effects on the structure and fluid conductance of monkey trabecular meshwork. *Arch Ophthalmol* 118:955-962, 2000.
229. Cai S, Liu X, Glasser A, Volberg T, Filla M, Geiger B, Kaufman PL: Effect of latrunculin-A on morphology and actin-associated adhesions of cultured human trabecular meshwork cells. *Mol Vis* 6:132-143, 2000 <http://www.molvis.org/molvis/v6/a18>.
230. Tian B, Brumback LC, Kaufman PL: ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey eye. *Exp Eye Res* 71:551-566, 2000.
231. Koretz JF, Cook CA, Kaufman PL: Aging of the human lens: changes in lens shape at zero diopters accommodation. *J Opt Soc Am A* 18:265-272, 2001.
232. Tian B, Sabanay I, Peterson JA, Hubbard WC, Geiger B, Kaufman PL: Acute effects of H-7 on ciliary epithelium and corneal endothelium in monkey eyes. *Curr Eye Res* 22:109-120, 2001.
233. Glasser A, Croft MA, Brumback L, Kaufman PL: Ultrasound biomicroscopy of the aging rhesus monkey ciliary region. *Optom Vis Sci* 78: 417-24, 2001.
234. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN: Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway following topical prostaglandin F_{2α}- isopropyl ester treatment. *Arch Ophthalmol* 119:1165-1170, 2001.
235. Lindsey JD, Gaton DD, Sagara T, Polansky JR, Kaufman PL, Weinreb RN: Reduced TIGR/myocilin protein in the monkey ciliary muscle following prostaglandin F_{2α} treatment. *Invest Ophthalmol Vis Sci* 42:1781-1786, 2001.
236. Liu X, Cai S, Glasser A, Volberg T, Polansky JR, Fauss DJ, Geiger B, Kaufman PL: Effect of H-7 on cultured human trabecular meshwork cells. *Mol Vis* 7:145-153, 2001 <http://www.molvis.org/molvis/v7/a21/>.
237. Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL: Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye *in vivo*. *J Gene Med* 3:437-449, 2001. (International Glaucoma Review Editors Selection)

238. Pena JDO, Agapova O, Kiland JA, Gabelt BT, Levin LA, Lucarelli MJ, Kaufman PL, Hernandez MR: Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. *Invest Ophthalmol Vis Sci* 42:2303-2314, 2001.
239. Ricard CS, Agapova OA, Salvador-Silva M, Kaufman PL, Hernandez MR: Expression of myocilin/TIGR in normal and glaucomatous primate optic nerves. *Exp Eye Res* 73:433-447, 2001.
240. Gabelt BT, Millar JC, Kiland JA, Peterson JA, Seeman JL, Kaufman PL: Effect of serotonergic compounds on aqueous humor dynamics in monkeys. *Curr Eye Res* 23:120-127, 2001.
241. Yücel YH, Zhang Q, Weinreb RB, Kaufman PL, Gupta N: Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. *Invest Ophthalmol Vis Sci* 42:3216-3222, 2001.
242. Kaufman PL: Scleral expansion surgery for presbyopia. *Ophthalmology*. 108:2161-2162, 2001 (Invited editorial).
243. Tian B, Kiland JA, Kaufman PL: Effects of the marine macrolides swinholide A and jasplakinolide on outflow facility in monkeys. *Invest Ophthalmol Vis Sci* 42:3187-3192, 2001.
244. Matsubara JA, Lam DY, Kalil RE, Gabelt BT, Nork TM, Hornan D, Kaufman PL: The effects of pan-retinal photocoagulation on the primary visual cortex of the adult monkey. *Trans Am Ophthalmol Soc* 99:33-43, 2001.
245. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. *Surv Ophthalmol* 2002 47 Suppl 1:S53-64.
246. Filla MS, Liu X, Nguyen TD, Polansky JR, Brandt CR, Kaufman PL, Peters DM: *In vitro* localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. *Invest Ophthalmol Vis Sci* 43:151-161, 2002.
247. Cook BE, Lucarelli MJ, Lemke BN, Dortzbach RK, Kaufman PL, Forrest L, Greene E, Gabelt BT: Eyelid lymphatics I: Histochemical comparisons between the monkey and human. *Ophthalmic Plast Reconstr Surg* 18:18-23, 2002.
248. Cook BE Jr, Lucarelli MJ, Lemke BN, Dortzbach RK, Kaufman PL, Forrest L, Greene E, Gabelt BT: Eyelid lymphatics II: A search for drainage patterns in the monkey and correlations with human lymphatics. *Ophthalmic Plastic Reconstr Surg* 18:99-106, 2002.
249. Koretz JF, Cook CA, Kaufman PL: Aging of the human lens: changes in lens shape upon accommodation and with accommodative loss. *J Opt Soc Am A Opt Image Sci Vis* 19:144-151, 2002.
250. Seeman J, Hubbard, WC, Gabelt, BT, Kaufman PL: 3α , 5β -Tetrahydrocortisol effect on outflow facility. *J Ocular Pharmacol Ther* 18:35-39, 2002.
251. DeBry PW, Perkins TW, Heatley GA, Kaufman P, Brumback LC: Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. *Arch Ophthalmol* 120:297-300, 2002.
252. Perkins TW, Faha B, Ni M, Kiland JA, Poulsen GL, Antelman D, Atencio I, Shinoda J, Sinha D, Brumback L, Maneval D, Kaufman PL, Nickells RW: Adenovirus-mediated gene therapy using human p21^{WAF/Cip-1} to prevent wound healing in a rabbit model of glaucoma filtration surgery. *Arch Ophthalmol* 120:941-949, 2002.
253. Taglia DP, Perkins TW, Gangnon R, Heatley GA, Kaufman PL: Comparison of the Ahmed glaucoma valve, the Krupin eye valve with disk, and the double-plate Molteno implant. *J Glaucoma* 11:347-353, 2002.
254. Volberg T, Tian B, Kaufman PL, Geiger B: Tyrphostins which disrupt the actin cytoskeleton do not increase outflow facility. *Exp Eye Res* 74: 411-416, 2002.
255. Firth SI, Kaufman PL, De Jean B, Byers J, Marshak DW: Innervation of the uvea by galanin and somatostatin immunoreactive axons in macaques and baboons. *Exp Eye Res* 75:49-60, 2002.
256. Heijl A, Leske MC, Bengtson B, Hyman L, Bengtson B, Hussein M, for the Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 120: 1268-1279, 2002. (member of Data & Safety Monitoring Committee)
257. Prasad SS, Schnerch A, Lam DY, To E, Jim J, Kaufman PL, Matsubara JA: Immunohistochemical investigations of neurofilament M' and α -crystallin in the magnocellular layers of the primate lateral geniculate nucleus. *Mol Brain Res*, 109: 211-215, 2002.

258. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, for the Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment. *Arch Ophthalmol* 121:48-56, 2003.
259. Liu X, Huang C-Y, Cai S, Polansky JR, Kaufman PL, Brandt CR. Transformation of human trabecular meshwork cells with SV40 TAg alters promoter utilization. *Curr Eye Res* 25:347-353, 2003.
260. Lam DY, Kaufman PL, Gabelt BT, To EC, Matsubara JA: Neurochemical correlates of cortical reorganization after unilateral elevated intraocular pressure in a primate model of glaucoma. *Invest Ophthalmol Vis Sci* 44:2573-2581, 2003.
261. Gabelt BT, Gottanka J, Lütjen-Drecoll E, Kaufman PL: Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. *Invest Ophthalmol Vis Sci* 44:2118-2125, 2003.
262. Agapova OA, Kaufman PL, Lucarelli MJ, Gabelt BT, Hernandez MR: Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. *Brain Res* 967:132-143, 2003.
263. Yücel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N: Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. *Prog Retina Eye Res* 22:465-481, 2003.
264. Liu X, Wu Z, Sheibani N, Brandt CR, Polansky JR, Kaufman PL: Low dose latrunculin-A inhibits dexamethasone-induced changes in the actin cytoskeleton and alters extracellular matrix protein expression in cultured human trabecular meshwork cells. *Exp Eye Res* 77:181-188, 2003.
265. Kaufman PL: The prostaglandin wars. *Am J Ophthalmol* 136:727-728, 2003 (Editorial at request of Editor).
266. Santas AJ, Bahler C, Peterson JA, Filla MS, Kaufman PL, Tamm ER, Johnson D, Peters DP: The Heparan II domain of fibronectin modulates aqueous outflow in cultured anterior segments of human eyes. *Invest Ophthalmol Vis Sci* 44: 4796-4804, 2003.
267. Camras CB, Hedman K for the US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. *J Glaucoma* 12:466-469, 2003.
268. Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL: Functional and structural reversibility of H-7 effects on the conventional aqueous outflow pathways in monkeys. *Exp Eye Res* 78:137-150, 2004.
269. Kiland JA, Gabelt BT, Kaufman PL: Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. *Exp Eye Res* 78:639-651, 2004 (Special issue in honour of David Maurice).
270. Gabelt BT, Seeman JL, Podos SM, Mittag TW, Kaufman PL: Aqueous humor dynamics in monkeys after topical 8-iso PGE₂. *Invest Ophthalmol Vis Sci* 45:892-899, 2004.
271. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. *Exp Eye Res* 78:767-776, 2004.
272. Filla MS, David G, Weinreb RN, Kaufman PL, Peters DM: Distribution of syndecans 1-4 within the anterior segment of the human eye: expression of a variant syndecan-3 and matrix associated syndecan-2. *Exp Eye Res* 79:61-74, 2004.
273. Heatley GA, Kiland JA, Faha B, Seeman J, Schlamp CL, Dawson DG, Gleiser J, Maneval D, Kaufman PL, Nickells RW: Gene therapy using p21^{WAF-1/Cip-1} to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension. *Gene Ther* 11:949-955, 2004.
274. Tamm ER, Carassa RG, Albert DM, Gabelt BT, Patil S, Rasmussen CA, Kaufman PL: Visco canalostomy in rhesus monkeys. *Arch Ophthalmol* 122: 1826-1838, 2004.
275. Gabelt BT, Hennes EA, Seeman JL, Tian B, Kaufman PL: H-7 effect on outflow facility after trabecular obstruction following long-term echthiophate treatment in monkeys. *Invest Ophthalmol Vis Sci* 45:2372-2376, 2004.
276. Okka M, Tian B, Kaufman PL: Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. *Arch Ophthalmol* 122:1482-1488, 2004.
277. Tian B, Wang R-F, Podos SM, Kaufman PL: Effects of topical H-7 on outflow facility, intraocular pressure and corneal thickness in monkeys. *Arch Ophthalmol* 122:1171-1177, 2004.

278. Kim CBY, Ver Hoeve JN, Kaufman PL, Nork TM: Interspecies and gender differences in multifocal electroretinograms of *Cynomolgus* and rhesus macaques. *Doc Ophthalmol* 109:73-86, 2004.
279. Okka M, Tian B, Kaufman PL: Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys. *Trans Am Ophthalmol Soc* 102:251-259, 2004.
280. Obstbaum SA, Cioffi GA, Krieglstein GK, Fennerty MB, Alm A, Araie M, Carassa RG, Greve EL, Hitchings RA, Kaufman PL, Kitazawa Y, RojanaPongpun P, Susanna R, Jr, Wax MB, Zimmerman TJ: Gold standard medical therapy in glaucoma: defining the criteria identifying measures for an evidence-based analysis. *Clin Ther* 26:2102-2120, 2004.
281. Wamsley S, Gabelt BT, Dahl DB, Case GL, Sherwood RW, May CA, Hernandez MR, Kaufman PL: Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. *Arch Ophthalmol* 123:64-70, 2005.
282. Luthra A, Gupta N, Kaufman PL, Weinreb RN, Yücel YH: Oxidative injury by peroxynitrite in neural and vascular tissue of the lateral geniculate nucleus in experimental glaucoma. *Exp Eye Res* 80:43-49, 2005. (Editor's Selection: International Glaucoma Review, Journal of the AIGS, Volume 7-1, page 21, 2005)
283. Tian B, Kaufman PL: Effects of the rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin-A on outflow facility in monkeys. *Exp Eye Res* 80:215-225, 2005.
284. Rasmussen CA, Kaufman PL: Primate glaucoma models. *J Glaucoma* 14:311-314, 2005.
285. Mattison JA, Croft MA, Dahl DB, Roth GS, Lane MA, Ingram DK, Kaufman PL: Accommodative function in rhesus monkeys: effects of aging and calorie restriction. *J Am Aging Assoc* 27: 59-67, 2005.
286. Rezaie T, Waitzman DM, Seeman JL, Kaufman PL, Sarfarazi M: Molecular cloning and expression profiling of optineurin in rhesus monkey. *Invest Ophthalmol Vis Sci* 46:2404-2410, 2005.
287. Eye Diseases in Diverse Populations: Challenges and Opportunities for Preventing and Treating Blindness. The Washington Advisory Group, Ranch Valencia, CA, June 12-14, 2005. Presentations: 1) Glaucoma: Clinical Management: Present and Into the Future; 2) General Recommendations and Final Report: Glaucoma; 3) Various discussion sessions.
288. Gabelt BT, Kaufman PL: Changes in aqueous humor dynamics with age and glaucoma. *Prog Retina Eye Res* 24:612-637, 2005.
289. Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK II, Heuer DK, Brandt JD, and the Tube Versus Trabeculectomy Study Group: The tube versus trabeculectomy study: design and baseline characteristics of study patients, *Am J Ophthalmol* 140:275-287, 2005
290. Gabelt BT, Okka M, Dean TR, Kaufman PL: Aqueous humor dynamics in monkeys after topical R-DOI. *Invest Ophthalmol Vis Sci*, 46:4691-4696, 2005.
291. Hashimoto K, Parker A, Malone P, Gabelt BT, Rasmussen CA, Kaufman PS, Hernandez MR. Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro. *Brain Res.* 1054(2):103-15, 2005
292. Liu X, Wang N, Kaufman PL: Experimental gene therapy for glaucoma with C3 transferase. *China Biotechnology* 25:109-117, 2005.
293. Liu X, Hu Y, Filla MS, Gabelt BT, Peters DM, Brandt CR, Kaufman PL. The effects of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. *Mol Vis.* 11:1112-1121, 2005<<http://www.molvis.org/molvis/v11/a129/>>.
294. Kiland JA, Gabelt BT, Kaufman PL: Effect of age on outflow resistance washout during anterior chamber perfusion in rhesus and *Cynomolgus* monkeys. *Exp Eye Res*, 81:724-730, 2005.
295. Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL: Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys. *Exp Eye Res* 82: 236-246, 2006.
296. Croft MA, Glasser A, Heatley GA, McDonald JP, Ebbert T, Dahl DB, Nadkarni, NV, Kaufman PL: Accommodative ciliary body and lens function in rhesus monkeys. I. Normal lens, zonule and ciliary process configuration in the iridectomized eye. *Invest Ophthalmol Vis Sci*, 47:1076-1086, 2006.

297. Croft MA, Glasser A, Heatley GA, McDonald JP, Ebbert T, Nadkarni NV, Kaufman PL: The zonula, lens and circumlental space in the normal iridectomized rhesus monkey eye. *Invest Ophthalmol Vis Sci* 47:1087-1095, 2006.
298. Filla MS, Woods A, Kaufman PL, Peters DM: Beta1 and beta3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells. *Invest Ophthalmol Vis Sci* 47:1956-1967, 2006.
299. Kiland JA, Miller CL, Kim CBY, Ver Hoeve JN, Gabelt BT, Peterson J, Nork TM, Kaufman PL: Effect of H-7 and Lat-B on retinal physiology. *Curr Eye Res*, 31:441-455, 2006.
300. Gabelt BT, Hu Y, Vittitow JL, Rasmussen CA, Grosheva I, Bershinsky AD, Geiger B, Borrás T, Kaufman PL: Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments. *Exp Eye Res*, 82:935-944, 2006.
301. Grosheva I, Vittitow JL, Goichberg P, Gabelt BT, Kaufman PL, Borrás T, Geiger B, Bershinsky AD: Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. *Exp Eye Res* 82:945-958, 2006.
302. Agapova OA, Kaufman PL, Hernandez MR: Androgen receptor and NFkB expression in human normal and glaucomatous optic nerve head astrocytes in vitro and in experimental glaucoma. *Exp Eye Res* 82:1053-1059, 2006.
303. May CA, Gottanka J, Kaufman PL, Lütjen-Drecoll E, Scholz M: Choroidal innervation and optic neuropathy in macaque monkeys with laser- or anterior chamber perfusion-induced short-term elevation of intraocular pressure. *Exp Eye Res* 82:1060-1067, 2006.
304. Hu Y, Gabelt BT, Kaufman PL: Monkey organ-cultured anterior segments; technique and response to H-7. *Exp Eye Res* 82:1100-1108, 2006.
305. Tian B, Hu Y, Gabelt BT, Kaufman PL: Factors affecting outflow facility calculations. *Exp Eye Res*, 83:1515-1520, 2006. PMID1779759
306. Maertz NA, Kim CBY, Nork TM, Levin LA, Lucarelli MJ, Kaufman PL, Ver Hoeve JN: Multifocal visual evoked potentials in the anesthetized non-human primate. *Curr Eye Res*, 31:885-893, 2006.
307. Gupta N, Ly T, Zhang Q, Kaufman PL, Weinreb RN, Yücel YH: Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain. *Exp Eye Res*, 84:176-184, 2007.
308. Nickells RW, Schlamp CL, Li Y, Kaufman PL, Heatley GA, Peterson JC, Faha B, Ver Hoeve JN: Surgical lowering of elevated intraocular pressure in monkeys prevents progression of glaucomatous disease. *Exp Eye Res* 84: 729-736, 2007.
309. Bengtsson B, Leske MC, Hyman L, Heijl A, EMGT Group: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmol.* 114:205-209, 2007.
310. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL and the Tube Versus Trabeculectomy Study Group: Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. *Am J Ophthalmol*, 143:9-22, 2007.
311. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC and the Tube Versus Trabeculectomy Study Group: Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. *Am J Ophthalmol*, 143:23-31, 2007.
312. Schmidt JF, Agapova OA, Yang P, Kaufman PL, Hernandez MR: Expression of ephrinB1 and its receptor in glaucomatous optic neuropathy. *Br J Ophthalmol* 91:1219-1224, 2007.
313. Tian B, Kaufman PL: Combined effects of H7 and pilocarpine on anterior segment physiology in monkey eyes. *Curr Eye Res* 32:491-500, 2007.
314. Wang H, Liu X, Lin G, Gabelt BT, Lee P-Y, Podos SM, Wang N, Kaufman PL. Effects of MISA A on actin cytoskeleton of cultured HTM cells and intraocular pressure of rats and glaucomatous monkeys. *Curr Eye Res* 32:843-850, 2007.
315. Peterson JC, Rasmussen CA, Kaufman PL. Green fluorescent protein imaging in a model for proposed gene therapy in glaucoma. *J Ophthalmic Photography* 29:106-111, 2007.
316. Hewitt AW, Poulsen JP, Alward WLM, Bennett SL, Budde WM, Cooper RL, Craig JE, Fingert JH, Foster PJ, Garway-Heath DF, Green CM, Hammond CJ, Hayreh SS, Jonas JB, Kaufman PL, Miller NR, Morgan WH, Newman NJ, Quigley HA, Samples JR, Spaeth GL, Pesudovs K, Mackey DA:

- Heritable features of the optic disc: A novel twin method for determining genetic significance. *Invest Ophthalmol Vis Sci* 48:2469-2475, 2007.
317. Rasmussen CA, Gabelt BT, Kaufman PL: Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine. *Trans Am Ophthalmol Soc* 105:225-239, 2007.
318. Kaufman PL: Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins, and understanding the pathophysiology of presbyopia. *Interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail. The 2006 Ernst H. Bérány Prize Lecture. Exp Eye Res* 86:3-17, 2008. PMID2213279
319. Wendt M, Croft MA, McDonald JP, Kaufman PL, Glasser A: Lens diameter and thickness as a function of age and pharmacologically stimulated accommodation in rhesus monkeys. *Exp Eye Res* 86:746-752, 2008.
320. Croft MA, McDonald JP, James RJ, Heatley GA, Lin T-L, Lütjen-Drecoll E, Kaufman PL: Surgical intervention and accommodative responses: I. Centripetal ciliary body, capsule, and lens movement in rhesus monkeys of various ages. *Invest Ophthalmol Vis Sci* 49:5484-5494, 2008. PMID2787242
321. Wasilewski R, McDonald JP, Heatley GA, Lütjen-Drecoll E, Kaufman PL, Croft MA: Surgical intervention and accommodative responses, II. Forward ciliary body accommodative movement is facilitated by zonular attachments to the lens capsule. *Invest Ophthalmol Vis Sci* 49:5495-5502, 2008. PMID2798153
322. Yu M, Chen X, Wang N, Cai S, Li N, Qui J, Brandt CB, Kaufman PL, Liu X: H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. *J Ocular Pharmacol Ther*, 24:373-379, 2008. PMID2810742
323. Toris CB, Gabelt BT, Kaufman PL: Update on the effects of topical prostaglandins on aqueous humor dynamics. *Surv Ophthalmol* 53:S107-120, 2008. PMID2727743
324. Bunch TJ, Tian B, Seeman JL, Gabelt BT, Lin T-L, Kaufman PL: Effect of daily prolonged ketamine anesthesia on intraocular pressure in monkeys. *Curr Eye Res* 33:946-953, 2008. PMID2605636
325. Kompass KS, Agapova OA, Li W, Kaufman PL, Rasmussen CA, Hernandez MR: Bioinformatic and statistical analysis of the optic nerve head in a primate model of ocular hypertension. *BMC Neurosci* 9:93-113, 2008. PMID2567987
326. Bhattacharya SK, Gabelt BT, Ruiz J, Picciani RG, Kaufman PL: Cochlin expression in anterior segment organ culture models after TGF(beta)2 treatment. *Invest Ophthalmol Vis Sci* 50:551-559, 2009. PMID268191
327. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL: Prostaglandin subtype-selective and non-selective IOP lowering comparison in monkeys. *J Ocul Pharmacol Ther* 25:1-8, 2009. PMID2815338
328. Gonzalez JM, Hu Y, Gabelt BT, Kaufman PL, Peters DM: Identification of the active site in the Heparan II domain of fibronectin that increases outflow facility in cultured monkey anterior segments. *Invest Ophthalmol Vis Sci*, 50:235-241, 2009. PMID2670490
329. Barraza RA, Rasmussen CA, Loewen N, Cameron JD, Gabelt BT, Teo W-L, Kaufman PL, Poeschla EM: Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of non-human primates. *Human Gene Ther* 20:191-200, 2009. PMID2839422
330. Flügel-Koch C, Neuhuber W, Kaufman PL, Lütjen-Drecoll E: Morphological indication for proprioception in the human ciliary muscle. *Invest Ophthalmol Vis Sci* 50:5529-5536, 2009. PMID2810743
331. Filla MS, Schwinn MK, Sheibani N, Kaufman PL, Peters DM: Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct (beta)1 and (beta)3 integrin pathways. *Invest Ophthalmol Vis Sci* 50:5723-5731, 2009. PMID250984
332. Lam D, Jim J, To E, Rasmussen CA, Kaufman PL, Matsubara J: Astrocyte and microglial activation in the lateral geniculate and visual cortex of glaucomatous and optic nerve transected primates. *Mol Vis* 15:2217-2229, 2009. PMID2773743
333. Kiland JA, Gabelt BT, Tezel G, Lütjen-Drecoll E, Kaufman PL: Effect of the AGE crosslink breaker alagebrium on anterior segment physiology, morphology and ocular AGE and RAGE. *Trans Am Ophthalmol Soc* 107: 146-160, 2009. PMID281473

334. Rauscher FM, Gedde SJ, Schiffman JC, Feuer WJ, Barton K, Lee RK; Tube Versus Trabeculectomy Study Group: Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. *Am J Ophthalmol* 147:458-466, 2009.
335. Croft MA, McDonald JP, Nadkarni NV, Lin TL, Kaufman PL: Age-related changes in centripetal ciliary body movement relative to centripetal lens movement in monkeys. *Exp Eye Res* 89:824-832, 2009. PMID278077
336. Buie LK, Rasmussen CA, Porterfield EC, Ramgolam VS, Choe VW, Markovic-Plese S, Samulski RJ, Kaufman PL, Borrás, T: Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. *Invest Ophthalmol Vis Sci* 51:236-248, 2010. PMID2869048
337. Lütjen-Drecoll E, Kaufman PL, Wasielewski R, Ting-Li L, Croft MA: Morphology and accommodative function of the vitreous zonule in human and monkey eyes. *Invest Ophthalmol Vis Sci* 51:1554-1564, 2010. PMID2829378
338. Lee E, Gabelt BT, Faralli JA, Peters DM, Brandt CR, Kaufman PL, Bhattacharya SK: COCH transgene expression in cultured human trabecular meshwork cells and its effect on outflow facility in monkey organ-cultured anterior segments. *Invest Ophthalmol Vis Sci*, 51:2060-2066, 2010, PMID2868402
339. Schwinn MK, Gonzalez JM Jr, Gabelt BT, Sheibani N, Kaufman PL, Peters DM: Heparin II domain of fibronectin mediates contractility through an alpha4beta1 co-signaling pathway. *Exp Eye Res*, 316:1500-1512, 2010. PMID2871963
340. Nork TM, Kim CB, Heatley GA, Kaufman PL, Lucarelli MJ, Levin LA, Ver Hoeve JN: Serial multifocal electroretinograms during long-term elevation and reduction of intraocular pressure in non-human primates. *Doc Ophthalmol* 120:273-289, 2010. PMID2933837
341. Tan JCH, Kiland JA, Gonzalez JM Jr, Gabelt BT, Peters DM, Kaufman PL: Sodium orthovanadate effect on outflow facility and intraocular pressure in live monkeys. *Exp Eye Res* 91:486-490, 2010. PMID2946324
342. Tian B, Heatley GA, Filla MS, Kaufman PL: Effect of H-7 on secondary cataract after phacoemulsification in the live rabbit eye. *J Ocular Pharm Ther* 26:533-539, 2010. PMID2990282
343. Ly T, Gupta N, Weinreb RN, Kaufman PL, Yücel YH: Dendrite plasticity in the lateral geniculate nucleus in primate glaucoma. *Vision Res* 51:243-250, 2011. PMID3125971
344. Gabelt BT, Kaufman PL, Rasmussen CA: Effect of nitric oxide compounds on monkey ciliary muscle in vitro. *Exp Eye Res* 93:321-327, 2011. PMID3299082
345. Elsmo EJ, Kiland JA, Kaufman PL, McLellan GJ: Evaluation of rebound tonometry in non-human primates. *Exp Eye Res* 92:268-273, 2011. PMID3060952
346. Kiland JA, Gabelt BT, Kaufman PL: Relationship of aqueous outflow resistance to age and total volume perfused in rhesus and cynomolgus monkeys. *Invest Ophthalmol Vis Sci* 52:6820-6824, 2011. PMID3176014
347. Sureshkumar J, Haripriya A, Muthukkaruppan V, Kaufman PL, Tian B. Cytoskeletal drugs prevent posterior capsular opacification in human lens capsule in vitro. *Graefe's Arch Clin Exp Ophthalmol* 250:507-514, 2012. PMID3310944
348. Kutuzova GD, Gabelt BT, Kiland JA, Hennes EA, Kaufman PL, DeLuca HF: 1a,25-Dihydroxyvitamin D₃ and its analog, 2-methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D₃ (2MD) suppress intraocular pressure in non-human primates. *Arch Biochem Biophys* 518:53-60, 2012. PMID3390938
349. Gabelt BT, Rasmussen CA, Tektas OY, Kim CBY, Peterson JC, Nork TM, Ver Hoeve JN, Lütjen-Drecoll E, Kaufman PL: Structure/function studies and the effects of memantine in monkeys with experimental glaucoma. *Invest Ophthalmol Vis Sci* 53: 2368-2376, 2012. PMC Journal in Process
350. Tian B, Kaufman PL: A potential application of canaloplasty in glaucoma gene therapy. *Translat Vis Sci Technol* 2:1-8, 2013. PMID3718561
351. Croft MA, Nork TM, McDonald JP, Katz A, Lütjen-Drecoll E, Kaufman PL: Accommodative movements of the vitreous membrane, choroid and sclera in young and presbyopic human and non-human primate eyes. *Invest Ophthalmol Vis Sci* 54:5049-5058, 2013. PMID37262242

352. Croft MA, McDonald JP, Katz A, Lin T-L, Lütjen-Drecoll E, Kaufman PL: Extralenticular and lenticular aspects of accommodation and presbyopia in human vs. monkey eyes. *Invest Ophthalmol Vis Sci* 54:5035-5048, 2013.PMCID3726241
353. Heyne GW, Kiland JA, Kaufman PL, Gabelt BT: Effect of nitric oxide on anterior segment physiology in monkeys. *Invest Ophthalmol Vis Sci* 54:5103-5110, 2013 PMCID3729238
354. Rasmussen CA, Kaufman PL, Kiland, JA: Benzalkonium chloride and glaucoma. *J Ocular Pharm* 30:163-169, 2014
355. Aktas Z, Tian B, McDonald JP, Yamamoto R, Larsen C, Kiland JA, Kaufman PL, Rasmussen CA: Application of canaloplasty in glaucoma gene therapy: where are we? *J Ocular Pharm Ther* 30:277-282, 2014.
356. Lee ES, Rasmussen CA, Filla MS, Slauson SR, Peters DM, Kaufman PL, Gabelt BT, Brandt CR: Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo. *Curr Eye Res* 39:859-870, 2014.
357. Wang Y, Yang Q, Wang Ying, Guo L, Yin Y, Fan N, Zhou X, Cai SP, Kaufman PL, Liu X: Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy. *Exp Eye Res* 125:128-134, 2014.
358. Rasmussen CA, Kaufman PL, Ritch R, Haque R, Brazzell RK, Vittitow JL: Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open angle glaucoma. *Translational Vis Sci Technology* 3(5):1-9, 2014. doi: <http://dx.doi.org/10.1167/tvst.3.5.1>
359. Flügel-Koch CM, Tektas OY, Kaufman PL, Paulsen FP, Lütjen-Drecoll E: Morphological alterations within the peripheral fixation of the iris dilator muscle in eyes with pigmentary glaucoma. *Invest Ophthalmol Vis Sci* 55:4541-4551, 2014. doi:10.1167/iovs.13-13765.
360. Braunger BM, Ademoglu B, Fuchshofer R, Gabelt BT, Kiland JA, Hennes EA, Brunner KG, Kaufman PL, and Tamm ER: Identification of adult stem cells in Schwalbe's line region of the primate eye. *Invest Ophthalmol Vis Sci* 55:7499-7507, 2014.
361. Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL, for the VOYAGER study group: A randomized, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study *Br J Ophthalmol* 99:738-745, 2015
362. Lu W, Hu HL, Sévigny J, Gabelt BT, Kaufman PL, Johnson EC, Morrison JC, Zode GS, Sheffield VC, Zhang X, Laties AM and Mitchell CH: Rat, mouse and primate models of chronic glaucoma all show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye. *Invest Ophthalmol Vis Sci.*; 56: 3075–3083, 2015. doi:10.1167/iovs.14-15891 [selected for research highlight: [Stamer](#) WD: Implications of Sustained Elevation in Extracellular ATP in Retina Following Chronic Ocular Hypertension *Investigative Ophthalmology & Visual Science* May 2015, Vol.56, 3084. doi:10.1167/iovs.15-17032]
363. Slauson SR, Peters DM, Schwinn M, Kaufman PL, Gabelt BT, and Brandt CR: Viral vector effects on exoenzyme C3 transferase-mediated actin disruption and on outflow facility. *Invest Ophthalmol Vis Sci*, 56:2431-2438, 2015; DOI:10.1167/iovs.14-15909
364. Flügel-Koch C, Croft MA, Kaufman PL, Lutjen-Drecoll E: Anteriorly located zonular fibers as a tool for fine regulation of accommodation. *Ophthalmic Physiol Optics*, 36:13-20, 2016
365. Croft MA, Heatley GA, McDonald JP, Katz A, Kaufman PL: Accommodative movement of the lens/capsule and the strand that extends between the posterior vitreous zonule insertion zone & the lens equator in relation to the vitreous face and aging. *Ophthalmic Physiol Optics*, 36:21-32, 2016.
366. McDonald JP, Kiland JA, Kaufman PL, Bentley E, Elinwood NM, McLellan GJ: Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats. *Vet Ophthalmol*, 19 Suppl 1:13-23, 2016;. NIHMSID: NIHMS699555 PMID: 26183373.
367. Li X, He Fen, Gabelt BT, Wang Y, Cai S, Cao J, Fang N, Kaufman PL, Liu X: Effects of latanoprost and bimatoprost on the expression of molecules relevant to ocular inflow and outflow pathways. *PLoS ONE* 11(3): 2016.

368. Croft MA, Lütjen-Drecoll E, Kaufman PL: Age-related posterior ciliary muscle restriction – a link between trabecular meshwork and optic nerve head pathophysiology. *Exp Eye Res* 158:187-189, 2016. <http://dx.doi.org/10.1016/j.exer.2016.07.007>
369. Vinod K, Brandt JD, Gedde SJ, Feuer WJ, Wei S, for the Tube Versus Trabeculectomy Study Group: Tube fenestration in the tube versus trabeculectomy study. *Ophthalmology* 123:2260-2262, 2016.
370. Aktas Z, Rao H, Slauson SR, Gabelt BT, Larsen IV, Sheridan RTC, Herrnberger L, Tamm ER, Kaufman PL, Brandt CR: Proteasome inhibition increases efficiency of lentiviral vector-mediated transduction of trabecular meshwork. *Invest Ophthalmol Vis Sci* 59:298-310, 2018.
371. Kotecha A, Feuer WJ, Barton K, Gedde SJ, and the Tube versus Trabeculectomy Study Group: Quality of Life in the Tube Versus Trabeculectomy Study. *Am J Ophthalmol*, 176:228-235, 2017.
372. Srinivasan S, Soundararajan AB, Chidambaranathan GP, Krishnadas R, Gabelt BT, Kaufman PL, Muthukkaruppan V: Intraocular pressure lowering effect of sb772077b (sb77), a rho kinase inhibitor, in human organ cultured anterior segments. *Exp Eye Res*, submitted, 2017
373. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL: Long-term efficacy and safety of latanoprotene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: integrated analysis of two phase 3 studies. *J Glaucoma* 27(1):7-15, 2018 doi: 10.1097/IJG.0000000000000831
374. Siegfried CJ, Shui Y-B, Tian B, Nork TM, Heatley GA, Kaufman PL Effects of vitrectomy and lensectomy on older rhesus macaques: Oxygen distribution, antioxidant status, and aqueous humor dynamics. *Invest Ophthalmol Vis Sci*, 58:4003-4014, 2017 doi:10.1167/iovs.17-21890.
375. Bhattacharya SK, Porciatti V, Kaufman PL, Toris C, Lee RK, Ziebarth NM, Gasuli X, Zode G, Sampathkumar S, Eedwards G, Sueiras VM, Liu Y, Ding D, Trzeciecka AM, Beltran NC, Arbelo U, Wang H, Callejo G: Identification of ocular lipids that lower intraocular pressure and promote neuroprotection as potential glaucoma therapeutics. *Nature Medicine*, submitted.
376. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network: Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. *JAMA Ophthalmol*, 135(6):558-568, 2017. doi: 10.1001/jamaophthalmol.2017.0821.

Books

1. Kaufman PL and Mittag TW, eds. *Glaucoma, Vol 7. Textbook of Ophthalmology Series (Series Editors: Podos SM, Yanoff M)*. London: Mosby-Year Book Europe Ltd., 1994.
2. Kaufman PL, ed. *Physiology of the Eye and Visual System. Duane's Foundations of Clinical Ophthalmology Series (Series Editors: Tasman W, Jaeger EA)*. Philadelphia: Lippincott-Raven, 1995.
3. Perkins TW, Kaufman PL, associate editors for Glaucoma Section. *Ophthalmic Surgery: Principles and Techniques (Albert DM, ed)*, Cambridge MA: Blackwell Scientific Publishers, Chapters 28-40, pp. 335-507, 1998.
4. Kaufman PL, Alm A, eds. *Adler's Physiology of the Eye, Tenth Edition*. St. Louis: Mosby, 2002.
5. Kaufman PL, Alm A, Levin LA, Nisson SF, VerHoeve JL, Wu S, eds. *Adler's Physiology of the Eye, Eleventh Edition*, [city?] Saunders/Elsevier, 2010.
6. Chader GJ, Frank RN, Kaufman PL, Beebe DC: *The Best of Investigative Ophthalmology & Visual Science: The First 50 Years – 1962-2012*, Rockville, The Association for Research in Vision and Ophthalmology, 2013.

Monographs

1. Langham ME, Kaufman PL, Pollack IP, Wilensky JT: *Carbonic anhydrase inhibitors in the 80s: A major reevaluation. Part I*. Pearl River, Lederle Laboratories, 1981.
2. Langham ME, Kaufman PL, Pollack IP, Wilensky JT: *Carbonic anhydrase inhibitors in the 80s: A major reevaluation. Part II*. Pearl River, Lederle Laboratories, 1981.

3. Gonnering RS, Erickson KA, Kaufman PL, Dortzbach RK: The Cynomolgus monkey as a model for orbital research. *Am Soc Ophthalmic Plast Reconstr Surg*, 1982 (Recipient of 1982 ASOPRS Research Award and Marvin H. Quickert Thesis Award).
4. Douglas G, Arzeno A, Bechetoille A, Gil-Carrasco F, Gillies B, Goldberg I, Honrubia F, Kaufman PL, Krieglstein G, Migdal C, Reiboldi A, Telkhasaene C, Trew DR: Current Issues in Glaucoma. A Closed Symposium held at the XXVII International Congress of Ophthalmology. June 29, 1994 Toronto, Canada. Irvine, Allergan, 1995.
5. Camras CB, Fiscella RG, Higginbotham E, Kaufman PL, Obstbaum SA, Singh K, Zimmerman TJ: Update on glaucoma medication therapy. *Rev Ophthalmol* 6 (1, Part 2):1A-23A, 1999 (Monograph of panel discussion held in Charleston, SC, October 2, 1998).
6. Kaufman PL: Aqueous outflow enhancer targets: current and future. In *Clinical Glaucoma: Advancing Science, Enhancing Care. Highlights of New Frontiers in Clinical Glaucoma II*, a conference sponsored by the College of Physicians and Surgeons, Columbia University, and held at Columbia University Medical Center, New York City, November 11–12, 2005, to Honor the Contributions to Glaucoma and Ophthalmology by Max Forbes, MD. *Ophthalmology Times*, volume 31 supplement, pp7-8, Advanstar Communications, Inc, May 1, 2006
7. Contributor, Basic Science of Intraocular Pressure, in *Intraocular Pressure, Consensus Series 4* (Eds: Weinreb RN, Brandt JD, Garway-Heath D, Medeiros F), World Glaucoma Association, Kugler Publications, The Hague, The Netherlands, 2007 pp.1-14.

Book Chapters/Reviews

1. Bárány EH, Kaufman PL: Versuche die Pharmakologie des Trabekelwerks bei Affen zu studieren. In: Leydecker W, ed. *Glaukom-Symposium Wurzburg 1974*. Stuttgart: Ferdinand Enke Verlag, pp. 50-56, 1976.
2. Kaufman PL, Brightbill FS: Drug therapy and common disorders of the eye. In: Wang RIH, ed. *Practical Drug Therapy*. Philadelphia: JB Lippincott, Chapter 49, pp. 621-643, 1979.
3. Kaufman PL, Wiedman T, Robinson JR: Cholinergics. In: Sears ML, ed. *Pharmacology of the Eye. Handbook of Experimental Pharmacology Series*. Berlin: Springer-Verlag, Vol 69, Chapter 4, pp. 149-191, 1984.
4. Kaufman PL: Aqueous humor outflow. In: Zadunaisky JA and Davson H, eds. *Current Topics in Eye Research*. Orlando, Academic Press. 4:97-138, 1984.
5. Kaufman PL: Mechanisms of actions of the cholinergic drugs in the eye. In: Drance SM and Neufeld AH, eds. *Glaucoma: Applied Pharmacology in Medical Treatment*. Orlando: Grune & Stratton, Chapter 17, pp. 395-428, 1984.
6. Kaufman PL: The effects of drugs on the outflow of aqueous humor. In: Drance SM and Neufeld AH, eds. *Glaucoma: Applied Pharmacology in Medical Treatment*. Orlando: Grune & Stratton, Chapter 18, pp. 429-458, 1984.
7. Kaufman PL: Cytochalasins and aqueous humor outflow. In: Ticho U and David R, eds. *Recent Advances in Glaucoma. Excerpta Medica International Congress Series, ICS 636*. Amsterdam: Elsevier Science Publishers, pp. 175-177, 1984.
8. Kaufman PL: Cholinergic drug effects in the primate anterior segment In: Ticho U and David R, eds. *Recent Advances in Glaucoma. Excerpta Medica International Congress Series, ICS 636*. Amsterdam: Elsevier Science Publishers, pp. 221-224, 1984.
9. Kaufman PL: Aqueous humor dynamics. In: Duane TD, ed. *Clinical Ophthalmology*. Philadelphia: Harper & Row, Vol 3, Chapter 45, pp. 1-24, 1985.
10. DeRousseau CJ, Bitto LZ, Kaufman PL: Age-dependent impairments of the rhesus monkey musculoskeletal and visual systems and apparent behavioral consequences. In: Rawlins RG and Kessler MJ, eds. *The Cayo Santiago Macaques: History, Behavior and Biology*. Albany: State University of New York Press, Chapter 11, pp. 232-251, 1986.
11. Kessler MJ, Rawlins RG, Kaufman PL: The golden rhesus macaques of Cayo Santiago. In: Rawlins RG and Kessler MJ, eds. *The Cayo Santiago Macaques: History, Behavior and Biology*. Albany: State University of New York Press, Chapter 13, pp. 263-268, 1986.

12. Kaufman PL: Aging and aqueous humor dynamics. In: DiVincentis M, ed. *The Fundamental Aging Processes of the Eye*. Florence: Baccini & Chiappi, pp. 41-46, 1987.
13. Crawford K, Kaufman PL, True-Gabelt B: Prostaglandins and aqueous humor dynamics. In: Shields MB, Pollack IP, Kolker AE, eds. *Perspectives in Glaucoma*. Transactions of the First Scientific Meeting of the American Glaucoma Society. Thorofare: Slack, Inc., Chapter 29, pp. 259-267, 1988.
14. Kaufman PL, Crawford K: Aqueous humor dynamics: How PGF_{2α} lowers intraocular pressure. In: Bito LZ and Stjerschantz J, eds. *The Ocular Effects of Prostaglandins and Other Eicosanoids*. Progress in Clinical and Biological Research. New York: Alan R. Liss, 312:387-416, 1989.
15. Kaufman PL: Pressure-dependent outflow. In: Ritch R, Shields MB, Krupin TH, eds. *The Glaucomas*. St Louis: Mosby, Vol 1, Chapter 9, pp. 219-240, 1989.
16. Kaufman PL, Crawford K, Gabelt BT: The effects of prostaglandins on aqueous humor dynamics. In: Kooner KS and Zimmerman TD, eds. *New Ophthalmic Drugs*. Ophthalmology Clinics of North America. Philadelphia: WB Saunders, 2:141-150, 1989.
17. Kaufman PL, Erickson-Lamy KA, Rohen JW, Polansky JR: The ciliary muscle and nerves after ciliary ganglionectomy. In: Krieglstein GK, ed. *Glaucoma Update IV*. Proceedings of the Symposium of the Glaucoma Society of the International Congress of Ophthalmology in Bali, March 1990. New York-Berlin: Springer-Verlag, pp. 36-51, 1991.
18. Kaufman PL: Physiology and pharmacology of aqueous humor outflow: Implications for treatment. In: Caprioli J, ed. *Contemporary Issues in Glaucoma*. Ophthalmology Clinics of North America. Philadelphia, WB Saunders. 4:781-802, 1991.
19. Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, Shaw B: New developments in the drug treatment of glaucoma. *Drugs* 41:514-532, 1991 (Invited Review).
20. Kaufman PL: How glaucoma medications work. *Focus on Glaucoma*, Volume 6(1):5-8, 1991 (Invited Review).
21. Kaufman PL: Accommodation and presbyopia: Neuromuscular and biophysical aspects. In: Hart WM Jr, ed. *Adler's Physiology of the Eye: Clinical Application*, 9th Edition. St. Louis: Mosby-Year Book, Chapter 11, pp. 391-411, 1992.
22. Kaufman PL, Gabelt BT: Cholinergic mechanisms and aqueous humor dynamics. In: Drance SM, Neufeld AH, Van Buskirk EM, eds. *Pharmacology of Glaucoma*. Baltimore: Williams and Wilkins, Chapter 5, pp. 64-92, 1992.
23. Kaufman PL, Gabelt BT: Aging, accommodation and outflow facility. In: Lütjen-Drecoll E, ed. *Basic Aspects of Glaucoma Research III*. Stuttgart: Schattauer, pp. 257-274, 1993.
24. Kaufman PL, Mittag TW: Medical therapy of glaucoma. In: Kaufman PL and Mittag TW, eds. *Glaucoma* (Vol 7 of Podos SM, Yanoff M, eds, *Textbook of Ophthalmology Series*). London: Mosby-Year Book Europe Ltd, Chapter 9, Section II, pp. 9.7-9.30, 1994.
25. Kaufman PL, Crawford KS: Prostanoid receptors in the eye - A physiologist's view. In: Anderson DR and Drance SM, eds. *Encounters in Glaucoma Research 1: Receptor Biology and Glaucoma*. Milan: Fogliazza Editore, pp. 159-202, 1994.
26. Kaufman PL, Gabelt BT: Presbyopia, prostaglandins and primary open angle glaucoma. In: Krieglstein GK, ed. *Glaucoma Update V*. Symposium Proceedings - Glaucoma Society of the International Congress of Ophthalmology, Quebec City, June 1994. New York-Berlin: Springer-Verlag, pp. 224-241, 1995.
27. Millar C, Kaufman PL: Aqueous humor: Secretion and dynamics. In: Kaufman PL, ed. *Section II, Physiology of the Eye and Visual System* (Tasman W and Jaeger EA, eds, *Duane's Foundations of Clinical Ophthalmology*). Philadelphia: Lippincott-Raven, Vol 2, Chapter 6, pp. 1-51, 1995.
28. Kaufman PL: Pressure-dependent outflow. In: Ritch R, Shields MB, Krupin TH, eds. *The Glaucomas*, 2nd Edition. St. Louis: Mosby-Year Book, Vol. I - Basic Sciences, Chapter 14, pp. 307-335, 1996.
29. Kaufman PL, Gabelt BT: Direct, indirect and dual-action parasympathetic drugs. In: Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD (eds): *Textbook of Ocular Pharmacology*. New York, Lippincott-Raven, 1997, Chapter 19, pp 221-238.
30. Kaufman PL, Gabelt BT: Pharmacologic enhancement of aqueous humor outflow. In: Van Buskirk EM and Shields MB, eds. *One Hundred Years of Progress in Glaucoma*. Philadelphia: Lippincott-Raven, pp. 237-261, 1997.

31. Millar JC, Gabelt BT, Kaufman PL: Aqueous humor dynamics. In: Tasman W and Jaeger EA, eds. *Duane's Clinical Ophthalmology*. Philadelphia: Lippincott-Raven, Vol 3, Chapter 45, pp. 1-34, 1998.
32. Gabelt BT, Kaufman PL: Uveoscleral outflow: Normal physiology. In: Alm A and Weinreb RN, eds. *Uveoscleral Outflow: Biology and Clinical Aspects*. London: Mosby-Wolfe, Chapter 3, pp. 25-39, 1998.
33. Liu X, Brandt CR, Gabelt BT, Kaufman PL: Gene therapy for glaucoma: anterior and posterior segment targets, delivery systems, constraints. In: Gramer E and Grehn F, eds. *Pathogenesis and Risk Factors of Glaucoma*. Berlin: Springer-Verlag, Chapter 11, pp. 93-100, 1999.
34. Kaufman PL, Tian B, Peterson JA, Gabelt BT, Geiger B: The actin cytoskeleton and aqueous outflow. In: Gramer E and Grehn F, eds. *Pathogenesis and Risk Factors of Glaucoma*. Berlin: Springer-Verlag, Chapter 14, pp. 117-122, 1999.
35. Kaufman PL, Gabelt BT, Tian B, Liu X: Advances in glaucoma diagnosis and therapy for the next millennium: New drugs for trabecular and uveoscleral outflow. In: Fanous M, ed. *Glaucoma*. *Semin Ophthalmol* 14:130-143, 1999.
36. Gabelt BT, Kaufman PL: Cholinergic drugs. In: Netland PA, Allen RC, eds: *Glaucoma Medical Therapy: Principles and Management*. *Ophthalmology Monographs* #13. San Francisco: The Foundation of the American Academy of Ophthalmology, Chapter 4, pp. 77-97, 1999.
37. Kaufman PL, Peterson JA, Tian B, Gabelt BT, Geiger B: Cytoskeletal and cell junctional modulation of aqueous outflow. In: Krieglstein GK, ed. *Glaucoma Update VI. Proceedings of the Symposium of the Glaucoma Society of the International Congress of Ophthalmology*, Edinburgh, Scotland, June 1998. Berlin: Springer-Verlag, Chapter 29, pp. 191-195, 1999.
38. Glasser A, Kaufman PL: Presbyopia. In: Fraunfelder FT and Roy FH, eds. *Current Ocular Therapy*. Philadelphia: WB Saunders, pp. 592-594, 1999.
39. Levin LA, Nickells RW, Kaufman PL: The role of neuroprotection. *Highlights Ophthalmol* 27(1. Glaucoma – New Horizons):11, 1999 (Invited Review).
40. Kaufman PL, Tian B, Gabelt BT, Liu X: Outflow enhancing drugs and gene therapy in glaucoma. In: Weinreb R, Krieglstein G, Kitazawa Y, eds. *Glaucoma in the 21st Century*. London: Harcourt-Mosby, Chapter 17, pp. 117-128, 2000.
41. Tian B, Geiger B, Epstein DL, Kaufman PL: Cytoskeletal involvement in the regulation of aqueous humor outflow. *Invest Ophthalmol Vis Sci* 41:619-623, 2000 (New Developments article-invited/peer reviewed). In: Chader GJ, Frank RN, Kaufman PL, Beebe DC: *The Best of Investigative Ophthalmology & Visual Science: The First 50 Years – 1962-2012*, Rockville, The Association for Research in Vision and Ophthalmology, 2013, special edition.
42. Glasser A, Kaufman PL: Presbyopia: A view. *eMedicine Journal* [serial online], *Ophthalmology>Presbyopia*, Vol 2, #8, 2001. Available at <http://www.emedicine.com/oph/topic699.htm#target1>.
43. Croft MA, Glasser A, Kaufman PL: Accommodation and presbyopia. *Int Ophthalmol Clin* 41(Presbyopia):33-46, 2001.
44. Glasser A, Croft MA, Kaufman PL: Aging of the human crystalline lens and presbyopia. *Int Ophthalmol Clin*, 41(Presbyopia):1-15, 2001.
45. Lütjen-Drecoll E, Gabelt BT, Tian B, Kaufman PL: Outflow of aqueous humor. *J Glaucoma* 10(Suppl 1):S42-44, 2001.
46. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL: Effects of prostaglandins on the aqueous humor pathways. *Surv Ophthalmol* 47 (Suppl 1):S53-S64, 2002.
47. Gabelt BT, Kaufman PL: Aqueous humor hydrodynamics. In: Kaufman P and Alm A, eds. *Adler's Physiology of the Eye, Clinical Applications*, 10th Edition. St. Louis: Mosby, Sect. 6, Chapter 8, pp. 237-289, 2002.
48. Glasser A, Kaufman PL: Accommodation and presbyopia. In: Kaufman P and Alm A, eds. *Adler's Physiology of the Eye, Clinical Applications*, 10th Edition. St. Louis: Mosby, Sect. 5, Chapter 7, pp. 197-233, 2002.
49. Levin LA, Nickells RW, Kaufman PL: The present status of neuroprotective agents in glaucoma. In: Boyd BF, Luntz MH, Boyd S, eds. *Innovations in Glaucoma: Etiology, Diagnosis and Management*. Bogota: *Highlights of Ophthalmology International*, Chapter 11, pp.103-106, 2002.
50. Gabelt BT, Ver Hoeve JN, Kaufman PL: Intraocular pressure elevation: Laser photocoagulation of the trabecular meshwork. In: Levin L, DiPolo A, eds. *Ocular Neuroprotection*. New York: Marcel Dekker, Chapter 5, pp 47-84, 2003.

51. Yücel YH, Weinreb RN, Kaufman PL, Gupta N: Koniocellular pathway damage in glaucoma. *Glaucoma Today* 2:12-14, 2004.
52. Kaufman PL: Gene therapy in glaucoma: will it replace drugs and surgery. Fifth International Symposium on Ocular Pharmacology and Therapeutics (5th ISOPT), Monte Carlo, Monaco, March 11-14, 2004. Bologna, Medimod Srl, pp 77-83.
53. Kaufman PL, Gabelt BT: The efficacy and mechanism of action of prostaglandin analogues. Fifth International Symposium on Ocular Pharmacology and Therapeutics (5th ISOPT), Monte Carlo, Monaco, March 11-14, 2004. Bologna, Medimod Srl, pp 85-90.
54. Gabelt BT, Kiland JA, Tian B, Kaufman PL: Aqueous humor: Secretion and dynamics. In: Kiel J, ed. Section II, Physiology of the Eye and Visual System (Tasman W and Jaeger EA, eds, Duane's Foundations of Clinical Ophthalmology on CD-ROM). Philadelphia: Lippincott Williams & Wilkins, Vol 2, Chapter 6, pp 1-72, 2006.
55. Kaufman PL, Gabelt BT: Future of IOP lowering medication for glaucoma therapy. In: Stamper R, Grehn F, eds. Essentials in Ophthalmology - Glaucoma. Heidelberg, Springer-Verlag pp138-155. 2006
56. Croft MA, Kaufman PL: Accommodation and presbyopia: The ciliary neuromuscular view: *Ophth Clin North Am* (eds: Packer M and Fine H), 19(1):13-24, 2006
57. Tan JCH, Peters DM, Kaufman PL: Recent developments in understanding the pathophysiology of elevated intraocular pressure. *Curr Opin Ophthalmol*, 17:168-174, 2006.
58. Kaufman PL, Gabelt BT: Future of IOP lowering medication for glaucoma therapy. In: Stamper R, Grehn F, eds. Essentials in Ophthalmology - Glaucoma. Heidelberg, Springer-Verlag pp138-155. 2006
59. Kaufman PL: Gene therapy for glaucoma. Sixth International Symposium on Ocular Pharmacology and Therapeutics (6th ISOPT), Berlin, Germany, March 30-April 2, 2006. Bologna, Medimod Srl, pp21-28.
60. Gabelt BT, Kaufman PL. Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy. *Expert Rev of Ophthalmol* 1(2):141-158, 2006. Future Drugs Ltd, London (invited review)
61. Croft MA, Kaufman PL. Accommodation and Presbyopia: The ciliary neuromuscular perspective. In: Fine IH, Packer M, eds. Accommodation and Presbyopia Correction Options. *Ophthalmol Clinics North Am* Vol 19:13-24, 2006 (Elsevier).
62. Liu X, Brandt CR, Rasmussen CA, Kaufman PL: Glaucoma gene therapy. *Expert Rev Ophthalmol*. 2:227-236, 2007 (Review)
63. Liu X, Brandt CR, Rasmussen CA, Kaufman PL. Ocular drug delivery: molecules, cells, and genes. *Canadian J Ophthalmol* 42:447-545, 2007 (review).
64. Liu X, Rasmussen CA, Bennett J, Brandt CR, Gabelt BT, Kaufman PL: Progress and prospects in ocular gene therapy. In *Ocular Therapeutics*. Eds: Yorio T, Clark AF, Wax MB. Academic Press, New York, Ch 18, pp393-402, 2008 (review)
65. Gabelt BT, Kaufman PL: Cholinergic Drugs, chapter 5. In *Glaucoma Medical Therapy, Principles and Management*, 2nd edition, Ophthalmology Monographs 13. Netland PA, editor; Parrish RK II, series editor. Oxford Univ Press in cooperation with the American Academy of Ophthalmology, New York, pp103-122, 2008
66. Kaufman PL: The aging anterior segment and glaucoma. Might the biomechanics of aging contribute to the disease? OGS Honoree Lecture. In: *Heralding Change in Glaucoma*. Proceedings of the Sixth Annual Meeting of the Optometric Glaucoma Society. *Review of Optometry* 45 (2): 8-9, 2008.
67. Kaufman PL: the future of glaucoma therapy. Options such as gene therapy are closer than you think. In: *Review of Optometry: Heralding change in glaucoma*. Proceedings of the Sixth Annual Meeting of the Optometric Glaucoma Society. *Review of Optometry* 45 (2):12-13, 2008
68. Tan JCH, Gabelt BT, Kaufman PL. Changes in aqueous dynamics with age and glaucoma. Chapter 19. In *Ophthalmology Research: Mechanisms of the Glaucomas. IV. Molecular and cellular responses in the eye to glaucoma*. Shields MB, Tombran-Tink J, Barnstable CJ (Eds). Humana Press, Totowa, NJ, p311-327, 2008
69. Kaufman PL: Increasing outflow facility – today and tomorrow. Seventh International Symposium on Ocular Pharmacology and Therapeutics (7th ISOPT), Budapest, Hungary, February 28-March 2, 2008. Bologna, Medimod Srl, pp 43-46, 2008.
70. Rasmussen CA, Kaufman PL: Medical therapy for glaucoma: the next 20 years. *Journal of Current Glaucoma Practice* 2:1-5, 2008.

71. Alio JL, Ben-Nun J, Kaufman PL: Shape-changing IOLs: NuLens. In Chang DF (Editor): *Mastering Refractive IOLs: The Art and Science*. Slack, Incorporated, Thorofare, NJ. Chapter 61, pp223-228, 2008.
72. Tan JCH, Kaufman PL: Primary open angle glaucoma. In Yanoff M, Duker JS, & Schuman JS. *Ophthalmology*, Third Edition, part 10 (Glaucoma), section 3 (Specific types of glaucoma), Ch 10.10, pp 59-63. Elsevier, Inc. 2008.
73. Tian B, Gabelt BT, Geiger B, Kaufman PL: The role of the actomyosin system in regulating trabecular fluid outflow. *Exp Eye Res* 88:713-717, 2008. (review) PMID2694502
74. Toris CB, Gabelt BT, Kaufman PL: Update on the effects of topical prostaglandins on aqueous humor dynamics. *Surv Ophthalmol* 53:S107-120, 2008.
75. Liu X, Rasmussen CA, Gabelt BT, Brandt CR, Kaufman PL: Gene therapy targeting glaucoma: where are we? *Surv Ophthalmol* 54:472-486, 2009. PMID2848072
76. Kaufman PL: Aqueous outflow biology and therapeutics: What's new? 8th International Symposium on Ocular Pharmacology and Therapeutics, Rome, Italy, Medimond s.r.l, Bologna, Medimond International Proceedings p45-49, December 3-6, 2009.
77. Flügel-Koch C, Neuhuber W, Kaufman PL, Lütjen-Drecoll E: Morphological indication for proprioception in the human ciliary muscle. *Invest Ophthalmol Vis Sci* 50:5529-5536, 2009. PMID2810743 In: Chader GJ, Frank RN, Kaufman PL, Beebe DC: *The Best of Investigative Ophthalmology & Visual Science: The First 50 Years – 1962-2012*, Rockville, The Association for Research in Vision and Ophthalmology, 2013, special edition.
78. Faralli JA, Schwinn MK, Peters DM, Kaufman PL: Sidebar: Cytoskeletal active agents for glaucoma therapy. *The Glaucoma Book* (eds: Schacknow P, Samples JR), Springer, 2010, Chapter 85, pp. 953-957.
79. Tian B, Gabelt BT, Kaufman PL, Geiger B: The cytoskeletal network of the trabecular meshwork. In *Encyclopedia of the Eye* (Dartt DA, Besharse JC, Dana R, eds), Vol 1 A-C, Amsterdam-Oxford-San Diego: Academic Press-Elsevier, pp549-555, 2010.
80. Gabelt BT, Kaufman PL: Production and flow of aqueous humor. *Adler's Physiology of the Eye*, 11th Edition (Eds: Kaufman PL, Alm A, Levin L, Nilsson S, VerHoeve J, Wu S), Elsevier, in press, 2010.
81. Caprioli J, Coleman AL, on behalf of the blood flow in glaucoma discussion group (Albert Alm, Arash Bereliani, Balwantray Chauhan, Paul Kaufman, Jeffrey Kiel, Theodore Krupin, Cristina Leske, Stuart McKinnon, and Larry Wheeler): Perspective: Blood pressure, perfusion pressure and glaucoma. *Am J Ophthalmol* 149: 704-712, 2010.
82. Rasmussen CA, Kaufman PL: Novel therapeutic approaches for glaucoma. *Drugs of the Future* 36: 287-300, 2011.
83. Tian B, Kaufman PL. Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications. *Expert Rev Ophthalmol* 7:177-187, 2012. PMID3378243
84. Kaufman PL, Rasmussen CA: Advances in glaucoma treatment and management: outflow drugs. *Invest Ophthalmol Vis Sci* 53:2495-2500, 2012. PMC Journal – in process
85. Gabelt BT, Kiland JA, Tian B, Kaufman PL: Aqueous humor: Secretion and dynamics. In: Kiel J, ed. *Section II, Physiology of the Eye and Visual System* (Tasman W and Jaeger EA, eds, *Duane's Foundations of Clinical Ophthalmology on CD-ROM*). Philadelphia: Lippincott Williams & Wilkins, Vol 2, Chapter 6, pp 1-72, 2012.
86. Croft MA, Kaufman PL: Role of the ciliary muscle and zonula in accommodation and presbyopia. In *Presbyopia: Origins, Effects and Treatment* (Ioannis Pallikaris, MSc, PhD; Sotiris Plainis, MSc, PhD; W. Neil Charman, PhD, DSc, editors), Charles B. Slack, Inc. Thorofare, NJ, pp 69-76, 2012.
87. Tan JCH, Kaufman PL: Primary open angle glaucoma. In Yanoff M, Duker JS, eds. *Ophthalmology*, 4th Edition, Part 10 (Glaucoma), Section 3 (Specific types of glaucoma), Ch 10.10, pp 1-5. Elsevier, Inc. 2013.
88. Rasmussen CA, Kaufman PL. Exciting directions in glaucoma. *Can J Ophthalmol*. 2014 Dec;49(6):534-43. doi: 10.1016/j.cjjo.2014.08.007. PMID: 25433744
89. Rasmussen CA, Kaufman PL: The trabecular meshwork in normal eyes and in exfoliation glaucoma. *J Glaucoma* 23 (Supplement; Proceedings of the 20th Annual Think Tank of the Glaucoma Foundation; "Exfoliation Syndrome: what we know and where we need to go"): 15S-19S, 2014.
90. Gabelt BT, Kaufman PL: Do prostaglandins make uveoscleral outflow more pressure-dependent? Sidebar for chapter 3, *Eye Anatomy and Physiology: Uveoscleral Outflow*. In, *Minimally Invasive Glaucoma Surgery*:

- the Science and the Practice. Francis BA, Sarkisian S, Tan J (eds). Thieme Publishers, New York, NY. 2015. In press. [Track this down; it should be published by now!]
91. Kaufman PL: New drugs in glaucoma treatment. Topics in glaucoma. September 2015, Issue 3, pp 1-4.
 92. Kaufman PL: A Perspective: How can gene therapeutics help address ophthalmic health issues in Asia? In Prakash G, Iwata, T: Advances in Vision Research, Volume I: Genetic Eye Research in Asia and the Pacific, Springer, Essentials in Ophthalmology Series, Arum Singh, Series Editor, 2017, Ch. 38, pp 509-513.
 93. Kaufman PL: Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opinion on Pharmacotherapy, 18 (4):433-444, 2017.
<http://dx.doi.org/10.1080/14656566.2017.1293654>
 94. Michalik AZ, Kaufman PL: Management of glaucoma in exfoliation syndrome: Medical. J Glaucoma: Exfoliation special supplement, 2017, in press.

Declined requests for 3 additional book chapters (1985, 86, 99) because of other commitments, and declined many additional invitations.

Scientific Advisory Panel Reports

1. Kaufman PL, Polansky JR, Southern AL, Anderson DR: Aqueous humor dynamics: Outflow. In: Vision Research - A National Plan: 1983-1987. The 1983 Report of the National Advisory Eye Council. Report of the Glaucoma Panel. US DHHS (NIH publ no 83-2474), 2(Part 4, Chapter 3):41-53, 1983.
2. Kaufman PL, Phelps CD, Polansky JR, Anderson DR: Secondary glaucomas. In: Vision Research - A National Plan: 1983-1987. The 1983 Report of the National Advisory Eye Council. Report of the Glaucoma Panel. US DHHS (NIH publ no 83-2474), 2(Part 4, Chapter 7):79-86, 1983.
3. Kaufman PL: ARVO: Association for Research in Vision and Ophthalmology. Fort Lauderdale FL, April 21-26, 1996. Glaucoma 1:1, 1996. Brussels, IME International (Meeting Summary).
4. Kaufman PL: Glaucoma Research Foundation Meeting Summary. J Glaucoma 6:65-68, 1997.
5. Vision for The Future: Moving Glaucoma Research Results into Clinical Practice. Summary of Workshop, June 26-27, 2000, Rancho Valencia, CA. The Washington Advisory Group, LLC, Washington, DC, December 2000, Summary of Presentation: Glaucoma Pathophysiology and Therapy, p. 16-17.
6. Crowston JG, Kaufman PL, eds: Association of International Glaucoma Societies Consensus Report on "Glaucoma Surgery – Open Angle Glaucoma - Wound Healing." Ft. Lauderdale, FL, April 30, 2005. [Consensus Panel. Glaucoma Surgery Open Angle Glaucoma: Consensus Series 2 Weinreb RN, Crowston JG (eds), Kugler Publications, The Hague, Netherlands, 2005.]
7. *Eye Diseases in Diverse Populations: Challenges and Opportunities for Preventing and Treating Blindness. The Washington Advisory Group, Ranch Valencia, CA, June 12-14, 2005. Presentations: 1) Glaucoma: Clinical Management: Present and Into the Future (104-109); 2) Executive Summary – Glaucoma (1-2); 3) Conclusions on Individual Eye Diseases- Glaucoma (26-32); 4) Various discussion sessions.
8. Balasubramanian D, Kaufman PL and US-Indo Collaborative Research Workshops Group: Research opportunities in vision: A report of the US-Indo workshops on collaborative research. Invest Ophthalmol Vis Sci 47:1717-1735, 2006.
9. Weinreb RN, Kaufman PL: The glaucoma research community and FDA look to the future; a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 50:1497-1505, 2009.
10. Limb GA, Martin KR, and the Sixth ARVO/Pfizer Ophthalmics Research Institute Conference Working Group: Current prospects in optic nerve protection and regeneration: Sixth ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci 52:5941-5954, 2011.
11. Weinreb RN, Kaufman PL: Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function. Invest Ophthalmol Vis Sci 52:7842-7851, 2011. PMID3207797

Letters to Editors, Memoria, & Mini-Commentaries / Mini-Reviews / Editorials

1. Kaufman PL: Subretinal fluids: Lipid analyses reanalyzed. *Invest Ophthalmol* 15:237-238, 1976.
2. Appen RE, Kaufman PL, Klewin KM: Reply to Laibovitz RA: Amaurosis and blood loss. *Am J Ophthalmol* 87:433-434, 1979.
3. Kaufman PL: Reply to Awan KJ: Unilateral Rieger's anomaly. *Am J Ophthalmol* 91:543, 1981.
4. Kaufman PL: Reply to Eifrig D, Lewicky A: Sidewall-holed needle for anterior chamber infusion. *Ophthalmic Surg* 13:144, 1982.
5. The Glaucoma Laser Trial Research Group: Glaucoma Laser Trial - reply to letters and editorial. *Ophthalmology* 98:842, 1991.
6. Kaufman PL, Lütjen-Drecoll E: In Memoriam: Ernst H. Bárány, MD (1911-1991). *Exp Eye Res* 54:157-158, 1992.
7. Kaufman PL, Lütjen-Drecoll E: Memoriam for Ernst H. Bárány, MD. *Invest Ophthalmol Vis Sci* 33:473, 1992.
8. Kaufman PL: PhXA34-induced ocular hypotension. *Arch Ophthalmol* 110:1042, 1992.
9. Kaufman PL: Reply to Shin DH: Dose-dependent suppression of aqueous humor formation by timolol in the Cynomolgus monkey. *J Glaucoma* 3:354-355, 1994.
10. Kaufman PL, Murphy CJ (for the Board of Trustees, Association for Research in Vision and Ophthalmology): Reply to Macek J: Animals in vision research. *Arch Ophthalmol* 113:139, 1995.
11. Kaufman PL: Reply to Taylor S, Heitmann T, re: A rational approach to adding glaucoma medications. *Rev Ophthalmol* 5(8):18-19, 1998.
12. Glasser A, Kaufman PL: Author's reply to Ludwig K and Kampik A, re: The mechanism of accommodation in primates. *Ophthalmology* 107:222, 2000.
13. Glasser A, Kaufman PL: Reply to Roy FH: Mechanism of accommodation in primates. *Ophthalmology* 108:1370-1371, 2001.
14. Kaufman PL: Medical treatment: Cytoskeleton/cell contractility. *Int Glaucoma Rev* 3-2:29, 2001.
15. Kaufman PL: Medical treatment: Prostaglandins. *Int Glaucoma Rev* 3-3:36, 2002.
16. Kaufman PL: Medical therapy: Prostaglandins. *Int Glaucoma Rev* 4-1:32, 2002.
17. Kaufman PL: Basic Science; Myosin light chain kinase. *Int Glaucoma Rev* 4-2:242, 2002.
18. Kaufman PL: Reply to Neufeld AH, Becker B: Some thoughts on the pressure-dependence of uveoscleral outflow. *J Glaucoma* 12:89, 2003.
19. Kaufman PL: Reply to Horn J: Regarding the surgical reversal of presbyopia (SRP) surgery for presbyopia. *Ophthalmology* 110:872, 2003.
20. Kaufman PL: Reply to Schachar RA: Regarding the surgical reversal of presbyopia (SRP) surgery for presbyopia. *Ophthalmology* 110:873, 2003.
21. Kaufman PL, Tian B: H-7 in live monkey vs. cultured human eyes. "Re: Glaucoma: Bahler CK, Hann CR, Fautsch MP, Johnson DH: Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes. *Invest Ophthalmol Vis Sci* 45: 2246-2254, 2004." *Invest Ophthalmol Vis Sci E-Letters*, <http://www.iovs.org/cgi/eletters/45/7/2246#180>
22. Kaufman PL: Gene therapy. *Int Glaucoma Rev* 6-1:11-12, 2004.
23. Kaufman PL: Latanoprost and posterior pole. *Int Glaucoma Rev* 6-2:174, 2004.
24. Okka M, Tian B, Kaufman PL: Correspondence Re: Effect of latrunculin B on IOP in the monkey eye. *Arch Ophthalmol* 122:1482-1488, 2004. *Arch Ophthalmol* 123:1457, 2005.
25. Tian B, Kaufman PL: Comment on Nakajima-E; Nakajima-T; Minagawa-Y; Shearer-TR; Azuma-M: Contribution of ROCK in contraction of trabecular meshwork: Proposed mechanism for regulating aqueous outflow in monkey and human eyes (*J Pharm Sci*. 94(4): 701-708, 2005). *Int Glaucoma Rev*:7-2:195, 2005.
26. Croft MA, Glasser A, Heatley GA, McDonald JP, Kaufman PL: ELETTERS: Mary Ann Croft Author Response: Alternative Interpretation of the Age-Related Decrease in Circumferential Space. <http://www.iovs.org/cgi/eletters/47/3/1087#393>, 23 June 2006.
27. Croft MA, Glasser A, Heatley GA, McDonald JP, Kaufman PL: ELETTERS: Mary Ann Croft Author Response: Additional Controls Required for Assessing In Vivo Accommodation <http://www.iovs.org/cgi/eletters/47/3/1076#375>, 26 May 2006.
28. Kaufman PL: Comment on Dawson JC, Hope GM, Brooks DE, Percicot CL: Repeat sample intraocular pressure variance in induced and naturally ocular hypertensive monkeys (*J Glaucoma* 14: 426-431, 2005). *Int Glaucoma Rev*:7-3; 362, 2006.

29. Kaufman PL: Jon R. Polansky (1948-2005): *Exp Eye Res*, 82:926, 2006.
30. Kaufman PL: Comment on Theime H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F₂ α and fluprostenol on trabecular meshwork contractility (*J Glaucoma* 14: 426-431, 2005). *Int Glaucoma Rev*:8-1; 24, 2006.
31. Kaufman PL: Comment on Lindsey JD, Crowston JG, Tran A, Morris C, Weinreb RN: Direct matrix metalloproteinase enhancement of transscleral permeability (*Invest Ophthalmol Vis Sci* 48: 752-755, 2007). *Int Glaucoma Rev*:9-1; 2007.
32. Kaufman PL: Comment on Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME: Bimatoprost, prostamide activity, and conventional drainage (*Invest Ophthalmol Vis Sci* 48: 4107-4115, 2007). *Int Glaucoma Rev*:9-3; 2007.
33. Kaufman PL: Comment on Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M: Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers (*Arch Ophthalmol* 126: 309-315, 2008). *Int Glaucoma Rev*:10-1; 2008.
34. Kaufman PL: Comment on Bakall B, McLaughlin P, Stanton JB, Zhang Y, Hartzell HC, Marmorstein LY, Marmorstein AD: Bestrophin-2 is involved in the generation of intraocular pressure (*Invest Ophthalmol Vis Sci* 49: 1563-1570, 2008). *Int Glaucoma Rev*:10-2; 2008.
35. Kaufman PL: State of the Journal. *Invest Ophthalmol Vis Sci*. 51:1, 2010.
36. Kaufman PL: Comment on Barraza RA, McLaren JW, Poeschla EM: Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure (*Mol Ther* 18: 491-501, 2010). *Int Glaucoma Rev*:11-4; 2010.
37. Kaufman PL: Suppression and reduction of corticosteroid-induced ocular hypertension by anecortave in sheep, editorial, *Arch Ophthalmol* 128:365-366, 2010.
38. Candia OA, Kaufman PL; Remembering Steven M. Podos, MD, 1937-2009. *Invest Ophthalmol Vis Sci*. 51:1261-1262, 2010.
39. Kaufman PL: Highlighted/Invited Editor's Selection Commentary on Stamer W, Lei Y: eNOS, a pressure-dependent regulator of intraocular pressure (*Invest Ophthalmol Vis Sci* 52: 9438-9444, 2011). *Int Glaucoma Rev*:13-4; 2012.
40. Read SA, Williams DR, Wojtkowski M, Roorda A, Nichols JJ, Mutti DO, Kaufman PL, Carney LG. Imaging and measurement in the eye: now and ahead (Guest editorial), *Optom Vis Sci*, 89:521-523, 2012.
41. Kaufman PL: Remembering Joanne Angle, 1941-2012. *Invest Ophthalmol Vis Sci* 53:2446-2447, 2012.
42. Kaufman PL: Editorial: IOVS 2008-2012. *Invest Ophthalmol Vis Sci* 53:8238-8239, 2012.
43. Rasmussen C, Kaufman PL: What's New: Trabecular meshwork and outflow. *Glaucoma Now*, Issue 1 [The Role of IOP in Glaucoma] 2013, pages 5-8.
44. Croft MA, Kaufman PL: Systematic Imaging Experiments of Accommodation Do Not Require Image Registration. Reply to Schachar RA: Image Registration Is Required for Experiments of Accommodation. *Invest Ophthalmol Vis Sci*, In Press 2013.
45. Kaufman PL: Remembering Bernard Becker, MD, 1920-2013. *Invest Ophthalmol Vis Sci* 54:7885-7886, 2013.
46. Kaufman PL: In memoriam: Bernard Becker, MD. *Trans Am Ophthalmol Soc*; 112: N2: 2014.
47. Rasmussen C, Kaufman PL: What's new in medical therapies *Glaucoma Now*, Issue no. 1, pp 6-9, 2016,
48. Kaufman PL: Editorial: Should the next step in glaucoma treatment be alternative drug therapies rather than gene therapy? *Expert Rev Ophthalmol* 12:1-2, 2017.
49. Kaufman PL: Research Highlight: Diurnal fluctuation of IOP (re: Miller S, et al: Evidence for a GPR18 role in diurnal regulation of intraocular pressure.) *Invest Ophthalmol Vis Sc*, 2017, in press.
50. Kaufman PL: New medical therapies for glaucoma. *GLEAMS* (Glaucoma Research Foundation newsletter), January 2017, in press.

Book Reviews

1. Kaufman PL: Review of Schachar R: *Presbyopia: Cause and Treatment*. (Kugler Publications: The Hague, The Netherlands, 2001). *Arch Ophthalmol* 120:107, 2002.

Published Abstracts

381 abstracts of authored/coauthored presentations at meetings of the Association for Research in Vision and Ophthalmology, International Society for Eye Research, Optical Society of America, American Academy of Ophthalmology, etc., published in the meeting program supplements of their journals (Investigative Ophthalmology and Visual Science, Experimental Eye Research, Ophthalmology, FASEB Journal, Am J Ophthalmol, etc.).

Trade Journal Articles

1. Langham ME, Kaufman PL, Pollack IP, Wilensky JT: Update on the use of carbonic anhydrase inhibitors. *Ophthalmol Times* 5:20-27, 1980.
2. Armstrong B, Kaufman PL: Of middle age, monkeys, and bifocals. Why middle-aged primates lose their close vision. *Touchstone* 22(3):8-11, 1990 [University of Wisconsin; University-Industry Research Program].
3. Henahan S, Kaufman PL: Current presbyopia theories challenged by new research. *Ophthalmol Times* 15(14):11, 1990.
4. Kaufman PL, Stone RA (for the Board of Trustees, Association for Research in Vision and Ophthalmology): ARVO speaks out on animals and vision research. Guest Editorial. *Argus* 16(12):8-10, 1993 [American Academy of Ophthalmology, San Francisco, CA].
5. Five Questions for Paul L. Kaufman, MD, PhD: *Glaucoma Today*, 2(1):78-79, 2004.
6. Rasmussen CA, Kaufman PL: Drug delivery in glaucoma: future possibilities. *Glaucoma Topics and Trends*, issue 8: 6-7, 2007.
7. Kaufman PL: A word from the editor of IOVS. *ARVO NEWS Summer/Fall*, p26, 2008.
8. Kaufman PL: When no really means NO. *ARVO NEWS Winter/Spring*, p22, 2009.
9. Glaucoma pipeline drugs: Targeting the trabecular meshwork. Karmel, M, (alphabetical) Cantor LB, Iwach AG, Kaufman PL, Novack GD, Rhee DJ. *Eyenet* 38-43, October 2013.
10. Croft MA, Kaufman PL: What is presbyopia? Supplement to *Cataract & Refractive Surgery Today/Europe*, page 7 Sidebar, Summer 2015.
11. Kahook MY, Kaufman PL, Noecker RJ, Radcliffe NM: Glaucoma drugs in the pipeline. *Glaucoma Today*, 13 (4, July/August):42-44, 2015.

Other

1. Invest *Ophthalmol Vis Sci* cover 41(5), April, 2000. Figure 3 upper-left panel, from original article #223 above.

Publications made possible by the resources and expertise available in the Kaufman laboratory but not authored by Paul Kaufman

1. Pelzel HR, Schlamp CL, Poulsen GL, Ver Hoeve JN, Nork TM, Nickells RW. Decrease of cone opsin mRNA in experimental ocular hypertension. *Mol Vis* 12: 1272-1282, 2006.
2. Gomes FE, Bentley E, Lin TL, McLellan GJ. Effects of unilateral topical administration of 0.5% tropicamide on anterior segment morphology and intraocular pressure in normal cats and cats with primary congenital glaucoma. *Vet Ophthalmol* 14 (Suppl 1):75-83, 2011.
3. Nork TM, Murphy CJ, Kim CB, Ver Hoeve JN, Rasmussen CA, Miller PE, Wabers HD, Neider MW, Dubielzig RR, McCulloh RJ, Christian BJ. Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. *Arch Ophthalmol* 130:65-75, 2012. PMID: PMC3254795.
4. Kim CBY, Ver Hoeve JN, Nork TM. The effect of pentobarbital sodium and propofol anesthesia on multifocal electroretinograms in rhesus macaques. *Doc Ophthalmol* 124: 59-72, 2012. PMID:3295608.
5. McLellan GJ, Rasmussen CA: Optical coherence tomography for the evaluation of retinal and optic nerve morphology in animal subjects: practical considerations. *Vet Ophthalmol Suppl* 2:13-28, 2012. PMID:3459243
6. McLellan GJ, Kemmerling JP, Kiland JA: Validation of the TonoVetR rebound tonometer in normal and glaucomatous cats. *Vet Ophthalmol* 16:111-118, 2012. PMID:3443498
7. Dashek RJ, Kim CB, Rasmussen CA, Hennes EA, Verhoeve JN, Nork TM: Structural and functional effects of

hemiretinal endodiathermy axotomy in cynomolgus macaques. Invest Ophthalmol Vis Sci 54:3479-3492, 2013. PMID3658266

UNSOLICITED INVITATIONS FROM SEARCH COMMITTEES

66 Unsolicited Invitations for Professorships/Chairmanships from Search Committees at Various Universities